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Type 1 diabetes mellitus is characterised by absolute insulin deficiency, chronic hyperglycaemia and intermittent
hypoglycaemia consequent upon treatment with insulin. Severe hypoglycaemia, defined as hypoglycaemia
sufficient to necessitate third party intervention for recovery, commonly complicates insulin therapy and repeated
exposure may be detrimental to the brain. Microvascular disease, manifest as retinopathy, neuropathy or
nephropathy, frequently complicates diabetes, the risk being related to long-term glucose control and increasing
disease duration. Microvascular disease may also affect the cerebral circulation and could potentially compromise
brain structure and intellectual performance. Type 1 diabetes commonly develops in childhood before full
maturation of the central nervous system and the developing brain may exhibit relative vulnerability to damage as
a consequence of exposure to severe hypoglycaemia, or the development of Diabetic Keto-Acidosis, in early
childhood. Genetic factors influence the vulnerability of an individual to develop cognitive impairment following
pathological processes known to disadvantage the central nervous system. Polymorphism of the Apolipoprotein-E
gene has been identified as one such factor and is known to influence the prognosis and cognitive outcomes
following a wide variety of cerebral insults.
The studies contained within this Thesis explore the long-term consequences the clinical factors described above
on brain structure and the cognitive performance of young adults with Type 1 diabetes mellitus of long duration.
The effects of polymorphism of the Apolipoprotein-E gene on the cognitive performance of young adults who
have Type 1 diabetes mellitus are also evaluated.
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SUMMARY OF STUDY 1
Objective
The childhood onset of type 1 diabetes (T1DM) may compromise intellectual
development, and ability; children who develop T1DM aged <7yrs more frequently
exhibit cognitive impairment, ofwhich the pathogenesis and structural brain associations
are unknown. Whether the pathogenesis relates to psychosocial and educational factors,
or to diabetes and its complications, remains unresolved. We hypothesised that if
neuroradiological abnormalities were present in association with differences in cognitive
ability then an organic aetiology to the "early onset" effect was likely.
Methods
The effects of diabetes onset age on cognitive ability (neuropsychological test battery)
and brain structure (magnetic resonance imaging) were examined in a cross-sectional
evaluation of 71 young adults with long-duration T1DM diagnosed during childhood or
adolescence. Severe hypoglycaemia exposure, retinopathy status and diabetes duration
were also examined as possible correlates of cognitive and brain structure differences.
No participants had previous neuropsychological pathology.
Results
In those who developed T1DM aged < 7yrs current intellectual ability (WAIS-R
performance IQ, p=0.03, Eta2=0.09) and information processing ability (Choice Reaction
time, p=0.006) were comparatively poorer than in those whose diabetes onset was later.
Furthermore, lateral ventricular volumes were greater (p=0.002, Eta2=0.16, MANCOVA)
and ventricular atrophy (60% vs. 20%, p=0.01, log regression) was more prevalent in
comparison with those diagnosed with T1DM aged >7yrs.
Conclusions
The onset of T1DM in early childhood was associated with modest differences in
intellectual performance in adulthood and mild central brain atrophy. The pathogenesis
of the differences observed in those with early onset T1DM remains unknown but is
likely to have an organic aetiology.
12
SUMMARY OF STUDY 2
Objectives
Type 1 diabetes (T1DM) is characterised by intermittent severe hypoglycaemia, chronic
hyperglycaemia and the development of microangiopathy, and commonly develops
before neurodevelopment is fully completed. The diabetes-specific factors may impact
upon brain structure. We aimed to determine the effects of these factors on the brain
structure of young adults with T1 DM.
Methods
133 normotensive people with T1DM [mean (range): age 32.3yrs (20-45), 51.9% male,
diabetes duration 16.1yrs (9-31), onset age 16.1yrs (1-36; 19.8% diagnosed <8yrs),
36.1% background retinopathy] participated in a cross-sectional study. Participants had
no neuropsychological pathology and varied by their severe hypoglycaemia exposure and
microangiopathy status. Correlation identified associations between diabetes-related
factors (severe hypoglycaemia, retinopathy, diabetes duration, diabetes onset age) and
brain structure (volumetric MRI analysis). Linear Modelling (brain volumes) and Log
Regression (atrophy, white-matter abnormalities) techniques identified independent
predictors of outcomes.
Results
Mild ventricular atrophy was common (30.8%) but Sulcal atrophy (10.5%) was
infrequent. An early diabetes onset age (< 8yrs) independently predicted ventricular
atrophy (p=0.01, Log Regression) and greater Lateral Ventricular volumes (p=0.01,
MANCOVA). Associations between diabetes-specific factors and volumetric measures
were not observed. Peri-ventricular white-matter lesions were common (60%), mild and
unrelated to diabetes-specific factors. Small Punctate White-Matter Lesions (SPWML)
were common (45.1%), located in distinct brain areas [Hippocampus (20.3%), Basal
Ganglia (39.3%), Centrum Semi-Ovale (31.1%)] and correlated with several diabetes-
specific factors (retinopathy, onset age, duration). Logistic regression identified diabetes
onset age as an independent predictor of Hippocampal (p=0.004) and Centrum Semi-
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Ovale (p=0.01) SPWML and the overall presence/absence of SPWML (p=0.02):
SPWML were more frequent in those with later onset diabetes. Retinopathy status
independently predicted Hippocampal SPWML (p=0.03, Log Regression). No
independent associations between diabetes duration, severe hypoglycaemia and SPWML
were identified.
Conclusions
Subtle brain structural abnormalities are common in young adults with T1DM. These are
characterised by mild brain atrophy, mild peri-ventricular white-matter abnormalities and
a specific type of white-matter lesion, the Small Punctate White-Matter Lesion. Early
diabetes onset appears to be the most important diabetes-specific determinant of the
differences observed, predisposing to central brain atrophy yet conferring relative
resistance to the development of white-matter abnormalities, particularly SPWML.
Intracranial microangiopathy, as background retinopathy, may also predispose to
SPWML in specific brain regions, whereas diabetes duration and severe hypoglycaemia
exposure do not appear to confer an obvious disadvantage to brain structure in a young
adult population with T1DM, within the sensitivity of the neuroimaging methodologies
utilised.
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SUMMARY OF STUDY 3
Objective
The e4 allele of the Apolipoprotein-E (APOE) gene is associated with poor outcome
following various cerebral insults. The relationship between APOE genotype and
cognitive function in patients with type 1 diabetes is unknown. We aimed to determine
whether the presence of the APOE e4 allele was associated with cognitive disadvantage
in people with Type 1 diabetes.
Methods
In a cross-sectional study of 96 people with Type 1 diabetes, subjects were APOE
genotyped, previous exposure to severe hypoglycaemia was estimated by questionnaire
and cognition assessed by neuropsychological testing. Cognitive abilities were compared
using multivariate general linear modeling (MANCOVA) in those with (n=21), and
without (n=75), the APOE e4 allele.
Results
APOE e4 selectively influenced cognitive ability in a gender-specific manner (F=2.3,
p=0.044, Eta =0.15); women with APOE e4 performed less well on tests of current, non¬
verbal intellectual ability (Wechsler Adult Intelligence Scale-Revised performance test
score, p=0.001, Eta2 0.26) and frontal lobe and executive function (Borkowski Verbal
Fluency, p=0.016, Eta2=0.15). Previous exposure to severe hypoglycaemia did not
interact with APOE e4 to produce cognitive disadvantage.
Conclusion
The APOE e4 genotype is associated with specific cognitive disadvantage in young







Since the introduction of insulin to clinical use in 1921 it has been readily apparent that an
excessive dose of insulin can lower the plasma glucose concentration to a sub-normal
concentration resulting in hypoglycaemia, potentially to a sufficient depth of hypoglycaemia such
that the supply of glucose to the brain becomes limited and temporary impairment of normal
neurological functions can develop. The clinically obvious presentation of neurological
compromise accompanying intermittent episodes of hypoglycaemia in patients with Type 1
diabetes has encouraged many researchers to explore the long-tenn consequences of these easily
apparent and clinically dramatic episodes, under the hypothesis that such episodes of
hypoglycaemia may have long-term detrimental sequelae for the central nervous system. A
substantial body of literature now exists which details the consequences of hypoglycaemia upon
the function of the brain, as evaluated by neuropsychological and neurophysiological tests, the
structure of the brain as determined by neuroimaging techniques and the neuropathological
sequelae as determined by histopathological techniques.
Traditionally, the clinical complications of Type 1 diabetes, which are manifest as microvascular
disease, have been thought to spare the microvasculature of the central nervous system, such that
the brain has not been considered as a primary target organ for the development of diabetes-
related microvascular damage (Plum F, 1960). Certainly, when compared to the detrimental
effects that Type 1 diabetes can inflict upon other organs, in particular the microvasculature of the
retina, peripheral nervous system and the kidneys, the brain does at first inspection appear
relatively resistant to clinically apparent disadvantage. However, as the retinal circulation is
derived from the same network of blood vessels as the remainder of the intra-cranial vasculature
this is perhaps an illogical assumption and subtle abnormalities of cerebral microvessels, similar
to those observed in the retinal circulation, have been observed in the brains of those with Type 1
diabetes (Johnson et ah, 1982). An increasing body of work, ranging from pre-clinical cell
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culture and animal work, through to human research has examined the impact of Type 1 diabetes
in the human brain. The published literature in humans consists of case reports, cross-sectional
and prospective clinical studies which have utilised a variety of neuropathological,
neurophysiological, neuropsychological and neuroradiological techniques and have provided
supportive evidence for the existence of a "Diabetic Encephalopathy". The introductory section
of the present thesis summarises the published data, with a particular focus on evidence
accumulated from human studies, touching on pre-clinical studies where data from research in
humans is unavailable.
1.2 DIABETES AND THE BRAIN: A HISTORICAL PERSPECTIVE
Type 1 diabetes mellitus is a chronic disorder characterised by absolute insulin-deficiency, which
can be acutely associated with intermittent metabolic decompensation, in the form of
hypoglycaemic or hyperglycaemic crises, and the long-term development of microvascular
complications traditionally reported to target the microvasculature of the retina, peripheral
nervous system and the kidneys. However, it has long been recognised by the medical literature
that Type 1 diabetes mcllitus may also be associated with central nervous system abnormalities.
Indeed, the association between "diabetes mellitus of the juvenile type" and abnonnalities of the
central nervous system was first reported by DeCalvi in 1864 (Marchal (deCalvi), 1864).
DeCalvi observed neuropathological changes at post-mortem in a young patient with "diabetes of
the juvenile type" who had exhibited a variety of neurological symptoms during life. DeCalvi
hypothesised that the brain abnormalities observed in this case may be the cause of diabetes, or
more likely represent a consequence of the disorder itself (Marchal (deCalvi), 1864). Seegen et al
reported corroborative neuropathological findings in a similar case report published in 1893
(Seegen J, 1893) but reports dwindled thereafter. Following the discovery of insulin by Banting
and Best in 1921 and its early clinical utilisation it became quickly apparent that insulin therapy
came with the potential for serious side-effects, in the form of a propensity towards severe
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hypoglycaemia. By 1922 Woodyatt and colleagues had reported a series of fatalities as a
consequence of severe hypoglycaemia secondary to the use of insulin therapy in juvenile-type
diabetes (Woodyat RT, 1922). Wohlwill (1928) first provided a detailed account of the
neuropathological changes following a fatal case of hypoglycaemia where widespread brain and
meningeal softening was observed (Baker AB, 1939). Baker (1939) and Lawrence (1942)
subsequently reviewed the neuropathological literature published in the 1920's and 1930's (Baker
AB, 1939;Lawrence RD et al., 1942) and identified a key pattern of selective neuropathological
abnonnalities following severe hypoglycaemia: selective loss of neurones predominantly in layers
2/3 of the neocortex, the basal ganglia and to a lesser extent the dentate nucleus of the
cerebellum. In 1943 Murphy and Purtcll summarised the literature pertinent to descriptions of
permanent impairment of cerebral function in diabetic survivors of severe hypoglycaemia:
personality changes and intellectual decline sometimes to the extent of "idiocy" were reported
(Murphy FD and Purtell J, 1943), with similar reports observed by Fineberg who reported
permanent neurological damage in a survivor of severe hypoglycaemia (Fineberg S.K. and
Altschul A., 1952). Fischer and Dolger thereafter suggested that cumulative exposure to severe
hypoglycaemia may be deleterious to intellectual capacity (Fischer AE and Dolger H, 1946), a
concept which Jones et al furthered by positing the existence of a 'post-hypoglycaemia
encephalopathy' in 1947. However, it was not until 1950 that DeJong (DeJong, 1977) proposed
the existence of a "diabetic encephalopathy" as a clinical complication of Type 1 diabetes, having
observed multiple cerebral abnonnalities at post-mortem in a young patient with long-duration
Type 1 diabetes, which were not solely in keeping with the pattern of hypoglycacmia-related
neuropathological damage previously summarised by Baker (1939) and Lawrence (1942), and
further explored by Lawrence in 1952 (Lawrence RD et al., 1942). Alex et al (Alex et al., 1962)
reported a higher prevalence of cerebro-vascular disease at post-mortem in those with diabetes
mellitus and Grunnet and co-workers reported an earlier age of onset of cerebro-vascular disease
in subjects who had Type 1 diabetes mellitus (Grunnct, 1963), each inferring that macrovascular
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disease of the cerebral circulation may also contribute central nervous system abnormalities in
Type 1 diabetes, even in chronologically young individuals. In 1961 Ack and colleagues
identified an early childhood onset of diabetes as a further potential aetiological factor to any
detrimental effects that Type 1 diabetes may confer upon the brain. Ack identified significantly
poorer scores on a test of general intelligence in children who had developed Type 1 diabetes
before their 5th birthday relative to their siblings, observing that those diagnosed in early life bore
a greater cumulative exposure to acute metabolic disturbances in the form of hypoglycaemia or
keto-acidosis. Reske-Nielsen et al (1963) described multiple neuropathological and histological
findings in three cases of "juvenile-type diabetes mellitus" and then extended the scope of the
initial study to perform a more detailed examination of the neuropathological consequences of
juvenile-type diabetes and its associated clinical complications in a post-mortem examination of a
series of 16 patients (Reske-Nielsen and Lundbaek, 1963). Reske-Nielsen observed gross
pathological differences affecting gray matter, white-matter and the lepto-meninges co-existent
with multiple histopathological abnonnalities, some of which were in keeping with diabetes
complications in other tissues. However, the cohort evaluated by Reske-Nielsen had extensive
co-morbidity and included patients with a long duration of diabetes generally diagnosed in early
childhood, advanced microangiopathic complications, previous exposure to severe
hypoglycaemia, uraemia and overt psychiatric symptomatology. The post-mortem observations
could not be directly correlated to the presence of any particular clinical complications of Type 1
diabetes and Reske-Nielsen and colleagues concluded that multiple different pathogenic factors
may be responsible for the gross changes described at autopsy. Bale used neuropsychological
tests to evaluate the cognitive ability of people with Type 1 diabetes relative to healthy controls
(Bale, 1973) using a test of short-term memory performance: lower scores were identified in
participants with diabetes, with a significant association observed between lower scoring and
previous hospital treatment for hypoglycaemic coma. Further studies provided data supportive of
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Bale's observations but did not provide further insight as to causality (Franceschi et al.,
1984;Meuter et al., 1980).
The early studies summarised above provided data to support the concept of a "Dabetic
Encephalopathy" as a complication of Type 1 diabetes and prompted further research, aimed at
dissecting which diabetes-specific factors may mediate the cerebral disadvantage reported in case
reports and early cross-sectional studies. Factors identified as potential mediators of
disadvantage by these early studies included recurrent exposure to Severe Flypoglycaemia, the
development of Macrovascular and Microvascular complications, the onset of diabetes during
early childhood neurodevelopment and a long disease duration of diabetes. Subsequent research
has hypothesised that other factors, including those known to play a role in the development of
peripheral neuropathy such as the accumulation of Advanced Glycation End products (AGE) or
increased Aldose Reductase Pathway activity (Tesfaye et al., 2005) may also be of importance.
Recent advances in genetic techniques have identified specific gene polymorphisms which may
confer relative susceptibility to cerebral disadvantage as a consequence of exposure to many
pathological processes known to affect the central nervous system. The following chapters




SEVERE HYPOGLYCAEMIA AND THE BRAIN
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2.1 HISTORICAL PERSPECTIVE
The negative consequences of severe hypoglycaemia induced by exogenous insulin first became
apparent shortly after the discovery and clinical utilisation of insulin as a treatment for Type 1
diabetes, as described above. As well as usage in Type 1 diabetes mellitus, Insulin was also used
in non-diabetic individuals, as "Insulin shock" therapy, a treatment administered for otherwise
incurable psychoses and drug addiction to patients in the 1930's (Sakel, 1994). This procedure
involved the induction of profound degrees of insulin-induced severe hypoglycaemia to produce
protracted cerebral glucodeprivation and resultant hypoglycaemic coma. It soon became
recognised that "Reversible coma" could be expected if the duration of profound hypoglycaemia
was less than 30 to 60 minutes, whereas more protracted glucodeprivation was noted to result in
neurological sequelae, permanent and "Irreversible coma", or in some cases death (Baker AB,
1939;Fazekas et al., 1951), leading to the withdrawal of "insulin shock" therapy from the
psychiatric treatment armamentarium in the 1950's.
2.2 DEFINITION OF SEVERE HYPOGLYCAEMIA
Severe hypoglycaemia is clinically defined as any episode of hypoglycaemia of sufficient severity
such that external third party assistance is necessary to facilitate recovery from the episode
(1991; 1997). This definition in not dependent on a specific blood glucose concentration but
rather depends on the individual with diabetes having hypoglycaemia of sufficient severity to lose
control and nonnal volition. The term "Severe hypoglycaemia" therefore encompasses a variety
of episodes of hypoglycaemia, ranging in severity from "milder" episodes where a loss of volition
to self-treat has occurred yet consciousness is maintained, through to more profound episodes of
glucodeprivation which can result in coma and eventually seizure as the blood glucose
concentration falls further.
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2.3 FREQUENCY OF SEVERE HYPOGLYCAEMIA
The frequency of severe hypoglycaemia in Type 1 diabetes varies according to the population
sampled but prospective reports vary from 35 episodes per 100 patient-years (Donnelly et al.,
2005) in a UK patient group, to 62 episodes per 100 patient-years in the Diabetes Control and
Complications Trial (DCCT) (1991), through to 170 events per 100 patient-years (MacLeod ct al.,
1993). Approximately one-third of insulin-treated patients will experience severe hypoglycaemia
at least annually, one-third of whom will experience coma (10%), and one-third of whom will
repeatedly experience severe hypoglycacmia on a recurrent basis (2-3%) (Tattersall RB, 1999).
2.4 SEVERE HYPOGLYCAEMIA AND BRAIN METABOLISM
2.4.1 Introduction
The human brain is a highly metabolically active tissue, estimated to have a metabolic and
therefore has a high obligate demand for energy. Despite only representing approximately 2% of
body weight, the human brain utilises approximately 20% of the oxygen delivered via the lungs,
receives 15% of cardiac output and metabolises 50-80% of circulating glucose in the fasting state
(Sokoloff, 1991). The processes responsible for this high obligate glucose consumption include
the biosynthesis and re-uptake of neurotransmitters, the generation of neuronal action potentials,
the maintenance of intra- and extra-cellular ion concentration gradients, axoplasmic flow and
protein synthesis, all ofwhich are reliant on the oxidative metabolism of glucose for their energy
demands (McCall, 2004).
2.4.2 Uptake of Glucose into the Brain
The adult human brain is almost exclusively dependent on glucose as its principal fuel and has a
limited capacity to utilise alternative sources of fuel. The brain is therefore almost entirely
dependent upon the delivery of a continual supply of glucose via the cerebral circulation and
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rapidly dysfunctions when this is interrupted. Glucose is transported into the brain interstitium
across the blood-brain barrier by the process of passive diffusion, a process which does not in
itself consume energy, but which is facilitated by a specific glucose transport protein (GLUT 1)
(McEwen and Reagan, 2004;Pardridge, 1991). Within the central nervous system other members
of the GLUT superfamily of glucose transporters, most notably GLUT 3, appear to be responsible
for facilitating the uptake of glucose by neurones, astrocytes and glial cells (McEwen and
Reagan, 2004). Under normal metabolic conditions, where the plasma glucose concentration is
strictly controlled within a tight reference range, the facilitated transport of glucose into the brain
does not limit the rate of neuronal glucose metabolism. However, in the setting of Type 1
diabetes mellitus, where plasma glucose concentrations can fluctuate between subnormal
(hypoglycaemia) or supra-normal concentrations (hyperglycaemia) the rate of facilitated glucose
diffusion from the plasma into the brain can influence the rate of neuronal metabolism. During
hypoglycaemia glucose transport across the blood-brain barrier becomes rate limiting resulting in
neuroglycopenia with prompt deterioration in neuronal metabolism (McCall, 2004) and the
development of cognitive dysfunction (Warren and Frier, 2005).
2.4.3 Glucose Metabolism in the Brain
As in other tissues Glucose undergoes oxidative metabolism via the Kerbs cycle to yield
Adenosine Tri-Phosphate (ATP), the cellular energy substrate. Each molecule of Glucose yields
42 ATP molecules when oxidatively metabolised. The anaerobic metabolism of Glucose to
Lactate can also occur which yields only 2 molecules of ATP per Glucose molecule.
2.4.4 Metabolic Consequences of Neuroglycopenia
As the transport of glucose into the brain occurs via carrier-mediated facilitated diffusion, rather
than via an active pump system, the plasma glucose concentration is the main determinant of
glucose availability for brain metabolism. As the plasma glucose falls during hypoglycaemia, the
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concentration of glucose in the brain interstitium falls accordingly in a progressive manner.
During severe neuroglycopenia, a state of partial cellular energy depletion develops where the
concentration of Adenosine Tri-Phosphate (ATP), the principal energy molecule, falls to
approximately one third of euglycaemic concentrations (Bischof et al., 2004). The partial
neuronal energy depletion that ensues following severe hypoglycaemia is in contrast to the
absolute energy failure that occurs during cerebral ischaemia, and may reflect the use of
alternative fuels by the brain during times of limited glucose availability (see Section 2.4.5).
Partial neuronal energy depletion has consequences for all of the active metabolic processes upon
which brain functionality depends. During hypoglycaemia a compensatory switch to the
catabolism of lipid and protein substrates occurs and cellular membrane pumps dysfunction,
resulting in diffusion of cellular ions to equilibriate with their extracellular concentrations (Auer
and Siesjo, 1993). The activity of the glycolytic pathway, which is responsible for the normal
oxidative metabolism of glucose, is markedly suppressed due to lack of substrate availability,
resulting in a fall in the concentration of Lactate and Pyruvate. Consequent upon this the activity
of the Krebs cycle is also minimal, such that the normal accumulation of hydrogen ions that
accompanies cellular metabolism does not occur, a degree of intracellular alkalosis develops and
Aspartate accumulates within neurones (Auer and Siesjo, 1993).
The term 'excitotoxic brain injury' was first proposed by Olney and colleagues in 1969 following
their observation that the application of the stimulatory neurotransmitter Glutamate to brain tissue
resulted in selective neuronal necrosis in mice (Olney, 1969). Glutamate and Aspartate are the
two major excitatory neurotransmitters in the human brain and each bind to TV-Methyl-D-
Aspartate (NMDA) receptors on post-synaptic membrane on the neuronal dendrite to produce
downstream signalling and cellular effects. During neuroglycopenia failure of neuronal and glial
cellular membrane pumps results in leakage of excitatory neurotransmitters into the synaptic cleft
which combined with a lack of active neurotransmitter re-uptake by the pre-synaptic neurone
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results in prolonged accumulation of excitatory neurotransmitters in the synapse. Subsequent
uncontrolled activation of stimulatory NMDA receptors results in the setting of partial neuronal
energy depiction results in a large inward calcium current which triggers downstream signalling
pathways triggering mitochondrial swelling, degradation and damage to the cellular cytoskeleton
by free radicals, breakdown of the cell membrane and apoptosis if the duration of insult is
protracted (Olney, 1994). During hypoglycaemia the excitatory neurotransmitter that
accumulates in the synaptic cleft is predominantly Aspartate, rather than Glutamate which is
typical of most other type of 'excitotoxic' brain injury e.g. ischaemia, status epilepticus. The
pattern of cellular death associated with Asparate induced 'excitotoxic' cell death produces the
characteristic neuropathological appearances associated with hypoglycaemic brain injury (Auer
and Siesjo, 1993).
2.4.5 Alternative Fuel Use by the Human Brain
Despite near total dependence upon glucose for its entire metabolic demands the human brain has
little capacity to synthesise glucose from precursors and has extremely limited carbohydrate
stores, in the form of glial glycogen (Gruetter, 2003;Suh et ah, 2007). The adult human brain also
appears to have a limited capacity to utilise energy sources other than glucose to support its
obligate metabolic requirements. Limited evidence suggests that the brain can utilise Ketone
Bodies (Amiel et ah, 1991;Veneman et ah, 1994), Lactate (Maran et ah, 1994;Maran et ah,
2000;Smith et ah, 2003), Amino Acids (Evans et ah, 2004) and Lipids (Evans et ah, 1998) to
support brain metabolism, at least to a limited extent.
Lactate may be used as an alternative metabolic fuel by the brain, through its ability to be
converted to Pyruvate by the enzyme Lactate Dehydrogenase. The entry of Lactate into the brain
is facilitated by the Monocarboxylate Transporter protein (MCT1), a protein which is
devclopmcntally regulated (Vannucci and Vannucci, 2001). Lactate can partly compensate for
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neuroglycopenia and has been estimated to provide approximately one-third of the energy
required to support brain metabolism in the neonate (Vannucci and Vannucci, 2001) and a
continuous intravenous infusion of Lactate has been demonstrated blunt the degree of
hypoglycaemia-induced cognitive dysfunction and counter-regulatory honnone release in adult
humans (Smith et ah, 2003). In both of these settings the availability of Lactate can only partly
compensate for neuroglycopenia and cerebral dysfunction is not reversed.
Following a period of adaptation, the oxidative metabolism of Ketone Bodies can chronically
provide two-thirds of the cellular energy necessary to support brain metabolism during periods of
prolonged fasting (Owen et ah, 1967), and infusion of Ketone Bodies during experimentally
induced hypoglycaemia has been shown to blunt, but not prevent, the decrement in cognitive
performance and counter-regulatory hormone release that is characteristically observed during
hypoglycaemia (Amiel et ah, 1991). More recently, it has become apparent that astrocytes, a type
of glial cell which supports neurones, have keto-genic abilities and could potentially shuttle
Ketone Bodies to neurones during times of glucodeprivation (Guzman and Blazquez, 2001).
The ability of the human brain to utilise alternative energy sources appears to be developmentally
regulated. In the neonatal period the brain appears to be more flexible in fuel utilisation. During
starvation, such as periods between suckling, ketone bodies can be readily utilised to maintain
neuronal metabolism. During periods of hypoglycaemia the neonatal brain appears to be able to
utilise amino acids, pyruvate, lactate and free fatty acids, all of which are transported into the
central nervous system by the Monocarboxylate Transporter protein (MCT1), a transporter
appears to be highly expressed in early life but decreases around the time of weaning (Vannucci
and Vannucci, 2001). However, recent evidence suggests that a degree of cerebral metabolic
adaptation may occur in adults with Type 1 diabetes who appear to have an enhanced ability to
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transport and cerebrally metabolise Acetate which is transported into the brain by MCT1, which
is double that of the non-diabetic (Mason et al., 2006).
For several reasons, the above discussion of alternative substrate use by the human brain may be
of academic interest rather than having practical meaning and applicability. Firstly,
hypoglycaemia in the individual with diabetes is induced by the presence of excessive
concentrations of insulin: hyperinsulinaemia potently inhibits the synthesis of Ketone Bodies,
Free Fatty Acids and Amino Acids, the very precursors which are necessary to support brain
metabolism during times of neuroglycopenia. Secondly, the entry of alternative fuels into the
adult human brain may be limited. Amino Acids, Pyruvate, Lactate and Free Fatty Acids are
transported into the central nervous system by the Monocarboxylate Transporter protein (MCT1),
a transporter which appears to be highly expressed in early life but which decreases around the
time of weaning (Vannucci and Vannucci, 2001). The developmental expression of this
transported may partly account for the flexibility of substrate usage apparent in the neonatal
period.
2.5 NEUROPATHOLOGICAL STUDIES OF SEVERE HYPOGLYCAEMIA
Flypoglycaemic brain damage is characterised by 'selective neuronal necrosis' with the
distribution of neuronal necrosis determined by the expression of the NMDA receptor on the
dendrite of the neurone. This selective apoptosis generally spares some cellular populations
within the brain but targets neurones and glia. However, all cellular types are affected if the
duration of profound hypoglycaemia is protracted. This has been demonstrated in the rodent
model of hypoglycaemic brain injury where neuronal necrosis occurs only after the Electro-
Enccphalogram (EEG) has been iso-electric for at least 10 minutes and continued durations of
profound glucodeprivation beyond this threshold result in greater necrosis, beginning with
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NMDA expressing neurones and glia, but developing into non-specific generalised necrosis
thereafter which is difficult to distinguish from ischaemic brain injury (Auer and Siesjo, 1993).
Characteristic histopathological appearances have been described following hypoglycaemic brain
injury in laboratory animals and humans: neurones in layer 2 of the cerebral cortex appear to be
most vulnerable (Auer et al., 1989;Lawrence RD et al., 1942;Patrick and Campbell, 1990) along
with the Hipocampus, particularly neurones in the dentate gyrus (Auer et ah, 1985a), with relative
sparing of cerebellar Purkinje cells(Kalimo and Olsson, 1980;Lawrence RD et ah, 1942;Patrick
and Campbell, 1990), the brain stem and white matter (Auer et ah, 1985c;Auer et ah,
1985b;Patrick and Campbell, 1990). The pattern of histopathological necrosis is thought to
represent NMDA receptor expression (Olney, 1994) and exposure of those neurones in close
contact with CSF to secondary 'excitotoxic' injury following diffusion of neurotransmitters (Auer
and Siesjo, 1993).
2.6 SEVERE HYPOGLYCAEMIA, COGNITION AND INTELLIGENCE
2.6.1 Case Reports
There are many case reports in the medical literature which report permanent cognitive
impairment and disability as a consequence of exposure to protracted and profound degrees of
severe hypoglycaemia. Such protracted and profound episodes of severe hypoglycaemia are rare
and their damaging effect on the central nervous system is without doubt. The importance of
these initial case reports is that they stimulated many research groups to investigate the
consequences of the more commonly encountered recurrent exposure to episodic severe
hypoglycaemia in a more structured and analytical manner. A detailed summary of these initial
case reports will not be provided as a sufficient body of structured evidence has now superseded
these early published reports.
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2.6.2 Cross-Sectional Studies
A number of cross-sectional studies have explored the relationship between previous exposure to
severe hypoglycaemia and subsequent cognitive ability as determined by neuropsychological
tests.
Bale first reported an association between a history of hospital treatment for hypoglycaemic coma
and poorer mental abilities (Bale, 1973). Bale evaluated performance on a test of word learning,
the Walton Black New Word Learning Test, in people with Type 1 diabetes relative to healthy
controls (Bale, 1973): lower scores were identified in participants with diabetes, with a significant
association observed between lower scoring and previous requirement for hospital treatment of
hypoglycaemic coma. However, Bale did not assess the pre-morbid ability of participants and the
differences observed between could reflect differing pre-morbid functional level between the
Type 1 diabetes group and healthy controls. Bale's conclusions that "Brain Damage in Diabetes
Mellitus" was related to exposure to severe hypoglycaemia were at best overstated and perhaps
misleading. Skenazy et al applied a battery of cognitive ability tests in a case-control study which
evaluated the abilities of a small number of people with Type 1 diabetes (n=19) relative to
healthy controls and a chronic illness control group: poorer performance on the Weschler
Performance IQ subtests, which measure current intellectual performance, and a complex test of
cognitive flexibility and visuomotor scanning was observed in the diabetes group. Furthermore,
the authors identified an association between the frequency of preceding severe hypoglycaemia,
retrospectively detennined from case records, and poorer Perfonnance IQ scores (Skenazy and
Biglcr, 1984). Similar caveats apply to these observations as pre-morbid ability was not
evaluated. Wredling examined a small group of patients with Type 1 diabetes (n=17) pre¬
selected from a group of 600 patients due to their high cumulative severe hypoglycaemic burden,
and compared neuropsychological perfonnance with an identical number of control subjects with
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Type 1 diabetes who were naive to severe hypoglycaemia. Groups were matched with respect to
diabetes-specific factors, educational level and socio-economic estimates, to provide roughly
matched groups with respect to pre-morbid attainment (Wredling et ah, 1990). Wredling
observed lower scores in those who had experienced severe hypoglycaemia on tests of simple
motor speed (finger tapping), short-term and associative memory and visuospatial tasks assessing
ability in general problem-solving, but did not report differences in Trail Making performance or
Performance IQ, with the exception of Digit Symbol Substitution scores. However,
methodological limitations could still not separate whether the ability differences observed
related to pre-morbid ability differences or reflected the consequences of severe hypoglycemia
and recruitment bias also seemed possible. In a study of 100 patients with Type 1 diabetes
diagnosed in adulthood Langan et al (Langan et ah, 1991) explored the relationship between
preceding exposure to severe hypoglycaemia and perfonnance on a range of cognitive ability
tests relative to pre-morbid ability, assessing the crystallised intelligence of participants with the
National Adult Reading Test (NART) (Nelson and Willison, 1991): performance on the NART is
highly resistant to the detrimental confounding effects of age and organic disease noted with
many other tests of cognitive ability and reliably estimates the 'best ever' intelligence of an
individual. Langan compared the performance of two sub-groups of patients, a group naive to
severe hypoglycaemia (n=23) and a group who had experienced in excess of five cumulative
lifetime episodes (n=24). The frequency of preceding severe hypoglycaemia, as determined by a
retrospective questionnaire, was the sole measure of estimated preceding exposure to severe
hypoglycaemia that was associated with aspects of intellectual performance: significantly poorer
performance of the order of 0.4 SD (6 IQ points) on the Perfonnance IQ subtests of the WAIS-R
and slower infonnation processing speed (Choice reaction time, decision component) was
observed in the hypoglycaemia-exposcd group. Other aspects of cognitive ability, including
Verbal IQ scores, tests ofmemory, attention and concentration and frontal and executive function
appeared unaffected by preceding severe hypoglycaemia exposure (Langan et al., 1991). The
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observations of Langan and colleagues were the first to robustly exclude disparities in pre-morbid
ability, age, or diabetes duration as being responsible for the relatively modest performance
differences observed between those exposed to severe hypoglycaemia and control groups.
Sachon performed a similar examination of a variety of cognitive abilities in a cross-sectional
study of three groups of patients matched for social class and age: a small healthy control group
and 55 patients with Type 1 diabetes, 30 of whom had impaired awareness of hypoglycaemia and
had experienced repeated episodes of severe hypoglycaemia, with the remainder naive to severe
hypoglycaemia (Sachon et al., 1992). Sachon reported poorer performance in four of the seven
tests administered in those with Type 1 diabetes, relative to healthy controls, but also observed a
significant performance difference on two ability tests, measuring word learning and verbal
fluency respectively, where those previously exposed to severe hypoglycaemia performed
significantly less well than those with Type 1 diabetes naive to severe hypoglycaemia. Again,
difficulties with pre-morbid ability assessment confound interpretation but the findings did infer
cognitive disadvantage consequent upon severe hypoglycaemia. In a further evaluation of the
cohort examined by Langan, Deary and colleagues extended the cognitive domains examined by
their previous assessment and included 100 healthy volunteers as a control group (Deary ct al.,
1993). After controlling for pre-morbid IQ (NART) the diabetes participants exhibited modest
but statistically significant lower WAIS-R scores for both Performance and Verbal IQ, equivalent
to a 5 IQ point deficit. Further statistical adjustment for the preceding frequency of severe
hypoglycaemia eliminated the differences observed in Performance IQ scores, suggesting that the
differences observed between the diabetes and healthy control groups were accounted for by
detrimental effects of severe hypoglycaemia (Deary et al., 1993). In 1996 Lincoln and colleagues
replicated the earlier findings of Langan et al in an identically designed study of 70 patients with
Type 1 diabetes which had developed in adulthood. Lincoln identified a modest correlation
between a calculated IQ decrement, as the difference in Z-scores between pre-morbid ability and
current performance, and preceding exposure to severe hypoglycaemia (Lincoln et al., 1996).
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Cross-sectional studies exploring the hypothesis that repeated exposure to severe hypoglycaemia
may be disadvantageous to aspects of human cognitive abilities have not been universally
supportive. In a carefully designed and thorough study, Ryan et al evaluated a large group of
patients with Type 1 diabetes (n=142) who had developed diabetes before the attainment of full
intellectual maturity and compared performance across a number of cognitive domains with
ability-matched controls (n=100) (Ryan et al., 1993). Sustained attention, visual scanning and
decision making, mental flexibility, psychomotor speed and short-term memory were examined
and multiple regression techniques were utilised to identify independent predictors of cognitive
performance. Ryan did not identify any independent detrimental effects relating to preceding
severe hypoglycaemia exposure across a broad selection of cognitive domains, although a
statistically significant interaction between severe hypoglycaemia exposure and the presence of
peripheral neuropathy was observed. However, this interaction predicted only a small additional
amount of variance in Trail Making (mental flexibility) and Embedded Figures (visual scanning
and rapid decision making) performance, the magnitude of which may be of statistical
significance rather than of clinical importance (Ryan et al., 1993). Snoeke and Heine assessed
aspects of attentional processes in a small study of 18 individuals free of microvascular
complications who had developed Type 1 diabetes in adulthood, nine of whom had a history of
recurrent severe hypoglycaemia (defined as greater than five lifetime episodes) with the
remainder being naive to severe hypoglycaemia, relative to nine healthy controls. No significant
differences in a two-choice reaction time vigilance test or in WAIS-R Digit Span scores were
observed between groups, leading the authors to conclude that the components of attention
assessed were unlikely to be negatively affected by previous exposure to severe hypoglycaemia
(Snoek et al., 1998). However, definitive conclusions are difficult to conclude from this
underpowered study which only evaluated select aspects of attention abilities. Kramer and
Grimm, utilising a strict definition of severe hypoglycaemia, studied the effects of hypoglycaemic
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coma on aspects of cognitive ability and neuro-physiological measures in 108 adult subjects with
Type 1 diabetes, of whom 55 had experienced severe hypoglycaemia (Kramer et al., 1998).
Kramer utilised the Trail Making (Part A) Test, performance on which had been previously
reported as being compromised by preceding severe hypoglycaemia, as well as the Mini Mental
State Examination (MMSE), a structured screening test designed to detect the degree of cognitive
impairment that could be reasonably expected in elderly individuals consistent with an underlying
diagnosis of dementia. The MMSE is an insensitive test for the detection of subtle differences in
cognitive ability of the type that could be reasonably expected, from published observations
(Deary et al., 1993;Langan et al., 1991;Lincoln et al., 1996;Sachon et al., 1992;Wredling et al.,
1990), to be associated with preceding exposure to severe hypoglycaemia in a young adult
population. Unsurprisingly, Kramer did not identify significant differences in MMSE scores in
relation to preceding hypoglycaemic coma, but did identify a trend towards poorer Trail Making
performance in those exposed to coma (Kramer et al., 1998).
Each of the studies outlined above utilised retrospective techniques, usually as a combination of
formatted questionnaires and case record validation, to estimate the preceding exposure to severe
hypoglycaemia of those studied. Such methodologies are only capable of providing an estimate
of the actual hypoglycaemic burden of an individual although these estimates do appear to
correlate well with prospective measures, at least over a relatively short 18-month period (Deary
et al., 1993). With this caveat, the majority of cross-sectional studies discussed above offer some
support for the hypothesis that severe hypoglycaemia may disadvantage select aspects of
cognitive ability in people who have Type 1 diabetes. In particular, those abilities evaluated by
the WAIS-R Performance IQ sub-tests and measures of psychomotor speed may be the most
sensitive to disruption. However, where performance differences were reported in the studies
summarised above the magnitude of difference between those exposed and naive to severe
hypoglycaemia appeared modest at best. The largest cross-sectional study within this research
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area, which was of robust design and sound interpretation, found no such association (Ryan et al.,
1993), confirming that the hypothesis that episodic exposure to severe hypoglycaemia is harmful
to intellectual abilities in adulthood remains contentious and certainly not proven.
2.6.3 Prospective Studies
Three prospective studies have examined the effects of repeated exposure to severe
hypoglycaemia on cognitive ability in people who had developed Type 1 diabetes in adulthood.
The Stockholm Diabetes Intervention Study was the first to prospectively evaluate the cumulative
effects of severe hypoglycaemia exposure on a limited range of cognitive abilities (Reichard et
ah, 1991). In this study Reichard and co-investigators sequentially examined 97 patients over a
7.5 year period, randomised into two well-matched subgroups: one received intensified insulin
therapy (IT, n=44), the remainder conventional insulin treatment (CT, n=53). The cumulative
burden of severe hypoglycaemia experienced by participants over the duration of study was
modest such that the two insulin treatment groups differed little in their experience of severe
hypoglycaemia: 1.1 episodes per patient per annum was observed in the IT group relative to 0.4
episodes in the CT group. Furthermore, the battery of cognitive ability tests utilised by the
researchers was limited to the assessment of simple reaction time, an assessment of short-term
memory, visuo-spatial ability and frontal lobe function. Performance IQ and more detailed
measures of psychomotor speed, identified as perhaps being vulnerable to deterioration following
severe hypoglycaemia by cross-sectional reports, were not assessed in this study which was
designed and executed before this knowledge was published. Reichard and co-investigators
reported no significant changes in the cognitive domains examined with respect to severe
hypoglycaemia exposure (Reichard et al., 1991). In addition to the limitations inherent in the
cognitive domains examined, the study had limited power to detect differences in cognitive
ability between groups. Because of these limitations the Stockholm Diabetes Intervention Study
may not have been optimal to address its main neuropsychological aims. In contrast to these
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limitations, the Diabetes Control and Complications Trial (DCCT) investigators prospectively
evaluated the impact of repeated exposure to severe hypoglycaemia across a wide range of
cognitive abilities using a thoughtfully constructed neuropsychological test battery. This
landmark diabetes study prospectively evaluated 1441 participants who were randomised to
receive either intensified insulin therapy (n=711) or conventional insulin treatment (n=730) over
an assessment period spanning 6.5 years, equating to 9300 patient years of observation. This
provided more than adequate statistical power to identify even modest changes in ability in
association with severe hypoglycaemia. The DCCT studied young adults of greater than average
intelligence, of higher than average social class, who had diabetes of relatively short duration,
each of whom underwent neuropsychological evaluation on three separate occasions: after two,
five and seven years from randomisation. The neuropsychological test battery provided 25
individual test scores which were summated into 8 subjectively determined cognitive domains
labelled as problem solving, learning, immediate memory, delayed recall, spatial ability,
attention, psychomotor efficiency and motor speed. Multiple regression analyses identified no
measure of cumulative severe hypoglycaemia exposure as being a statistically significant
independent determinant of performance within any cognitive domain. However, despite
impressive statistical power to detect change, the DCCT excluded from study those who may
could perhaps be considered to be at the greatest risk of developing cognitive disadvantage as a
consequence their diabetes-related problems: those who had experienced in excess of two
episodes of severe hypoglycaemic coma in the year leading up to study, or who were prone to
repeated episodes of Diabetic Keto-Acidosis, or who had advanced microangiopathy. Through
the application of these exclusion criteria the sensitivity of the DCCT to detect cognitive change
as a consequence of any of the clinical complications associated with Type 1 diabetes is likely to
have been truncated but this carefully executed prospective study does provide reassurance that
intensified insulin treatment and its clinical bedfellow, recurrent severe hypoglycaemia, is not
detrimental to the cognitive abilities of young patients with Type 1 diabetes who have a limited
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microangiopathic burden (1996). The analytical methodologies utilised by the DCCT
investigators in their approach to domain allocation were criticised by Deary et al who argued
that the allocation of subtests to each of the 8 pre-defined cognitive domains was performed on an
ad hoc basis rather than through robust statistical data reduction methodologies. Austin and
Deary thereafter re-analysed the entire DCCT dataset utilising validated psychometric techniques.
Principal components analysis identified four underlying key factors corresponding to spatial
ability, memory, processing speed and verbal ability. However, despite the differing
methodological approach to analysis this psychometric re-analysis did not identify any evidence
to support the hypothesis that recurrent exposure to severe hypoglycaemia is detrimental to
human cognitive abilities, at least in the patient group studied in the DCCT (Austin and Deary,
1999).
The EDIC Study, the on-going research product of the Diabetes Control and Complications Trial
(DCCT) recently re-evaluated the effects of intensive insulin therapy on neuropsychological
function in 1144 participants from the original DCCT cohort after a median duration of diabetes
of 18 years. A detailed battery of neuropsychological tests were utilised which encompassed all
recognised cognitive domains. The EDIC follow up validated the observations of the earlier
DCCT paper which addressed neuropsychological function: no detrimental effect of repeated
exposure to severe hypoglycaemia was detected despite 40% of participants having experienced
coma due to severe hypoglycaemia (Jacobson et al., 2007).
In summary, there is no evidence from prospective studies in relatively young adults with Type 1
diabetes that severe hypoglycaemia is detrimental to cognitive abilities, although the prospective
studies reported to date may not perhaps have evaluated those at the highest risk. The hypothesis
that repeated exposure to moderate degrees of severe hypoglycaemia is damaging to cognitive
abilities in adults with Type 1 diabetes remains contentious and unproven.
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2.6.4 Meta-Analyses
Brands et al performed a meta-analysis of 33 studies in which the cognitive abilities of those with
Type 1 diabetes were contrasted to those of healthy controls. Whilst the primary objective of this
meta-analysis was to define and determine the presence and magnitude of any cognitive
disadvantage associated with Type 1 diabetes per se, the authors also performed a meta-analysis
of the eight studies, from which sufficient information was available for the purpose of meta¬
analysis, which evaluated the long-term sequelae of repeated exposure to severe hypoglycaemia
on cognitive abilities. Cognitive abilities were categorised into an overall summary measure of
cognitive performance and seven separate categorical sub-domains: intelligence, learning and
memory, speed of information processing, attention, mental flexibility and visual perception. The
authors concluded that evidence to support the existence of a negative effect of preceding severe
hypoglycaemia exposure on overall cognitive ability, or on any of the cognitive domains
examined, was lacking with the caveat that those with multiple diabetes complications were
excluded from participation in published reports (Brands et ah, 2005).
2.7 NEUROIMAGING ASSOCIATIONS OF SEVERE HYPOGLYCAEMIA
2.7.1 Case Studies
Severe hypoglycaemia has been recognised as being potentially injurious to the human brain
since the discovery, purification and initial clinical usage of insulin. However, permanent
neurological deficits or obvious cognitive impairment are extremely uncommon following a
single episode of severe hypoglycaemia, most commonly being observed following alcohol
ingestion (Arky et ah, 1968), which disables effective hypoglycaemic counter-regulation, or
consequent upon deliberate attempts at self harm. Those adults who go on to develop permanent
neurological sequelae following a single episode of profound hypoglycaemia are almost always
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comatose on presentation. Richardson and colleagues first described the neuroimaging sequelae
of profound severe hypoglycaemia (Richardson et al., 1981). A comatose male patient with Type
1 diabetes complicated by profound severe hypoglycaemia and circulatory collapse was observed
to have generalised infarction of cortical gray matter on CT neuroimaging in the days following
initial presentation. However, it was not until the 1988 that further case reports detailing the
neuroimaging consequences of exposure to a single episode of profound severe hypoglycaemia
began to emerge, at a time when Magnetic Resonance Imaging (MRI) techniques were in their
relative infancy. Meer et al first described the MRI neuroimaging associations of severe
hypoglycaemic coma in a 33 year old woman with Type 1 diabetes. An initial non-contrast
enhanced CT scan of the brain identified no abnormalities but subsequent contrast-enhanced CT
neuroimaging identified transient enhancement in the region of the right Putamen. This
corresponded to identically placed high-intensity signal abnormalities subsequently observed on
MRI of the same case (Meer et ah, 1988). In another patient with Type 1 diabetes, Chalmers et al
thereafter reported high-intensity signal abnormalities on T1-weighted MRI images in the left
hippocampus and medial temporal lobe following an episode of protracted severe hypoglycaemia.
The patient exhibited a permanent short-term memory deficit and a persistent Hippocampal
abnormality which remained evident 6-months later when the MRI examination was repeated
(Chalmers et ah, 1991). Koppel reported the development of a transient left internal capsule
hypodensity visible on CT scanning of the brain in a middle-aged patient with Type 1 diabetes
who developed severe hypoglycaemia whilst fasting pending a procedure whilst a hospital in¬
patient (Koppel and Daras, 1993). Boeve et al reported a further case following coma induced by
severe hypoglycaemia in which a male with Type 1 diabetes developed bilateral hippocampal
high-intensity signal lesions evident on MRI, with scattered abnormalities also evident in the
temporal and occipital gray matter. These abnormalities were not visible on CT scanning and the
patient developed permanent cognitive impairment with prominent learning and memory deficits
(Boeve et ah, 1995). Holcmans et al reported a similar case where bilateral Hippocampal
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hyperintensities were observed on T2-weighted MR images in a young male with Type 1 diabetes
who also experienced learning and memory deficits subsequent to hypoglycaemic coma. Yet
again, no abnormalities were observed on initial CT brain imaging in this case (Holemans et al.,
2001). Gold and co-workers thereafter reported a case of permanent cortical blindness and
marked cognitive impairment following severe hypoglycaemic coma in a young woman with
Type 1 diabetes. Initial CT imaging in this case identified no abnormalities but repeat CT
scanning 4 months later revealed severe global cerebral atrophy with low attenuation areas
suggestive of infarction of the posterior parietal lobe (Gold and Marshall, 1996). Perros et al
described pennanent pontine dysfunction in association with an abnormal high-intensity lesion in
the pons following hypoglycaemic coma (Perros et al., 1994) and Rajbhandari and colleagues
observed similar radiological changes consistent with central pontine myelinolysis in a further
case report of pontine dysfunction following hypoglycaemic coma (Rajbhandari et al., 1998).
Bakshi reported the presence of high-intensity signal lesions in the caudate and Putamen in a 41
year old woman with Type 1 diabetes following severe hypoglycaemic coma which subsequently
proved fatal. No abnormalities were apparent on CT imaging, MRI abnormalities were subtle on
T2-weighted images but were readily apparent when FLAIR sequences were utilised, inferring a
greater sensitivity for this sequence in detecting hypoglycaemia-related lesions relative to the
other MRI sequences utilised (Bakshi et al., 2000).
Finelli and colleagues first utilised Diffusion-Weighted Imaging (DWI) techniques in their
evaluation of hypoglycaemia-related brain damage (Finelli, 2001). DWI is an advanced MRI
echo planar technique, which allows contrast to be applied across relative proton diffusion
gradients, thereby highlighting areas where proton diffusion is increased or restricted relative to
the surrounding normal brain tissue. DWI is capable of highlighting focal areas of cerebral
energy depletion and cytotoxic oedema and has been demonstrated to be superior to conventional
MRI neuroimaging methodologies in the early diagnosis of stroke, particularly in identifying
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early ischaemia or small foci of ischaemia. Finelli reported a fatal case of hypoglycaemic coma
in a middle-aged male who in addition to Type 1 diabetes, had other co-morbidity known to
impact upon the central nervous system in the form ofHIV and a history of previous intravenous
substance misuse. An initial CT brain scan in this case was unremarkable, but 4 hours later a
further CT brain scan revealed subtle reduced attenuation in the basal ganglia. MRI incorporating
DWI at 48 hours revealed widespread bilateral high-signal intensity in the basal ganglia,
hippocampi and neocortex, whereas standard T2-weighted images revealed only the basal ganglia
changes, and Tl-weighted images were unremarkable (Finelli, 2001). Chan described a further
case of fatal hypoglycaemic coma complicating Type 1 diabetes in a middle-aged male in which
MRI neuroimaging was performed. Consistent with Finelli's findings Tl-weighted sequences
were unremarkable, T2-weighted images revealed subtle areas of increased signal, whereas DWI
revealed diffusion restriction in the cerebral cortex, most marked in the temporo-occipital areas
and basal ganglia (Chan et ah, 2003). Yoneda and colleagues described a case of fatal
hypoglycaemic coma complicating Type I diabetes in which diffusion-weighted MRI
appearances suggested widespread laminar necrosis of the neocortex, most prominently in the
frontal lobes. DWI identified the gross widespread cortical abnormalities, similar to those
observed by Chan et al (2003) whereas T2-images revealed only subtle areas of high signal
intensity and Tl-weighted images were normal (Yoneda and Yamamoto, 2005). Maekawa and
colleagues described a case of severe hypoglycaemic coma in a middle-aged male with Type 1
diabetes in which transient MRI abnormalities and clinical recovery were observed. Initial CT
scanning of the brain revealed slight cerebral atrophy, as did repeat CT at 48 hours, whereas MRI
evaluation at the time of the second CT revealed multiple abnonnalities apparent on T2, FLAIR
and DWI in the occipital cortex and basal ganglia. The temporal evolution of the MRI changes
revealed a diminution ofDWI abnormalities by day 7 and near resolution by day 14, whereas the
T2-weighted and FLAIR high-intensity lesions remained apparent (Maekawa et al., 2006). A
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similar temporal evolution of MRI abnormalities was previously described in a case of
hypoglycaemic coma complicating Type 2 diabetes (Aoki et al., 2004).
The generalised pattern of brain injury reported in the neuroimaging case studies summarised
above, which demonstrate cortical gray matter injury, followed by injury to deep gray matter
structures such as the hippocampus and basal ganglia, thereafter by damage to the midbrain
before finally involving the cerebellum and spinal cord appears to be consistent with the
neuropathological observations from animal and human post-mortem work (Auer and Siesjo,
1993).
These cases also identify beyond doubt that profound severe hypoglycaemia can be permanently
damaging to the adult brain in Type 1 diabetes. In addition to this somewhat obvious conclusion,
the neuroimaging studies give some insight to the relative sensitivity of the radiological
techniques utilised in the evaluation of hypoglycaemia-related brain damage. Uncontrasted
Computerised Tomography (CT) appears a relatively insensitive test for the evaluation of early
hypoglycaemia-related brain injury, at least in the first 24-48 hours following the brain insult.
Contrast enhanced CT techniques appear to offer greater sensitivity but consistently appear
inferior to MRI methodologies, although both techniques were not employed simultaneously in
the majority of cases summarised above. Many of the reports which MRI techniques
demonstrated abnormalities also utilised CT scans. In many of the above cases CT techniques
failed to identify any focal abnormalities in association with severe hypoglycaemia (Chalmers et
al., 1991 ;Finelli, 2001;Holemans et al., 2001;Maekawa et al., 2006;Perros et al., 1994;Yoneda
and Yamamoto, 2005) when abnormalities were readily apparent on MRI. These observations
infer that MRI may offer greater sensitivity in detecting subtle structural brain changes related to
severe hypoglycaemia. Some forms of MRI neuroimaging may be more sensitive in detecting
more subtle degrees of hypoglycaemia-related brain injury. Case reports infer that DWI may be
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the present optimal technique in the acute assessment of hypoglycaemic brain injury, followed by
FLAIR, T2-weighted, T1-weighted images, contrast CT and finally CT in descending order of
sensitivity. This hierarchical interpretation may be over simplistic for two reasons. Firstly, the
timing of neuroimaging studies in many of the cases may partly confound the interpretation
offered above: many of the cases had CT brain scans performed on admission with MRI
techniques performed days to weeks later. However, the more recent case described by Maekwa
and colleagues (Maekawa et al., 2006) may mitigate against this as a confounder and does infer
true superiority for MRI based techniques. Secondly, selection bias may have occurred as only
those cases in which initial CT imaging was negative or inconclusive in the face of neurological
compromise would have been likely to have MRI neuroimaging, thereby potentially adding bias
in the favour of these techniques.
Irrespective of the relative sensitivity of the MRI techniques outlined above, the presence of
structural brain abnormalities on MRI appears to be indicative of a poor prognosis. However,
reporting and publication bias could confound this interpretation.
2.7.2 Cross-Sectional Studies
Only two cross-sectional studies have attempted to delineate the structural brain correlates of
repeated exposure to severe hypoglycaemia in people with Type 1 diabetes. In a small
underpowered cross-sectional study Lunctta and co-workers examined brain structure using MRI
in ten patients with Type 1 diabetes, who had a relatively short median duration of diabetes,
variable hypoglycacmia exposure and differing degrees of microangiopathy and contrasted the
appearances observed with a control group (Lunetta et al., 1994). The MRI sequences utilised
included T1 and T2-weighted images and post-scan analysis included calculation of the cerebro-
ventricular index (CVI), a surrogate measure of dilatation of the lateral ventricles. Lunetta
reported a significantly increased CVI in 70% of the diabetes group, as well as a degree of
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subjectively-rated cortical atrophy. The manuscript provides scant demographic details of the
control group, may rely on a definition of an elevated CVI that is not robust, and reported no
significant statistical correlation between preceding history of severe hypoglycaemia and the
presence of central brain atrophy, defined by the relatively greater CVI observed in the diabetes
group. However, the study was underpowered to address any of its primary aims and its negative
findings should be viewed accordingly. Perros et al examined 22 participants of a previously
published cohort (Langan et al., 1991), in whom the preceding frequency of severe
hypoglycaemia was associated with poorer current intellectual performance (WAIS-R
Performance IQ). This modestly sized study examined MRI brain structure in two equally sized
(n=l 1) well-matched groups of adult participants with Type 1 diabetes of long duration; a group
naive to severe hypoglycaemia and a group with more than five cumulative episodes of severe
hypoglycaemia. Perros identified two types of structural brain abnormalities in those with Type 1
diabetes: high-intensity lesions in the peri-ventricular white matter and generalised cortical
atrophy. Cortical atrophy was observed more frequently (45.5% vs. no cases) in those with a
previous history of exposure to severe hypoglycaemia and the presence of any structural brain
abnormality (defined as either white matter lesions or atrophy) was also significantly more
frequent in this group (63.6% vs. 18.2%) (Perros et al., 1997). The preliminary observations of
this modestly sized pilot study were the primary driver for the subsequent neuroimaging studies
presented in this thesis.
2.7.3 Prospective Studies
No studies have been published to date that have attempted to prospectively evaluate the
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3.1 HISTORICAL PERSPECTIVE
Since 1961 it has been recognised that the onset of Type 1 diabetes in early childhood may confer
disadvantage upon the development and attainment of certain intellectual abilities (Ack et al.,
1961). Ack's seminal cross-sectional study identified significantly lower general intelligence
scores relative to non-diabetic sibling controls in those who had developed T1DM before their 5th
birthday, observing that those diagnosed in early life bore a greater cumulative exposure to acute
metabolic disturbances in the form of hypoglycaemia or keto-acidosis. These metabolic
decompensations of T1DM were suggested as potential organic mediators of the differences
observed between cases and their sibling pairs. However, others have posited socio-educational
factors, rather than the consequences of acute metabolic deteriorations, as being responsible for
such differences. The following sections introduce the basics of structural brain development
across childhood and adolescence before summarising the evidence base from
neuropsychological and neuroradiological studies.
3.2 NEUROIMAGING OF NORMAL CHILDHOOD NEURODEVELOPMENT
Since the emergence of Magnetic Resonance Imaging (MRI) techniques in the late 1980's it has
become possible to determine the neuroimaging associations of childhood and adolescent
neurodevelopment in health and disease on a sequential basis, without the negative consequences
incumbent upon previous X-ray based methodologies. MRI has allowed the chronological
development of cortical gray matter, sub-cortical gray matter, white matter and the cerebral
ventricles to be determined in detail and the use of computer-based volumetric analysis has
provided further insights into the subtleties of regional neurodevelopment, details which were
previously unknown. Using such techniques investigators have begun to explore the structural
brain changes that accompany the development of cognitive abilities, identifying regional
differences in the timing and rate of brain growth associated with cognitive maturation (Durston
et al., 2001).
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3.2.1 Whole Brain Volume and Neurodevelopment
At the time of birth the size of the human brain is disproportionate to that of the remainder of the
body and the total brain volume of the newborn is approximately 80% of final adult volumes. In
early childhood total brain volume steadily increases to attain 95% of peak volume at the age of 5
years with volume increases thereafter being limited to a further 5%. Despite this tailing off of
cerebral enlargement neurodevelopment is far from complete (Lenroot and Giedd, 2006). After
the age of five, subtle differential changes in the growth and regression of gray and white matter
occurs. The processes underlying these relatively modest changes appear to reflect selective glial
and neuronal apoptosis and ongoing myelination which continues into the 3rd decade of life
(Durston et al., 2001). The temporal changes in total brain volume are illustrated in Figure 3.1.
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Adapted from Lenroot et al 2006.
3.2.2 Cortical Gray Matter Volumes and Neurodevelopment
Cortical gray matter, consisting primarily of the cell bodies of neurones and their supporting glial
cells, increases in volume by approximately 10-15% from birth across the first five years of life,
thereafter reaching peak volumes in a regionally-specific manner. Peak frontal and parietal
cortical gray matter volumes are attained at age 10-12 years, whereas peak temporal gray matter
volumes are not attained to age 16-17 years. The last area to attain peak volume is the pre-frontal
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cortex, an area associated with higher intellectual functioning and reasoning (Lenroot and Giedd,
2006). The overall changes observed from the age of five to adulthood reflect a reduction in
volume of the order of 20-30% (Durston et ah, 2001). At least two distinct processes appear to
account for the overall reductions in gray matter from early childhood to adulthood.
Neuropathological studies confirm that selective programmed neuronal necrosis, a process termed
"pruning", combined with necrosis of supporting glial cells does occur between early childhood
and adulthood and contributes to some of the reduction in gray matter volume observed in
neuroimaging studies. This loss of glia and neurones is thought to underlie the 60-150% increase
observed in the volume of the lateral ventricles that has been observed across the same timeframe
and which appears more marked in males relative to females (Durston et al., 2001). In addition to
neuronal loss, a further contributor to the apparent reduction in cortical gray matter volume
observed using MRI appears to be sub-cortical myelination which occurs late in
neurodevelopment and which gives the neuroradiological appearance consistent with that of
white matter, whereas the tissue appears to be an admixture of gray and white matter components
on histological analysis. A summary diagram of the developmental changes which occur in gray
matter volumes is provided in Figure 3.2.
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Figure 3.2 Temporal Development of Lateral Ventricle Volumes in 532 Subjects.
Age (yeais)
Adapted from Lenroot et al 2006.
3.2.3 Sub-Cortical Gray Matter Volumes and Neurodevelopment
The sub-cortical gray matter consists of the basal ganglia and the amygdalo-hippocampal
complex. The temporal changes observed in the development of sub-cortical gray matter
structures across neurodevelopment appear to differ from those affecting the cortical gray matter.
The amygdala and hippocampus, located in the medial temporal lobe, appear to modestly increase
in volume (10-20% for Hippocampus; 40-50% for Amygdala) from childhood to adulthood. The
basal ganglia, which consist of five separate nuclei; the caudate nucleus, putamen, globus
pallidus, substantia nigra and the sub-thalamic nucleus decrease in volume from their peak
volumes at age 7-10 years (Lenroot and Giedd, 2006) by 10-15% (Durston et al., 2001) to reach
adult volumes in a manner similar to that observed in accordance with cortical gray matter.
3.2.4 Cerebral White Matter Volumes and Neurodevelopment
Cerebral white matter is composed of the axons of neurones, linking different regional cortical
and sub-cortical brain areas, oligodendrocytes and the myelin sheaths that they synthesised to
enhance the speed of conduction of action potentials following neuronal depolarisation. Much of
the process of myelination appears to have taken place by the time of birth. In the post-natal
period white matter volumes rapidly increase, notably so during early childhood, with an
increment of 75% being observed from birth to 5 years. The majority of this increase is observed
during the first and second year of life (Hermoye et al., 2006). Thereafter, a further increase of
the order of 10-20% occurs from the age of five until adult life. This increase in volume is
though to represent the progressive myelination of axons by oligodendrocytes. Thereafter, the
process of myelination continues at a lesser rate into the 3rd decade of life, generally proceeding
from inferior to superior and posterior to anterior brain regions. Notable exceptions to this over
simplification exist, particularly with respect to the corpus callosum, the largest white matter tract
within the human brain which connects the cerebral hemispheres. The volume of the corpus
callosum increases well into adulthood with the posterior aspects maturing last. The overall
change in white matter volume which occurs with age is illustrated in Figure 3.3.
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Adapted from Lenroot et al 2006.
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3.2.5 Gender-Specific Neurodevelopment and Brain Volumes
Gender is a powerful determinant of total and regional brain volumes. In all published series and
across all age groups, from birth to adulthood, the male brain is consistently larger in volume than
that of the female brain by approximately 10% and the majority of intra-cranial structures are
proportionally smaller in women. However, certain regional brain areas differ in their
proportional volume (i.e. the absolute volume relative to the intra-cranial volume) between the
genders. Women have proportionally larger caudate nuclei, hippocampi and smaller amygdala
relative to males but absolute volumes are similar (Lenroot and Giedd, 2006).
3.3 AGE AT BRAIN INJURY AND NEURODEVELOPMENTAL OUTCOME
There are two distinct outcomes that have been recognised with respect to the timing and type of
cerebral insult during childhood and the subsequent risk of cognitive impairment: the developing
brain appears to have the ability to adapt and correct for loss of specific functions, at least in part,
through the process of synaptic plasticity, whereas generalised cerebral insults, such as those
which could be expected to occur in association with severe hypoglycaemia or during Diabetic
Keto-Acidosis, may potentiate sufficient brain injury to result in permanent neurological
sequelae, developmental delay or cognitive impairment which may only become apparent in later
life. Insults occurring within the first two years of life, during the period of relatively rapid
cerebral growth are likely to result in a greater magnitude of permanent disability and dysfunction
than those which occur during adolescence when the neurodevelopment is by comparison a
relatively subtle process. This phenomenon has been clinically apparent for decades but was first
documented in children with Epilepsy but thereafter has been described in association with severe
hypoglycaemia in the neonatal period (Persistent Hyperinsulinaemic Hypoglycaemia of Infancy)
as well as in a spectrum of other pathological processes known to affect the central nervous
system (Tranel and Eslinger, 2000). In theory at least, the clinical consequences of
decompensated T1DM, manifest as Severe Hypoglycaemia or Diabetic Keto-Acidosis, are
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therefore most likely to incur negative consequences for the central nervous system if they occur
early in life, particularly within the first two years where brain growth is at its most rapid. This
concept is largely supported by data from clinical and pathological studies in humans. Severe
Hypoglycaemia appears to be a reasonable example with a sufficient evidence base to support this
theory. The occurrence of severe hypoglycaemia during the neonatal period, particularly when
complicated by seizures, is associated with a poor clinical outcome with developmental delay,
disability or death (Vannucci and Vannucci, 2001). Repeated exposure to severe hypoglycaemia
during early childhood appears to incur subtle disadvantage upon the acquisition of certain
cognitive abilities (Northam et al., 2001;Rovet and Ehrlich, 1999), whereas prospective studies of
adults with T1DM have shown no detrimental association between repeated exposure to severe
hypoglycaemia and subsequent cognitive abilities (Reichard et al., 1991; Austin and Deary, 1999;
Jacobson et al., 2007).
3.4 NEUROPATHOLOGICAL STUDIES IN CHILDREN WITH T1 DM
No studies have been published which have evaluated the neuropathological consequences of the
development of Type 1 diabetes in early life. However, data from post-mortem studies of
neonates who had experienced profound and protracted severe hypoglycaemic episodes appear to
confirm a similar pattern of hypoglycaemic brain damage to that reported in adults, with severe
neuronal injury to the Neocortex, Basal Ganglia and Hippocampus and a lesser degree of injury to
the Thalamus, Brain Stem and Spinal Cord (Vannucci and Vannucci, 2001). In childhood, a
single published case report describes the neuropathological appearances consequent upon
insulin-induced severe hypoglycaemia in a previously healthy 8 year old non-diabetic girl who
was rendered hypoglycaemic in a Munchausen's by Proxy case. The child developed a
permanent right hemiparesis followed by the development of refractory epilepsy necessitating a
excision of the left cerebral hemisphere. Histological examination of the excised hemisphere
revealed a complete absence of cortical neurones, reactive gliosis, vacuolation of the white
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matter, yet with sparing of the Basal Ganglia, Cerebellum and Brain Stem (Christiaens et al.,
2003). The neuropathological sequelae of severe hypoglycaemia cannot be determined from this
case study as repeated status epilepticus may potentially confound the histopathological
appearances.
3.5 NEUROPSYCHOLOGICAL STUDIES IN CHILDREN WITH T1 DM
3.5.1 Cross-Sectional Studies
Ack et al (Ack et al., 1961) first described the association between the development of Type 1
diabetes in early childhood, defined as an onset before the 5th birthday, and relatively poor
performance on a test of general intelligence. Ack studied 38 sibling pairs discordant for Type 1
diabetes and compared performance on the Stanford-Binet Intelligence Scale and identified a
correlation between general intelligence performance and the age of diagnosis of diabetes: in the
13 sibling pairs which included a child who had developed Type 1 diabetes before their 5th
birthday, significantly poorer scores were observed, a difference equivalent to 10 IQ points (0.66
SD). In exploring the reasons underlying these observations, Ack noted that those diagnosed with
diabetes in early life exhibited a trend towards a greater exposure to acute metabolic
decompensations, in the form of severe hypoglycaemia or diabetic keto-acidosis, hypothesising
that these two potential aetiological organic factors could explain some of the performance
differences observed between cases and controls. Ryan and colleagues extended the breadth of
knowledge within the field with their examination of cognitive abilities and intelligence in a study
of 116 adolescents with T1DM, 46 of whom were diagnosed before their 5th birthday. Ryan
found corroborative evidence that severe hypoglycaemia may be detrimental to the developing
brain: deficits in attention, learning and memory, visuo-spatial ability, psychomotor speed, motor
speed and verbal intelligence were observed in those who developed diabetes aged less than 5
years relative to those with a later onset of diabetes. Deficits were sufficient in magnitude to
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classify a proportion of "early onset" children as cognitively impaired (Ryan et al., 1985a). This
led Ryan and many subsequent investigators to assume that exposure to severe hypoglycaemia
was primarily responsible for the broad-based deficits observed in association with "early onset"
diabetes. This hypothesis was not without foundation as a greater cumulative burden of
metabolic decompensations, particularly as severe hypoglycaemia, has been consistently reported
for those diagnosed with T1DM in early life, relative to those diagnosed later in childhood
(Daneman et al., 1989;Davis and Jones, 1998;Golden et al., 1985;Ternand et al., 1982).
Following on from the observations of Ryan, others have expanded the breadth of cognitive
domains that appear to be affected by an "early onset " of T1DM and attempted to separate the
specific effects of severe hypoglycaemia and early disease onset per se. Rovet examined the
intellectual consequences of the development of T1DM in early childhood in 27 children who had
developed the disorder before their 4th birthday, 24 children with T1DM who had developed
diabetes at a later age and 30 sibling controls. An early onset of T1DM was associated with
broad-based intellectual deficits in girls who exhibited poorer performance IQ scores, poorer
reading and spelling abilities. Although the early onset group in this study had a slightly greater
cumulative exposure to severe hypoglycaemia, the poorer performance of the "early onset" group
could not be directly attributed to severe hypoglycaemia (Rovet et al., 1987a). Bjorgaas and
colleagues performed a detailed neuropsychological assessment in a small study of 28 children
with T1DM and 28 age and 28 ability-matched controls, relating their observations to the
occurrence of severe hypoglycaemia. Those children who had experienced severe hypoglycaemia
(n=15) consisted of a group who were diagnosed before their 5th birthday (EOD-SH, n=5) with
the remainder diagnosed after this age (LOD-SH, n=10). The exposure of the T1DM group to
severe hypoglycaemia was very modest and no child experienced severe hypoglycaemia before
the age of 4 years. Bjorgaas identified significantly poorer performance on tests of attention and
psychomotor efficiency in the EOD participants, all of whom had experienced severe
hypoglycaemia. Rather oddly, the performance of the EOD-SH group was thereafter compared
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relative to the LOD-SH and remaining T1DM participants, rather than an EOD group naive to
severe hypoglycaemia which was not possible. These groups were not matched for educational
or pre-morbid ability. The authors concluded, somewhat inappropriately, that severe
hypoglycaemia exposure was causative of the deficits in attention and psychomotor efficiency
(Bjorgaas et al., 1997). Rovet examined general intelligence and attentional abilities in detail in a
large group of children and adolescents with T1DM (n=103) relative to matched controls
(n=T00). The attentional abilities of the diabetes group differed little from those of control
subjects. However, sub-analysis identified a broader spectrum of deficits in several aspects of
attention in association with an early onset of T1DM, defined as an onset before the 6lh birthday
and a history of preceding exposure to severe hypoglycaemia. An early onset of diabetes
specifically affected the 'select' aspect, whereas severe hypoglycaemia exposure affected the
'inhibit' and 'focus' subcomponents. Those with an early onset of diabetes and exposure to
severe hypoglycaemia exhibited lower verbal IQ scores and multiple attentional deficiencies.
However, the magnitude of the differences observed in attentional processes was small and of the
order of 0.2SD when present. An early onset of diabetes was not associated with any difference
in general intelligence, Performance IQ or Verbal IQ, whereas a history of preceding exposure to
severe hypoglycaemia was associated with a small difference in verbal IQ scores of the order of
0.3SD (4.5 IQ points) (Alvarez and Rovet, 1997). In a small and perhaps underpowered study
Hershey et al examined medial temporal function, as declarative memory ability, in 25 children
with T1DM randomised to receive either "intensive" insulin treatment, geared towards the
attainment of strict glucose control, or "conventional" insulin treatment where glycaemic targets
were more lax. The "intensive" group experienced a three-fold increased incidence of severe
hypoglycaemia, defined as an episode of sufficient severity to necessitate 3rd party intervention to
facilitate recovery (The DCCT Research Group, 1991; The DCCT Research Group, 1997).
Hershey observed poorer delayed spatial memory function in those children receiving "intensive"
insulin treatment although the statistically significant disadvantage in performance was small in
58
magnitude. However, when comparing those children who had experienced severe
hypoglycaemia relative to those who were naive to severe hypoglycaemia no significant
difference in abilities was observed. Whilst this modestly powered study identified inferred that a
specific aspect of memory function may be associated with "intensive" insulin therapy, no
detrimental effects of severe hypoglycaemia per se were identified (Hershey et al., 1999).
Other cross-sectional studies have consistently identified relatively poorer performance across a
broad base of cognitive domains in children who had developed Type 1 diabetes in early life
(Hagen et al., 1990;Holmes and Richman, 1985;Wolters et al., 1996). However, studies which
have examined the effects of severe hypoglycaemia exposure in children have provided
inconsistent results. Deficits in declarative memory (Hershey et al., 1997;Kaufman et al.,
1999;Rovet and Ehrlich, 1999), spatial memory (Hershey et al., 2004), word recall (Wolters et al.,
1996), attention (Alvarez and Rovet, 1997;Rovet and Ehrlich, 1999) and Verbal IQ (Alvarez and
Rovet, 1997;Rovet and Ehrlich, 1999) have been reported in association with severe
hypoglycaemia. Other studies have found no association between severe hypoglycaemia
exposure and poorer neuropsychological functions (Bjorgaas et al., 1997;Strudwick et al.,
2005;Wysocki et al., 2003). Drawing definitive conclusions from these studies are difficult due
to the heterogeneity of neuropsychological tests used and the differing definitions of "early onset"
diabetes.
Others have postulated alternative hypotheses to account for the differences observed, placing an
emphasis on socio-economic factors rather than organic factors. Children with T1DM diagnosed
early in life have been shown to have poorer school attendance and are more likely to exhibit
behavioural difficulties. Children with diabetes have been demonstrated to have poorer school
attendance than their peers (Hagen et al., 1990;McCarthy et al., 2002;McCarthy et al.,
2003;Parker et al., 1994;Rovet et al., 1987b;Ryan et al., 1985b). However, reports on the school
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performance of children with T1DM are conflicting. Rovet observed poorer school performance,
perhaps related to deficits in the ability to learn, in children with T1DM (Rovet et ah, 1993) and
also reported that children with T1DM were more likely to require to repeat a school year (Rovet
et ah, 1987a). However, McCarthy and colleagues examined the learning and memory abilities
and academic prowess of children in a large study of significant statistical power of three groups
of children: a Type 1 diabetes group (n=244), sibling controls (n=110) and matched-classmate
controls (n=209). No differences between those with T1DM and matched controls were
observed. No difference in academic performance was associated with the presence of diabetes
relative to siblings and classmates (McCarthy ct ah, 2002;McCarthy et ah, 2003). Children with
T1DM have also been shown to exhibit greater difficulties with behaviour in school. Fallstrom
first demonstrated behavioural difficulties and anxiety problems, relative to non-diabetic children,
which correlated with exposure to severe hypoglycaemia (Fallstrom, 1974). Others have since
corroborated the higher prevalence of behavioural problems in children with an early onset of
diabetes, although not consistently associated with severe hypoglycaemia (McCarthy et al.,
2002;Rovetet ah, 1987b).
Separating the disease-specific organic factors, such as contributions from severe hypoglycaemia
and chronic hyperglycaemia, from the socio-economic and behavioural contributors to the
cognitive differences observed in association with an early onset of diabetes has proved difficult
and beyond the design limitations of cross-sectional studies, necessitating the collection of
prospective data.
3.5.2 Prospective Studies
Rovet et al first prospectively examined the associations of exposure to severe hypoglycacmia in
early life with later cognitive abilities and general intelligence scores in a small study of 16
subjects with T1DM evaluated over a 7 year period. Rovet identified that subjects exposed to
60
hypoglycaemic seizures at or before the age of five (n=4 subjects) exhibited a selective
performance deficit restricted to lower verbal IQ scores and poorer scores on tests of attention
and memory abilities (Rovet and Ehrlich, 1999). However, limitations inherent upon the
statistical power of this study and the retrospective collection of severe hypoglycaemia data
prevent definitive conclusions.
Hershey and colleagues examined the effects of two different insulin treatment strategies on a
range of cognitive abilities in 25 older diabetic children (average age 12 years) were followed
from diagnosis for a mean 36 months (Hershey et al., 1999). Participants were randomised to
receive "intensive insulin" therapy, with the aim of attaining near normoglycaemia, or
"conventional insulin" treatment. Those children receiving intensive insulin therapy had a
threefold increased risk of hypoglycaemia and performed slightly less well on a single test of
declarative memory, from an extensive battery which included several other assessments of
memory. Across many of the other cognitive abilities examined those receiving "intensive
insulin" therapy perfonned better than those receiving "conventional insulin". The investigators
concluded that the "intensive insulin" strategy may be harmful to aspects of cognitive ability in
developing children, not addressing the potential for Type 1 statistical in their interpretation of
their results (Hershey et al., 1999). Had multivariate statistical techniques been utilised the
observations from this small study may have been reported in an entirely different manner.
Northam and colleagues thereafter evaluated the impact of a childhood diagnosis of T1DM on the
attainment of general intelligence and specific neuropsychological abilities in a well-characterised
cohort of children with diabetes relative to age and ability-matched healthy controls. At the
outset of this prospective study no differences in general intelligence, as determined by the
Weschsler Intelligence Scale for Children, were observed between cases and controls. Two years
following the diagnosis of T1DM differences in the processing speed and learning abilities of
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those with T1DM were apparent (Northam et al., 1998). By the third evaluation after 6 years of
prospective assessment significant differences between cases (n=92) and controls (n=84) were
clearly evident and specific effects relating to diabetes-related variables discernable. Multivariate
analysis identified diabetes per se as an independent predictor of lower general intelligence
scores, predominantly determined by poorer performance on the verbal IQ subtests of the WISC,
with a small magnitude of deficit. Those with an early onset of diabetes, defined as onset before
the 4th birthday, also exhibited a broad range of neuropsychological deficits with poorer
performance on tests of attention, processing speed and executive function being apparent. By
the 6 year assessment 25% of the cohort had experienced severe hypoglycaemia, but only one
child had experienced an episode of hypoglycaemic seizure before their 4th birthday. Exposure to
hypoglycaemic seizure was associated with significantly poorer verbal IQ scores and lower FSIQ
scores. However, the amount of variance explained by exposure to severe hypoglycaemia was
modest, equating to 0.4SD for verbal IQ and 0.2SD for FSIQ scores. Unlike the findings with
respect to an early onset of diabetes, the influence of severe hypoglycaemia exposure was limited
to detrimental effects on verbal IQ and was not associated with poorer performance on any of the
neuropsychological test battery (Northam et al., 2001). Due to the temporal occurrence of severe
hypoglycaemia in this cohort, the hypothesis that severe hypoglycaemia exposure in early life is
especially injurious to the human brain remained untested.
Schoenle and colleagues prospectively evaluated the general intelligence of a Austrian cohort of
children age 7-16 years with T1DM relative to healthy controls, using the German version of the
Weschsler Intelligence Scale for Children (WISC) to determine Verbal IQ, Performance IQ and
Full-Scale IQ (FSIQ) scores. IQ scores were evaluated with respect to the disease-specific
variables of interest: severe hypoglycaemia and degree of metabolic control. Schoenle reported a
gender-specific pIQ deficit in boys who developed T1DM before their 6th birthday, most notably
so in those with poor glycaemic control. In contrast to the observations of Northam, no
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differences in verbal IQ or FSIQ were observed in either gender and no detrimental effects of
severe hypoglycaemia on general intelligence were identified. Schoenle concluded that an early
onset of diabetes and poor metabolic control may be disadvantageous to current intellectual
performance in males. Despite these apparently reassuring negative findings with respect to
severe hypoglycaemia, it should be borne in mind that no participant in this Austrian cohort was
exposed to severe hypoglycaemia before the age of five years, again failing to test the hypothesis
that early life severe hypoglycaemia is particularly detrimental to the brain (Schoenle et ah,
2002).
The prospective studies summarised above strongly suggest that the development of diabetes in
early childhood may confer modest disadvantage on the acquisition of a broad range of
neuropsychological abilities, most notably attention, information processing speed, aspects of
memory abilities and executive functions. The cognitive disadvantage associated with childhood
exposure to severe hypoglycaemia appears to be more specific and may selectively affect the
attainment of verbal intelligence. The hypothesis that early life exposure to severe
hypoglycaemia, before the 6lh birthday, may be more deleterious than exposure in later childhood
remains unproven largely through the lack of severe hypoglycaemia exposure in early life of the
participants of the above studies.
63
3.6 NEUROIMAGING ASSOCIATIONS OF CHILDHOOD ONSET T1 DM
Ack and colleagues in 1961 proposed two major organic factors that could, at least in part,
account for the significantly poorer intellectual performance observed in children who had
developed diabetes before their 5th birthday: exposure to episodes of severe hypoglycaemia and
hyperglycaemic decompensations in the form of Diabetic Keto-Acidosis (Ack et al., 1961). The
neuroimaging associations of these acute metabolic decompensations have been described in case
reports and small cross-sectional studies and will be discussed separately as they appear to
differentially impact upon the central nervous system.
3.6.1 Neuroimaging Sequelae of Severe Hypoglycaemia in Childhood
No cases describing permanent hypoglycaemic brain damage with associated neuroimaging
abnormalities have been published in children and adolescents with Type 1 diabetes in the
mainstream medical literature, in contrast to the body of literature which exists in adults.
Whether this reflects reporting bias, difficulties in the practicalities of the neuroimaging of
children, the smaller absolute number of children with Type 1 diabetes relative to adults, or a
genuine reflection of a lesser propensity towards brain injury following severe hypoglycaemia in
this age group remains unclear. Christiaens and colleagues described a single case of
hypoglycaemic coma associated with the development of hemiparesis, expressive aphasia,
cognitive impairment and neuroimaging abnormalities in a non-diabetic 8 year old girl, rendered
comatose through hypoglycaemia in a Munchausen's by proxy case. Early CT imaging revealed
loss of the normal differentiation between gray and white matter and increased density of the left
cerebral hemisphere. Subsequent MRI revealed gross abnormalities of the entire left neocortex
on Proton Density/T2-weightcd sequences with sparing of the Basal Ganglia, Brain Stem and
Cerebellum and entire right cerebral hemisphere (Christiaens et al., 2003).
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3.6.2 Neuroimaging Sequelae of Diabetic Keto-Acidosis in Childhood
Diabetic Keto-Acidosis (DKA) remains the leading cause of death during childhood and
adolescence in people with Type 1 diabetes (Edge et al., 1999). In contrast to the paucity of
published evidence to support the hypothesis that episodes of severe hypoglycaemia during
childhood may adversely affect brain structure in children with Type 1 diabetes, a large number
of published case reports and several case series document the neuroimaging abnonnalities
associated with hyperglycaemic decompensation, as DKA. Children and adolescents with Type 1
diabetes are known to develop cerebral oedema more frequently and with modest degrees of
metabolic derangement during DKA relative to adults with T1DM. Cerebral oedema is said to
classically present 4-16 hours following the commencement of active treatment for DKA, with
intra-venous insulin and fluid resuscitation, and is heralded by the onset of confusion, localising
neurological signs or a reduction in the conscious level of the child (Edge et ah, 2006a;Figueroa
et ah, 2005). The development of clinically apparent cerebral oedema, which complicates
approximately 1% of childhood DKA cases (Edge et ah, 2006b;Roe et ah, 1996) is a poor
prognostic feature with a reported mortality of 24% and disability or developmental delay in 35%
of those who survive (Edge et ah, 2001). Due to the obvious propensity for neurological sequelae
in the acute phase of treatment ofDKA an extensive body of literature has accumulated. Krane et
al first reported subtle structural brain abnormalities in association with DKA in children. In a
small case series serial CT imaging of the brain was perfonned in neurologically asymptomatic
children with DKA: an initial image was acquired during the early phase of treatment with
intravenous fluids and insulin, with a follow up scan obtained around the time of discharge from
hospital. Krane identified temporal changes in the cross-sectional diameter of the cerebral
ventricles which were interpreted as reflecting a degree of sub-clinical brain swelling present
during the early stages of DKA treatment (Krane et ah, 1985). An alternative interpretation
would be that reductions in the diameter of the cerebral ventricles may represent partial collapse
of these structures consequent upon dehydration and reduced CSF volumes in untreated DKA,
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with re-expansion on the attainment of euvolaemia. Irrespective, these changes were observed in
children in whom no apparent neurological or cognitive deficit was apparent. Hoffman and
colleagues also utilised serial CT scans to evaluate the temporal evolution of brain structure
changes during the active treatment of DKA in nine children. Hoffman also observed smaller
volumes of the lateral and 3rd ventricles before treatment was commenced, relative to subsequent
scans obtained 6-8 hours later and at seven days following treatment (Hoffman et ah, 1988).
Again, the authors interpreted the smaller ventricular volumes observed at presentation as being
representative of sub-clinical brain swelling. Rogers et al described the ncuroimaging sequelae
observed in three non-fatal cases of DKA presenting between 1984-1987, each complicated by
neurological deterioration of the child. CT and MR1 scans obtained in these clinically more
severe cases revealed haemorrhagic infarction of the thalamus, basal ganglia and lcntiform nuclei
associated with permanent physical and developmental disabilities (Rogers et ah, 1990).
McAloon (McAloon et ah, 1990) and Greene (Greene et ah, 1990) reported similar CT
abnormalities and adverse developmental outcomes in a small number of cases of childhood
DKA complicated by neurological deterioration after the commencement of treatment. Lebrun
and colleagues subsequently reported the MRI associations of a case of hemiparesis as a
consequence of cerebral oedema in the setting ofDKA (Lebrun et ah, 1994). Roe et al reported
the neuroimaging and clinical associations observed in a retrospective series of 5 cases of DKA
complicated by neurological sequalae. Consistent with previous reports neuroimaging revealed
infarction in the region of the thalamus, basal ganglia and lentiform nuclei but also infarction of
the cingulate gyrus and occipital lobes were observed in some patients. Roe suggested that these
specific territories were vulnerable to infarction due to their dependency on perforator branches
of the major cerebral arteries for blood supply. The thalamus receives its vascular supply from
branches of the posterior cerebral artery, whereas the basal ganglia and lentiform nuclei receive
supply from the middle cerebral artery, yet each of these subcortical gray matter structures is
reliant on perforator branches for arterial supply (Roe et ah, 1996). Shrier reported a fatal case of
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cerebral oedema complicating DKA resulting in central brain herniation, infarction of the medial
temporal lobe structures and central brain atrophy in a nine year old girl (Shricr et al., 1999).
Hoffman utilised conventional MRI sequences to evaluate the neuroradiological appearances at
two time points in six children with DKA: initial scans revealed increased T2-weighted signal in
the cortex, which had resolved by the second scan on day 14. Hoffman also reported an increase
in the size of the lateral ventricles across the same time frame and interpreted this as being
secondary to the resolution of subclinical brain oedema which was compressing the ventricular
cavity on the initial scan (Hoffman et al., 1999). However, no evidence of cerebral oedema was
observed on the initial imaging and two other explanations could be offered: firstly, the
dehydration incumbent upon the development of DKA may reduce CSF production and hence
cerebro-ventricular volumes, or secondly, that the temporal increase in volume could reflect the
development of central brain atrophy. Neither of these alternative hypotheses were entertained by
the authors. Keane reported a case of venous sinus thrombosis of the straight sinus complicating
a case of DKA, where the child deteriorated following the commencement of replacement fluid
and insulin, resulting in characteristic appearances on CT imaging and a temporary hemiparesis
which resolved to leave mild learning difficulties (Keane et al., 2002). Cameron described the
serial MRI appearances observed in 5 cases of DKA in children in whom no signs of cerebral
oedema were clinically apparent and reported transient increases in signal on FLAIR and T2-
weighted sequences in the frontal lobes, which resolved over a period of days (Cameron et al.,
2005). Glaser utilised Diffusion (DWI) and Perfusion (PWI) Weighted neuroimaging techniques
in a small study of 14 children with DKA, obtaining images shortly after the initiation of
treatment and 48 hours later. Changes on DWI in the frontal, temporal and parietal cortices were
suggestive of vasogenic oedema in these areas. None of those children studied had concerning
features, inferring that sub-clinical vasogenic oedema may be more common than previously
considered (Glaser et al., 2004). Figueroa utilised multiple MRI sequences, which included
Diffusion Weighted (DWI) and T2-weightcd imaging, to examine the neuroradiological
67
associations of DKA in a small series of children. MRI scans were obtained at 6-12 hours and
repeated at 96 hours and revealed a transient increase in T2-weighted signals in cortical areas
which had resolved by the second scan. In contrast to the observations of Glaser, no DWI
abnormalities were observed inferring that oedema may not have been present (Figueroa et al.,
2005). Glaser used MR] methodologies to sequentially assess pre and post-treatment lateral
ventricular diameters in 41 children undergoing treatment for DKA. In keeping with the earlier
reports from Hoffman (Hoffman et al., 1988;Hoffman et al., 1999) an increase in the diameter of
the lateral ventricular cavity was observed following treatment of DKA, with 50% of children
exhibiting narrowing of the lateral ventricles during the early phase of DKA treatment. Glaser
interpreted this observation as being indicative of sub-clinical cerebral oedema in a considerably
greater proportion of children than was previously recognised (Glaser et al., 2006).
In summary, Diabetic Keto-Acidosis is frequently accompanied by measurable ncuroradiological
abnormalities even in asymptomatic children. DKA can be complicated by neurological
deterioration which is associated with a poor prognosis, subsequent developmental delay and
permanent neuroradiological abnormalities, most commonly as cerebral infarction in severe
cases. The pattern of brain injury differs significantly from that associated with hypoglycaemic
brain damage.
3.6.3 Prospective Studies
No studies have prospectively examined the neuroimaging correlates of Type 1 diabetes
diagnosed during childhood, with respect to evaluating the brain structural associations of
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4.1 BASICS OF NEUROIMAGING
4.1.1 Introduction to Magnetic Resonance Imaging
Magnetic resonance (MR) imaging generates images by applying a varying magnetic field to the
body, which aligns the hydrogen atoms of the tissue under evaluation in accordance with the
polarity of the applied magnetic field. When the field is released, radio waves are generated as
the polarised hydrogen atoms return to their resting state. The frequency of the emitted radio
waves is related to the chemical environment of the atoms as well as to their location. With
computer analysis of these data, MR images can be generated.
Magnetic Resonance imaging systems are formed from several key components. These include a
large magnet supplemented by shim coils to generate a sufficiently uniform powerful magnetic
field. A radiofrequency (RF) coil is used to transmit controlled radio signals into the body tissue
under evaluation. The characteristics of the transmitted radio signals are altered as they penetrate
tissues, according to the properties of each specific tissue, and such alterations are detected by the
receiver coil. Additional gradient coils assist in delineating the spatial localisation of the
returning radio signals, which are then computer integrated to generate reconstructed images for
interpretation by a radiologist. A major advantage ofMR techniques is the ability to alter radio
signal settings to selectively enhance and delineate intra-cranial tissues. With the notable
exception of bony structures most tissues within the skull vault can be outlined. This allows the
accurate definition of white matter, gray matter, cerebrospinal fluid, adipose tissue and their
interfaces, which facilitates volumetric analysis of specific tissue types. Alteration of the plane of
imaging can also be manipulated to the specific anatomical brain area being studied, allowing
regional brain areas to be outlined with a greater degree of accuracy than that permitted by
previous neuroimaging techniques.
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4.1.2 Alteration of Radio Signal Intensity and MR Sequences
Different image contrasts can be achieved by using specific RF pulse sequences and imaging
parameters. The basic signal intensity parameters that can influence imaging are:
Proton Density
The proton density (PD) of a tissue reflects the concentration of protons in the tissue, in the form
ofwater and contained within macromolecules.
T1 Relaxation Time
The T1 relaxation time reflects the longitudinal relaxation time taken by protons to revert back to
their resting states after exposure to an RF pulse.
T2 Relaxation Time
The T2 relaxation time reflects the transverse relaxation time taken by protons to revert back to
their resting states after exposure to an RF pulse.
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Blood Flow
Blood flow can affect signal acquisition as rapidly flowing arterial blood produces deficits in
signal. Exploitation of this characteristic underlies the development of specific sequences that
facilitate MR angiography techniques.
The contrast on MR images can be manipulated by changing the parameters which characterise a
pulse sequence. A pulse sequence defines the specific strength, number, timing and gradient of
the RF pulses applied to the body tissue under evaluation. The two most important parameters
are the repetition time (TR) and the echo time (TE). The TR is the time between consecutive 90
degree RF pulses. The TE is the time between the initial 90 degree RF pulse and the echo. Tl-
weightcd sequences use a short TR and short TE (TR < 1000msec, TE < 30msec). T2-weighted
sequences use a long TR and long TE (TR > 2000msec, TE > 80msec). T2-weighted sequences
can be employed as a dual echo sequence to further enhance the contrast between tissues of
interest. The first or shorter echo (TE < 30msec) is proton density-weighted, or a mixture of T1
and T2-weighted images. This image is very helpful for evaluating changes in the peri¬
ventricular white matter, such as those observed in demyelination or cerebral microangiopathy,
because hyperintense white matter lesions are contrasted against the lower signal observed in the
CSF. FLAIR (Fluid Attenuated Inversion Recovery) sequences are a further enhancement of the
basic PD imaging sequence. FLAIR images are a special inversion recovery sequence in which
the TI time is adjusted to match the relaxation time of the tissue whose image should be
suppressed. This sequence is an important technique used to differentiate lesion type within the
central nervous system.
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4.1.3 Magnetic Resonance Imaging of the Brain
Magnetic resonance (MR) imaging is an ideal modality for the imaging of brain structure, and has
several advantages over X-ray dependent technologies such as CT scanning. The advantages of
MR imaging include:
1. MR imaging does not involve the delivery of a dose of ionising radiation;
2. The imaging study can be tailored to the brain region of interest and to the disease process
being studied. Radio signal intensities observed on T-l, T-2, and proton density-weighted images
relate to specific characteristics of the tissues being evaluated.
Due to its high sensitivity for brain water, MR is generally more sensitive for detecting subtle
brain abnormalities, during the early stages of disease, than CT based techniques. In addition,
MR imaging is exquisitely sensitive for the detection of white matter changes, such as those
caused by demyelination and cerebral microvascular disease. Patients with substantial white
matter abnormalities on MR imaging may have an apparently normal CT scan.
4.2 STRUCTURAL BRAIN ABNORMALITIES
Two major types of structural brain abnormalities are commonly reported in neuroimaging
epidemiology studies: high-intensity white matter lesions and cerebral atrophy.
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4.2.1 Neuropathology of High Intensity White Matter Lesions
White matter lesions differ in their type, size, location within the brain, neuropathological
associations and hence prognosis.
Types of White Matter Lesions:
1. Peri-ventricular White Matter Lesions
Peri-ventricular White Matter Hyperintensities (PVWH) are abnormalities of the white matter,
located in the white matter adjacent to the lateral ventricles. PVWH vary in severity: early
punctate lesions and peri-ventricular rims or caps (mild); patchy white matter with early
confluence (moderate); large confluent white matter lesions (severe). Pathologically, early
punctate lesions are characterised by peri-vascular hyalinosis and do not appear to have the same
associations with stroke, myocardial infarction and vascular death associated with more advanced
lesions. Progression of PVWH appears proportional to lesion burden at baseline and data for the
effects of hypertension are inconsistent (De Leeuw et ah, 2001;Schmidt et ah, 1992;Schmidt et
ah, 2003). The neuropathological appearances of moderate PVWH are those of demyelination,
reactive gliosis without substantial changes in blood vessels, whereas severe PVWH, which are
associated with advancing age and hypertension, exhibit similar pathology but with the additional
features described with DWMH, as described below. The Rotterdam Scan Study suggested that
moderate to severe PVWH were more closely associated with cardiovascular risk factors rather
than DWMH (De Leeuw et ah, 2001).
2. Deep White Matter Lesions
Deep White Matter Hyperintensities (DWMH), also termed 'Leukoaraiosis', are typically located
adjacent to areas of cortical infarction or within the deep white matter. Epidemiological studies
have identified an association between DWMH and the subsequent risk of CVA and death from
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IHD (Launer, 2004). The presence of DWMH can be associated with cognitive impairment,
although this is generally noted for gross changes leading some experts to propose a "threshold"
effect, such that a certain cumulative white matter burden is required before cognition suffers.
Similar to PVWH, progression of DWMH appears proportional to lesion burden at baseline and
data for the effects of hypertension are inconsistent (De Leeuw et al., 2001;Schmidt et al.,
1992;Schmidt et al., 2003). The neuropathological appearances of DWMH reveal reduced
myelin and oligodendrocytes, reduced axonal density, axonal fragmentation and small blood
vessels show hyalinosis and variability of luminal cross-sectional diameter. The pathological
findings are consistent with focal microvascular ischaemia with reactive gliosis and
demyelination (Englund, 2002).
3. Small Punctate White Matter Lesions
Small Punctate White Matter Lesions (SPWML) are small hyperintense white matter
abnormalities, l-2mm in diameter, that can be observed throughout the entire brain, although are
most typically observed in the region of the Basal Ganglia and Centrum Semi-Ovale. The clinical
associations of SPWML appear less well characterised, relative to PVH and DWMH, but this
type of lesion is considered to be relatively benign abnormalities due to the lack of a strong
association with the subsequent risk of macrovascular disease in the few studies that have
assessed SPWML (Fazekas et al., 1991;Schmidt et al., 2003). The risk of progression to more
severe manifestations of white matter abnormalities appears small, at least in elderly populations
at high risk of cerebrovascular disease (Schmidt et al., 2003). Histologically, SPWML consist of
areas of focal demyelination and rarefaction of myelinated fibres with hyalinosis of small
arterioles (Fazekas et al., 1991). The peri-vascular appearance of SPWML share significant
commonality with the limited evidence from histological studies of the brain in Type 1 diabetes
(Reske-Nielsen and Lundbaek, 1963a).
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4.2.2 Epidemiology ofWhite Matter Lesions
White Matter Lesions are present within the brain from an early age, with their frequency being
partly dependent on the mode of neuroimaging utilised. CT imaging is relatively insensitive for
detecting white matter pathology, whereas MRI based techniques are more sensitive. MRI pulse
sequences also differ in their sensitivities in detecting of WML: T-l weighted images are
relatively insensitive, whereas sensitivity increases stepwise for Proton Density, T2-weighted,
FLAIR and DWI techniques. The type of sequence utilised therefore impacts upon the
epidemiological interpretation ofWML distribution and burden (Fazekas et al., 2002) as inter-
observer variability in the rating ofMRI scans (Wardlaw et ah, 2004).
WML are apparent on MRI scans from a relatively young age. The CAMERA study identified a
point prevalence of 42% in normal healthy adults aged 30-40 years, rising to 70% in those aged
50-65 years (Kruit et ah, 2004), whereas the ARIC study identified that 88% of 55 year olds had
some degree ofWML, increasing to 92% in 65 year olds (Liao et ah, 1997). The progressive rise
in WML incidence with age was confirmed by the large Rotterdam Scan Study of adults aged 60-
90 years in which 95% of participants had some degree of WML: WML incidence and burden
increased progressively with chronological age (De Leeuw et ah, 2001).
Risk Factors for WML:
1. Hypertension
The presence of hypertension appears to be the most important determinant of white matter
abnormalities in middle age and later life. The presence of hypertension, blood pressure
variability, isolated systolic hypertension (Liao et ah, 1996), or the development of Left
Ventricular Hypertrophy (De Leeuw et ah, 2001) as a consequence of hypertension are major risk
factors for white matter pathology. These factors are modified by the degree of anti-hypertensive
control and the presence of the APOE e4 allele; those with good anti-hypertensive control have
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fewerWML (Dufouil et al., 2001;Liao et al., 1996), whereas those with the e4 allele (De Leeuw
et al., 2004) appear to develop a greater WML burden when hypertensive. The degree of
hypertension also appears to influence the rate of progression ofWML (Schmidt et al., 2003).
2. Diabetes and WML
The development of microvascular complications of diabetes, particularly as diabetic retinopathy,
has been hypothesised as being a likely surrogate for the presence of intra-cerebral
microangiopathy elsewhere. However, little epidemiological evidence exists to support this
hypothesis. Of the major large scale population-based MRJ neuroimaging studies in middle-aged
and elderly subjects only the Cardiovascular Health Study (Manolio et al., 1999) identified an
association between the presence of Type 2 diabetes and WML. In Type 1 diabetes limited
neuroimaging data exist. In a smaller case-control study Dejgaard and colleagues described the
Magnetic Resonance neuroimaging correlates of the clinical complications of Type 1 diabetes a
long-duration T1DM group with extensive microangiopathy (n=16) and an age-matched healthy
control group (n=19) (Dejgaard et al., 1991a). The MRI techniques utilised by Dejgaard were
commensurate with the year of study and could be considered relatively insensitive compared to
current methodologies. White-matter lesions (69%) were significantly more common in the
microangiopathic group relative to healthy age-matched controls (12%), being distributed evenly
throughout the white matter of the cerebral hemispheres (as PVWH and DWMH), cerebellar
hemispheres and brain stem. WML were small in size, infrequent in number and modest at
worse. Dejgaard et al interpreted the higher prevalence of white-matter lesions observed in the
T1DM group as being indicative of the presence of intra-cranial microangiopathy, complicating
Type 1 diabetes, or alternatively as being indicative of small foci of ischaemia, known as
'Leukoaraiosis', as part of a subcortical arteriosclerotic encephalopathy (Dejgaard et al., 1991a).
Youssem compared the frequency of white-matter lesions in 25 adult patients with Type 1
diabetes complicated by proliferative diabetic retinopathy (severe retinopathy) relative to 10 age-
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matched healthy control subjects using MRJ techniques consisting of Tl-weighted and Proton
Density images. In contrast to the observations of Dejgaard, no white-matter lesions were
identified in any study participant and Youssem concluded that proliferative diabetic retinopathy
was not associated with white-matter pathology and that microangiopathy of the brain was
unlikely in T1DM (Yousem et al., 1991). Advances in MRI technology in the intervening years
since publication have since revealed that the imaging sequences utilised by Youssem are not
ideal for the determination and quantification ofwhite-matter changes, being insensitive to detect
subtle differences of the type that could be expected in young adults. Lunetta and co-workers
thereafter examined the MRI neuroimaging appearances (T1 and T2-weighted sequences) in a
small heterogeneous group of ten patients with Type 1 diabetes, who had relatively short diabetes
duration and varying degrees of microangiopathy. No mention of white-matter abnormalities
were discussed in the manuscript (Lunetta et al., 1994). The relationship between Type 1
diabetes and white matter lesions remains under evaluated at present with limited data inferring
that the prevalence of white matter change may be greater in those with T1DM complicated by
microangiopathy.
4.2.3 Neuropathology and Subtypes of Cerebral Atrophy
Cerebral atrophy is a hallmark ofmany of the diseases that affect the brain and reflects a loss of
neuronal bodies, their axonal interconnections, and their supporting glial cells. Atrophy can be
generalised, such that a symmetrical reduction in brain tissue volume occurs, or it can be focal,
affecting only a limited area of the brain and resulting in a decrease of the functions that area of
the brain controls. Additionally, cerebral atrophy is frequently subdivided into two types: Sulcal
atrophy with widening of the cerebral sulci; Ventricular atrophy with an increased cerebral
ventricle cavity size. The pattern and rate of progression of cerebral atrophy depends on the
underlying aetiological process. Potential aetiologies are multiple, the most common of which
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are vascular disease and Alzheimer's disease. Almost any pathological process that affects the
brain can result in a degree of brain atrophy.
4.2.4 Epidemiology of Cerebral Atrophy
Cerebral atrophy is most commonly associated with vascular disease (Mungas et al., 2001) and
Alzheimer's disease (Silbert et al., 2003) and its incidence rises progressively with age
(Longstreth, Jr. et al., 2000). The Atherosclerosis Risk In Communities (ARIC) study examined
the epidemiological associations of brain atrophy in a large sample of middle-aged individuals
and identified the independent predictors of cerebral atrophy. The sole independent predictors
included age and the presence of "diabetes": age increased the risk of subjectively-rated
Ventricular and Sulcal atrophy, whereas the presence of "diabetes" was independently associated
with Ventricular atrophy, such that a 63% increased risk of Ventricular atrophy was reported for
those with "diabetes", although the sub-type of diabetes (Type 1 or 2) was not further defined
(Knopman et al., 2005). The Cardiovascular Health Study, another large population-based
neuroimaging study which examined an older cohort (aged > 65 years), noted that age and gender
were significant predictors of subjectively-rated atrophy and that diabetes was associated with
Sulcal atrophy in women [1288]. The Framingham Offspring Study used volumetric analyses
and reported independent associations for age, smoking, diabetes, hypertension, the presence of
cardiovascular diseases and global cerebral atrophy (Seshadri et al., 2004). Schmidt and
colleagues reported a strong association between the presence of Type 2 diabetes, an interaction
with hypertension and cortical brain atrophy in a large cross-sectional study (Schmidt et al.,
2004).
In summary, the major risk factors for the development of brain atrophy appear to be advancing
age and factors associated with the development of vascular disease and their interaction: Type 2
diabetes, hypertension and cigarette smoking.
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4.3 CEREBRO-VASCULAR DISEASE IN T1 DM
4.3.1 Epidemiology of Cerebrovascular Disease in T1 DM
Relatively few studies have examined the relationship between Type 1 diabetes and the
subsequent risk of developing cerebral macrovascular disease. Alex et al (Alex et ah, 1962)
identified a higher prevalence of cerebro-vascular disease at post-mortem in those with juvenile-
type diabetes mellitus relative to controls and Grunnet and co-workers reported an earlier age of
onset of cerebro-vascular disease in subjects who had Type 1 diabetes mellitus (Grunnet, 1963),
both inferring that macrovascular disease of the cerebral circulation may be a significant
contributor to any central nervous system abnormalities observed in Type 1 diabetes, even in
chronologically young individuals. Krowelski et al suggested that the relative risk of developing
cerebro-vascular disease in people who have T1DM was approximately double that observed in
healthy age-matched controls (Krolewski et ah, 1977) Laing et al reported the mortality from
cerebrovascular disease in a very large cohort of 23,751 patients with T1DM recruited from the
UK and analysed over a median 17 year review period. Laing reported the Standardised
Mortality Rate (SMR) from cerebrovascular disease for the diabetes group relative to SMR from
the non-diabetic population: a significantly increased SMR for cerebrovascular death was
observed in all age groups of those with insulin-treated diabetes. Eighty deaths in the diabetes
group were attributed to cerebrovascular disease, reflecting 6% of deaths and 4% of deaths in the
under 40 years age group. Despite identifying SMR's as high as 7.6 for cerebrovascular deaths in
the 20-39 year age group, the absolute risk of cerebrovascular death was small at 12 deaths per
100,000 patient-years of follow up for the entire cohort, with considerably lower absolute risks in
those under the age of forty. The overall incidence of fatal cerebrovascular disease in this cohort
was extremely small, of the order of 0.37%, despite the analyses including participants up to the
age of 84 years (Laing et al., 2003).
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The Diabetes Control and Complications Trial (DCCT) compared the incidence of diabetes-
related complications in a large cohort of 1441 participants with T1DM who were of relatively
young age and largely free of co-morbid diseases. The DCCT evaluated the risks and benefits
two alternative insulin treatment strategies, "conventional" insulin treatment versus "intensified"
insulin treatment, the latter of which aimed to attain near normal glucose concentrations. Those
who were randomised to receive "intensified" insulin treatment had persistently better long-term
glucose control as determined by Glycosylated Haemoglobin (HbA|C) concentrations during the
6.5 years of study. The DCCT reported the incidence of new microvascular and macrovascular
complications in participants who were subdivided into a primary prevention cohort, who had no
evidence of complications of diabetes at entry into the study, and a secondary prevention cohort
in whom modest microvascular complications were already present. No cerebro-vascular events
occurred during the median 6.5 years of follow up in the DCCT in either the primary prevention
cohort, or the secondary prevention cohort, presumably as a consequence of the relatively young
age and modest complication burden of those studied (1995). The Epidemiology of Diabetes
Interventions and Complications (ED1C) study extended the evaluation of the participants of the
DCCT to a mean of duration of follow up of 17 years and reported the incidence of
macrovascular complications of T1DM: a total of 144 cardiovascular events occurred in 83
patients, with a significantly higher incidence of events reported in those initially allocated to the
"conventional" ann of the study, with 0.80 events per 100 patient-years observed as opposed to
0.38 events per 100 patient-years in the "intensive" group. Risk factors associated with the
development of macrovascular disease in the EDIC study included the traditional risk factors of
age, dyslipidaemia, obesity as well as diabetes-specific predictors such as the presence of
retinopathy, albuminuria and degree of glycaemic control (Nathan et al., 2005). The incidence of
cerebro-vascular events was low being recorded at 0.44%, of the EDIC cohort who had a mean
age of 45 years, consistent with previous observations that overt cerebro-vascular disease is
uncommon in young and middle-aged people with Type 1 diabetes.
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Fuller et al examined the risk factors for the development of macrovascular complications in 1260
individuals with Type 1 diabetes who participated in the World Health Organisation
Multinational Study of Vascular Disease in Diabetes (WHO MSVDD). Those studied were
middle-aged, had a long duration of diabetes and were evaluated over a 12 year period. Using a
Cox Proportional Hazards Model, the major independent clinical risk factors for fatal and non¬
fatal cerebrovascular events were the presence of isolated systolic hypertension and proteinuria,
present as either microalbuminuria or dipstick positive proteinuria. Other microvascular
complication of Type 1 diabetes, such as retinopathy or peripheral neuropathy, did not
independently predict the occurrence of overt cerebrovascular disease (Fuller et al., 2001).
Klein and colleagues reported the incidence of cerebrovascular disease in 996 participants of the
Wisconsin Epidemiologic Study of Diabetic Retinopathy over a 20 year follow up period . Those
studied had T1DM of long duration and at baseline 36% were aged 20-45 years, with half of the
cohort aged greater than 50 years. At the 20 year follow up 5.9% of the entire study cohort had
overt cerebrovascular disease, although the incidence was only 1.3% in those aged less than 40
years at the time of follow up. Cerebrovascular disease was significantly more prevalent in older
participants, especially those with poorly-controlled diabetes, diabetes of long duration, essential
hypertension or a wide pulse pressure. Those with microvascular complications of diabetes had a
greater incidence of cerebrovascular disease, with the severity of diabetic retinopathy being
correlated to the incidence of cerebrovascular disease: those with proliferative diabetic
retinopathy were at particularly elevated risk.
Davis and colleagues reported the incidence of new clinically apparent cerebro-vascular events,
for fatal and non-fatal cerebrovascular disease, in 126 patients with Type 1 diabetes evaluated
over a median duration of follow up of 7.2 years in the Freemantle Diabetes Study. Six new
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cerebrovascular events occurred within the period of follow up of which 5 were thrombotic
strokes. Cerebro-vascular events were uncommon with an estimated incidence of 7.0 per 100,000
person years of follow up and tended to occur in middle-aged participants known to have
essential hypertension, or who were receiving treatment with anti-hypertensive medications. The
only independent predictor of incident cerebro-vascular disease was a low HDL concentration at
baseline, although treated hypertension may mask any effect of essential hypertension in this
study (Davis et al., 2005).
In a meta-analysis exploring the relationship between degree of glycaemic control and risk of
macrovascular disease Stettler and colleagues evaluated eight studies in people with Type 1
diabetes (Stettler et ah, 2006). Despite including 1800 patients and reporting observations over
11,293 person-years of follow up only six cerebrovascular events occurred in the eight studies
included for meta-analysis. The finding from this meta-analysis, although heavily influenced by
the DCCT cohort, confirm that the incidence of clinically apparent cerebrovascular disease is
very low, at least in the studies of younger adults up to an approximate age of 50 years which
were included in the meta-analysis (Stettler et ah, 2006).
In summary, the incidence, prevalence and absolute risk of clinically apparent fatal and non-fatal
cerebrovascular disease appears to be very low in Type 1 diabetes, particularly those aged less
than 50 years. Despite this low absolute risk, the relative risk of cerebrovascular disease in
T1DM approximates double that observed in the non-diabetic population.
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4.4 Neuroimaging Studies of Cerebral Macrovascular Disease in T1DM
4.4.1 Case Studies
Bellassoued et al described a case where the acute onset of hemiballism occurred in a 26 year old
male with T1DM of 13 years duration, complicated by advanced microvascular manifest as
proliferative retinopathy, peripheral neuropathy and diabetic nephropathy. Infarction of the
Caudate Nucleus and anterior part of the Putamen was confirmed with neuroimaging, utilising CT
and MRI techniques. Bellassoucd concluded that advanced microvascular complications may be
associated with similar disease affecting the lenticulo-striatal arteries which provide the arterial
supply to the Caudate Nucleus (Bellassoued et al., 2001). No other case reports appear to have
been published to assist in identifying which territories of the intra-cranial vasculature appear
most vulnerable to macrovascular disease in those with T1 DM.
4.4.2 Cross-Sectional Studies
No neuroimaging studies have aimed to determine the prevalence of the structural correlates of
cerebrovascular disease in people with Type 1 diabetes relative to controls. In particular, the
prevalence of silent cerebrovascular disease in Type 1 diabetes mellitus is not known.
4.4.3 Prospective Studies
No studies have prospectively examined the radiological neurovascular associations of Type 1
diabetes.
4.5 MICROVASCULAR DISEASE IN TYPE 1 DIABETES
The microangiopathic complications of Type l diabetes have long been recognised to have a
predilection for the retinal circulation, the vasa nervosum which provide the arterial supply to
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peripheral nerves, and the renal microvasculature contributing to the respective development of
Diabetic Retinopathy, Peripheral Neuropathy and Diabetic Nephropathy.
4.5.1 Epidemiology of Microvascular Disease in T1DM
The Diabetes Control and Complications Trial (DCCT) showed that the cumulative lifetime
exposure to hyperglycaemia, as measured by the Glycosylated Haemoglobin (HbAic)
concentration, was the principal detenninant of the risk for the development of microangiopathy
in Type 1 diabetes (The DCCT Investigators, 2002), and that any degree of hyperglycaemia
above the normal biological range was associated with an increased relative risk of
microangiopathy, e.g. The relative risk of retinopathy increases by 39% for every 1% rise in the
HbAjc above the nonnal reference range (The DCCT Investigators, 1996). The lack of a
glycaemic threshold above normality beneath which microvascular complications could be
prevented was first identified by the EURODIAB research group (Chaturvedi et ah, 2001), and
thereafter confirmed by the DCCT investigators (The DCCT Investigators, 1996). The DCCT
compared two insulin treatments strategies, "intensive" and "conventional" insulin therapy, which
achieved a 1.8% mean difference in the HbAic concentrations across the study. This
improvement in glycaemic control was associated with substantial benefits for those in the
"intensive" treatment group. In the Primary Prevention subgroup the incidence of diabetic
retinopathy was reduced by 76%, microalbuminuria by 39% and neuropathy by 69%. The
progression of diabetic microangiopathy was retarded by "intensive" insulin treatment in the
Secondary Prevention subgroup: progression of retinopathy was reduced by 54%, progression to
albuminuria was reduced by 56% and neuropathy by 57%. However, despite the strict glycaemic
control attained in the DCCT microangiopathy still developed in a significant proportion of
participants such that 24% of the "intensive" group had developed Retinopathy and 23% early
Diabetic Nephropathy (as microalbuminuria) by 9 years of follow-up (The DCCT Investigators,
2000a). However, despite the DCCT/EDIC study clearly demonstrating clinically meaningful
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reductions in the incidence and severity of microangiopathic complications and lasting benefits
associated with the period of "intensive" treatment during the DCCT study, the most recent paper
from the EDIC cohort published highlights the relative inevitability of diabetic microangiopathy
in Type 1 diabetes: 89% of the "intensive" treatment group had evidence of Diabetic Retinopathy
relative to 97% of the "conventional" group after 18 years of follow-up (Jacobson et al., 2007).
This observation is entirely consistent with the earlier observations of the Pittsburgh
Epidemiology of Diabetes Complications Study which prospectively evaluated a cohort of 657
subjects with T1DM and identified that almost all participants has at least some degree of
Diabetic Retinopathy after 14 years (Orchard et al., 1990). Orchard attempted to quantify the
degree of cumulative exposure necessary for the development of clinically detectable
microvascular complications in 353 young adults with Type 1 diabetes of long duration,
sequentially evaluated over a six year period in the Pittsburgh Epidemiology of Diabetes
Complications Study. Orchard identified that an increasing burden of glycaemic exposure,
defined in terms of HbA,c months, was associated with the sequential development of clinical
microangiopathic complications, such that early Background Diabetic Retinopathy was the first
manifestation, followed by Proliferative Diabetic Retinopathy, thereafter by early Diabetic
Nephropathy (microalbuminuria), overt proteinuria and eventually Peripheral Neuropathy as the
cumulative hyperglycaemic burden increased. The observations of Orchard et al infer that the
development of Diabetic Retinopathy is the first clinically detectable manifestation of
microangiopathy, reflecting a lesser cumulative glycaemic burden than that necessary for the
development of other microvascular complications ofT1DM (Orchard et al., 1997).
4.5.2 Aetiology and Pathogenesis of Microangiopathy
As was clearly demonstrated by the DCCT, the principal driver for the development of
microvascular complications in Type 1 diabetes is cumulative hyperglycaemia exposure, such
that the degree of glycaemic control and duration of disease are important clinical factors.
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Hyperglycacmia appears to be the fundamental risk factor for microangiopathy and the attainment
of near normoglycaemia dramatically retards, but does not completely abolish the development of
clinically detectable microangiopathy (1996). The importance of hyperglycaemia in the
pathogenesis of microangiopathy is demonstrated by the Primary Prevention Cohort of the
DDCT: maintenance of strict glycaemic control, equivalent to a Glycosylated Haemoglobin
(HbAic) concentration of 7.5% or less, reduced the incidence of new cases of diabetic retinopathy
by 76% over a mean duration of review of 6.5 years. However, despite the attainment of strict
glycaemic control in the DCCT "intensive" group, microangiopathy still developed in some
participants, inferring either that degree of glycaemic control attained during the DCCT was
insufficiently strict to nonnalise microvascular function, or that factors other than hyperglycaemia
per se may also influence the susceptibility to and progression of microangiopathy. The former
assertion is supported by epidemiological evidence from the EURODIAB (Chaturvedi et ah,
2001) and DCCT cohorts (1996). A brief overview of the sub-cellular mechanisms thought to
underpin the effects of hyperglycaemia and an introduction to the effects of other potential factors
is provided subsequently.
4.5.3 Hyperglycaemia and the Development of Microangiopathy
Exposure of the cell to intermittent hyperglycaemia results in a sequence of alterations of cellular
metabolism, some of which may predispose to diabetic microangiopathy. Metabolic alterations
induced by hyperglycaemia which have been implicated in the pathogenesis of diabetic
microangiopathy include alterations in the cellular NADH/NAD ratio, the accumulation of
Sorbitol accumulation via overactivity of the Aldose-Reductase Pathway, intra-cellular




D-Glucose can be metabolised to Sorbitol catalysed by the enzyme Aldose Reductase, the rate of
which is determined primarily by the prevailing cellular concentration of substrate, D-Glucose,
such that during hyperglycaemia Sorbitol synthesis is accelerated.
Figure 4.1. The Polyol Pathway.
In some tissues Sorbitol is further metabolised to D-Fructose, catalysed by the enzyme Sorbitol
dehydrogenase, an energy requiring reaction which consumes NAD+. Sorbitol does not easily
cross cell membranes and accumulation within the cell predisposes to cellular damage through
osmotic swelling of the cell, or through altering the NADH/NAD4 ratio which results in a degree
of cellular energy depletion similar in pattern to that observed during hypoxia-ischacmia. The
intra-cellular accumulation of Sorbitol also has detrimental effects on Myoinositol metabolism.
Despite there being considerable evidence in laboratory animals of the importance of the Aldose
Reductase pathway in the pathogenesis of diabetic microangiopathy, the evidence in humans is
lacking. Trials of Aldose Reductase inhibitors, which potently inhibit hyperglycaemia-induced
cellular Sorbitol accumulation, have failed to reveal any clinically meaningful benefits in human
studies of neuropathy and retinopathy despite earlier work in animal models which inferred the
potential for clinical utility (Chung and Chung, 2005).




The majority of Myoinositol is derived from dietary intake and is present in high intra-cellular
concentrations, with considerably lower extra-cellular concentrations. Myoinositol is the
precursor for Phoshotidylinositol, an important regulator of the cellular membrane Na+-K+-
ATPase via a signalling pathway which also involves Diacylglycerol and Protein Kinase C. The
cellular membrane Na+-K+-ATPase regulates intra-cellular Sodium and Potassium concentrations
and maintains the gradient of these ions between the intra-cellular and extra-cellular
compartments. The accumulation of intra-cellular Sorbitol during hyperglycaemia inhibits the
entry of Myinositol into cells and can produce relative intra-cellular Myoinositol depletion. This
deficiency reduces membrane Na+-K+-ATPase activity, promoting the intra-cellular retention of
Sodium and interfering with the generation of action potentials, the most notable effect of which
is to slow peripheral nerve conduction velocities. The effects of Myoinositol depletion on the
neurophysiology of central nervous system neurones remains poorly defined (Chung and Chung,
2005).
Protein Kinase C
Protein Kinase C (PKC) is a ubiquitous cellular enzyme and one of a large super-family of serine-
threonine kinases. PKC is known to have at least 12 protein isoforms, the expression of which is
tissue-specific and tightly regulated. Physiological activators of PKC include specific hormonal,
neuronal and growth factor stimuli. However, intra-cellular hyperglycaemia through an indirect
effect which increases Diacylglycerol concentrations can result in increased activation of some
PKC isoforms in specific cell types. In particular, increased activity of the PKC isoforms (3 and 5
have been implicated in the development of a pro-microangiopathic state through at least three
separate mechanistic pathways. Firstly, activation of the p and 5 isoforms of PKC induces the
expression of Transforming Growth Factor p (TGFP), the net effect of which is increased
synthesis of extracellular matrix and thickening of the cellular basement membrane. Secondly,
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PKC activates NADPH oxidase which leads to the production of oxygen free radicals and
resultant tissue oxidative stress. Thirdly, PKC activation appears to inhibit Nitric Oxide
synthesis, a potent vasodilator and determinant of vascular smooth muscle relaxation, resulting in
a degree of microvascular hypertension and endothelial dysfunction (Tooke et al., 1996). The
development of basement membrane dysfunction and permeability, oxidative stress and
endothelial dysfunction appear to be integral factors in the development of diabetic
microangiopathy (Williams, 2006). In rodent models Ruboxistaurin, a potent of inhibitor of the
PKC isoforms implicated in the pathogenesis of diabetic microangiopathy, has been shown to
substantially reduce many of the histological abnormalities characteristic of diabetic
microangiopathy. Studies in the setting of human diabetic nephropathy are underway but clinical
trials of PKC inhibition in diabetic retinopathy have shown modest beneficial effects at best
(Williams, 2006).
Advanced Glycosylation End-Products
Glucose is able to become non-enzymatically attached to the amino acid side chains of proteins,
the rate of which is determined by the ambient glucose concentration. During hyperglycaemia
this non-enzymatic glycosylation is accelerated and initially results in the formation of potentially
reversible intermediate products, tenned Schiff bases, which then undergo rearrangement in the
setting of continuing hyperglycaemia to form more stable glycation products, known as Amadori
products. This process is identical to that which is responsible for the non-enzymatic
glycosylation of Haemoglobin, to form Glycated Haemoglobin (HbA|C), which is presently
accepted as the gold-standard surrogate measure of glycaemic exposure over preceding weeks.
Non-enzymatic glycosylation of proteins affects many protein sub-classes across many tissues
and such glycation may interfere with functionality. In the face of chronic hyperglycaemia,
Amadori products can form irreversible glycosylated protein structures called Advanced
Glycation End-Products (AGE), through the fonnation of glucose-derived cross-links with other
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glycosylated proteins. Such AGE's cannot be enzymatically degraded and accumulate in affected
tissues. AGE accumulation is particularly notable in proteins with a long lifespan such as those
present in the skin and connective tissues, including the basement membrane and adventitia of
blood vessels. Accumulation of AGE within these sites can interfere with the normal synthesis,
metabolism and enzymatic degradation of cellular and extracellular proteins, thereby affecting
their functional characteristics. In blood vessels and capillaries AGE accumulation promotes
thickening of the basement membrane and altered membrane permeability, which is one
characteristic of diabetic microangiopathy. Circulating AGE also have the ability to bind to
receptors for AGE (RAGE) which are expressed on endothelial cells, macrophages, renal
mesangial cells and other cell types. Activation of RAGE receptors modulates the behaviour of
target cell types, promote the release of vasoactive factors, cytokines and growth factors, all of
which can modify microvascular function, membrane permeability and induce cellular
proliferation in a disadvantageous manner (Williams, 2006). The clinical relevance of the tissue
accumulation of AGE was first demonstrated by Schalkwijk and colleagues who reported an
independent association between the concentration of circulating AGE-Albumin and the
development of diabetic retinopathy and microalbuminuria in the 447 T1DM participants of the
EUCLID study (Schalkwijk et ah, 2002). The DCCT investigators confirmed the potential
clinical utility of AGE in T1DM: baseline concentrations of skin glycosylation products, notably
as Furosine (AGE-Collagen) predicted the 10-year risk of developing diabetic retinopathy or
nephropathy with considerably greater accuracy than that predicted by the presently accepted
gold-standard methodology for assessing cumulative glycaemic exposure, the glycated
haemoglobin, HbAlc (Genuth et ah, 2005). The effects on microangiopathy of inhibitors of
glycation, AGE cross-link breakers and other modifiers of AGE biology are presently under
evaluation in laboratory animals and the clinical efficacy of such compound remains untested.
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4.5.4 Factors other than Hyperglycaemia
Apart from cumulative exposure to hyperglycaemia, which explains the majority of variance
observed in the development of microangiopathy, other factors appear to play a role of lesser
importance. These factors may increase the vulnerability to developing microangiopathy, or
alternatively, may accelerate the progression of established microvascular disease. This section
will briefly review those factors of relevance, with a particular focus on their impact upon
diabetic retinopathy, which is a potential surrogate marker for the presence of intra-cranial
microangiopathy.
Essential Hypertension and Microangiopathy
Hypertension is itself an independent risk factor for the de novo development ofmicroangiopathy,
independent of any disturbances of glucose tolerance. Hypertensive retinopathy, the development
of microvascular abnormalities of the retinal circulation, is a common complication of untreated
essential hypertension. Hypertension causes progressive abnormalities of the retinal
microvasculature which are graded by severity using the Keith-Wagner Scale (Dodson et al.,
1996). Clinically these microvascular changes are manifest as Silver Wiring of arterioles (Grade
1 retinopathy), Arterio-Venous Nipping (Grade 2 retinopathy), breakdown of the blood-retinal
barrier to produce flame-shaped intra-retinal haemorrhages, lipid leakage termed as 'hard
exudates' and ischaemia of the nerve fibre layer known as 'soft exudates' (Grade 3 retinopathy).
The most severe degree of hypertensive retinopathy is associated with the development of
cerebral oedema and ischaemia of the optic nerve head to produce papilledema (Grade 4
hypertensive retinopathy). These abnormalities are commonly observed in the non-diabetic
population over the age of 40 years, with a reported prevalence range from 2-14% in
epidemiological studies (Wong and Mitchell, 2007). In addition, the presence of hypertensive
retinopathy increases Stroke risk two to four-fold, after adjustment for confounding effects of
diabetes, age, blood pressure and hyperlipidaemia, strongly supporting the concept that
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hypertensive retinopathy is a marker for microangiopathy elsewhere in the brain (Wong and
Mitchell, 2007). Furthermore, the presence of hypertensive retinopathy is a marker of generalised
target organ hypertensive damage being associated with the presence of microalbuminuria, renal
impairment and left ventricular hypertrophy in Type 1 diabetes (Chaturvedi et ah, 2001).
In addition to its de novo effects on the microvascular circulation, essential hypertension appears
to accelerate the rate of progression of diabetic microvascular disease. The EUCLID study
examined the effects of the Angiotensin-Converting Enzyme Inhibitor (ACEI) in a double-blind
placebo-controlled study of the incidence and progression of diabetic retinopathy and
nephropathy in a population with T1DM, 15% of whom had early nephropathy in the fonn of
microalbuminuria. The EUCLID study identified that treatment with the blood pressure lowering
ACEI was independently associated with a statistically significant 50% reduction in the
progression of diabetic retinopathy or the development of proliferative diabetic retinopathy, as
defined by the use of a standardised grading system (Chaturvedi et al., 1998). Klein et al in the
14 year report from the Wisconsin Epidemiology of Diabetic Retinopathy Study identified
hypertension as a clinically significant factor in the progression to proliferative retinopathy
[(Klein et al., 2003).
Dyslipidaemia and Microangiopathy
Limited data exist which address the relationship between dyslipidaemia and the development of
microvascular complications. In a large cross-sectional cohort of 1362 subjects with T1DM from
the EURODIAB study, Karamanos observed significant differences in the fasting lipid profiles of
those with microangiopathy relative to those free of microangiopathy: the presence of
microangiopathy was associated with lower HDL-cholesteroI and higher Triglyceride
concentrations (Karamanos et al., 2000). The EURODIAB group also identified a modest
independent association between fasting hypertriglyceridaemia, defined as triglycerides >
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1.7mmol/L, and the prospective development of retinopathy in a cohort of 764 T1DM
participants evaluated over a 7 year period (Chaturvedi et al., 2001): the relative risk of
retinopathy was 24 % greater in those with baseline hypertriglyceridaemia. Thomas and
colleagues reported similar associations between an adverse lipid profile and the progression of
diabetic nephropathy in a prospective study of 152 individuals with T1DM (Thomas et al., 2006).
In a more detailed analysis of lipid sub-fractions and their relationship to the development of
diabetic retinopathy, the DCCT/EDIC investigators reported a similar association between
hypertriglyceridaemia and a low HDL-cholesterol in a study of 988 subjects with T1DM but also
identified the presence small dense LDL particles, small dense HDL particles and
Apolipoprotein-B concentrations as independent predictors of the presence and severity of
diabetic retinopathy. Epidemiological data appear to suggest that a pro-atherogenic lipid profile
may also be disadvantageous to the microvascular circulation, in addition to the well described
effects of such a lipid profile on the risk of macrovascular disease. This has led to the hypothesis
that lipid-lowering drugs may have the potential to reduce the incidence diabetic microangiopathy
(Leiter, 2005) a hypothesis which has not as of yet been formally tested.
Pregnancy and Microangiopathy
The association between pregnancy and the potential for rapid progression of diabetic retinopathy
has been common clinical knowledge for decades. The DCCT investigators confirmed this
supposition in a sub-study of 270 women who became pregnant during their participation relative
to 500 female controls who did not: a tripling of the risk of clinically meaningful progression of
retinopathy was observed in pregnant women, but longer term follow up indicated that the risks
conferred by pregnancy were transient, rapidly returning to baseline risk within the first post¬
partum year. Despite accelerated progression of retinopathy during pregnancy no long-term
negative impact on visual function was observed, perhaps relating to the careful ophthalmological
care provided. Pregnancy therefore appears to be a state which may significantly accelerate pre-
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existing retinopathy or promote the development of early retinopathy in those without any
existing retinopathy (2000b).
Smoking and Microangiopathy
Smoking is known to adversely affect vascular biology [(Lehr, 2000) and the accumulation of
AGE is greater in smokers (Nicholl et ah, 1998), factors which could potentially influence the
development and rate of progression of microvascular complications. Reichard reported an
association between smoking and the progression ofmicrovascular complication of T1DM in the
96 participants of the Stockholm Diabetes Intervention Study (Reichard, 1992). The EURODIAB
group identified that microvascular complications, as retinopathy and microalbuminuria, were
more prevalent in smokers relative to non-smokers with Type 1 diabetes (Chaturvedi et al., 2001)
and demonstrated that smoking independently predicted the development of early retinopathy in
T1DM (Karamanos et al., 2000). Chase et al evaluated the impact of smoking on the
development and progression of microangiopathy in T1DM and identified an association between
cigarette smoking and a higher prevalence of diabetic retinopathy, microalbuminuria (an early
manifestation of diabetic nephropathy) and the rate of progression of these complications.
Following multivariate adjustment for the potential confounding effects of age, glycaemic
control, blood pressure and gender the detrimental influence of smoking persisted with respect to
the deterioration of diabetic nephropathy but no significant effect on retinopathy progression was
apparent (Chase et al., 1991). However, these findings conflict with the observations of the
EURODIAB group who found no independent association between cigarette smoking and the
progression of diabetic nephropathy in a 7 year prospective evaluation of 532 subjects with
T1DM complicated by microalbuminuria (Giorgino et al., 2004). Data which have evaluated the
relationship between diabetic retinopathy and cigarette smoking are contradictory and the case for
a definitive detrimental appears unproven.
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Genetic Polymorphisms and Diabetic Retinopathy
Genetic susceptibility to the development of diabetic retinopathy has been described but the
associations identified between potential candidate genes studied and the development or
progression of retinopathy have been statistically weak and often not replicated by other studies
(Warpeha and Chakravarthy, 2003). The association between diabetic retinopathy and
polymorphisms of the following genes have been examined. Studies have reported weakly
positive associations between polymorphisms of the HLA genes and the Immunogloblin-G gene
and retinopathy in T1DM, whereas mixed findings have been reported in association with
polymorphisms of the promoter region of the Aldose Reductase gene. No associations between
diabetic retinopathy were reported in association with polymorphisms of the GLUT-1,
Plasminogen-Activator-1 Apolipoprotein-E, Type IV Collagen, Angiotensin Converting Enzyme,
Nitric Oxide Synthase or Endothelin-1 genes (Warpeha and Chakravarthy, 2003).
4.6 DIABETIC RETINOPATHY
The retinal circulation, although technically extra-cranial in site, is derived from the Ophthalmic
Artery, a terminal branch artery of the Middle Cerebral Artery. The retinal circulation therefore
shares embryological commonality with the remainder of the intra-cranial vasculature which
fostered the hypothesis that the presence of diabetic retinopathy may be a marker for
microangiopathy elsewhere within the cerebral brain. Diabetic retinopathy varies in its clinical
severity and is formally categorised from the most minor changes termed "Background Diabetic
Retinopathy" (BDR) through to "End-Stage Diabetic Eye Disease". The progression from the
early changes of BDR through to more advanced degrees of sight-threatening retinopathy tend to
occur in a stepwise manner, driven predominantly by hyperglycaemia (2000a), although essential
hypertension (Klein et al., 2003), pregnancy (2000b), and perhaps smoking (Reichard, 1992)
appear to accelerate the rate of progression. Counter intuitively, sudden improvements in
glycaemic control have also been long recognised to have the potential to accelerate diabetic
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retinopathy. This supposition was confirmed by the DCCT investigators (1998) and may account
for at least part of the negative consequences of pregnancy on retinopathy progression. Genetic
polymorphisms have been posited as potential mediators and could be of some influence,
although studies to date have not identified any association which appears to have more than a
minor influence on the development or progression of diabetic retinopathy (Warpeha and
Chakravarthy, 2003).
4.6.1 Grading the Severity of Diabetic Retinopathy
The most widely accepted grading system for the epidemiological study of diabetic retinopathy is
the modified Airlie House Grading system (1991). The development and progression of Diabetic
Retinopathy is primarily determined by cumulative glycaemic exposure and the prevailing degree
of glycacmic control, as determined by the Glycated Haemoglobin concentration (HbA]c) (The
DCCT Investigators 2000a; The DCCT Investigators, 2002). The accepted gradings of severity
of Diabetic Retinopathy are:
1. Background Diabetic Retinopathy
Characterised by the presence of two or more microaneurysms in at least one eye as a minimum
diagnostic criteria, often with scattered areas of exudation, superficial retinal haemorrhages,
minor venous changes and occasionally areas of focal retinal ischaemia, present as 'Cotton Wool
Spots', ofwhich no more than 5 lesions are present.
2. Pre-Proliferative Retinopathy
Pre-proliferative Diabetic Retinopathy has all of the features of Background Retinopathy but with
additional features which are indicative of severe retinal ischaemia. These include the presence
of Intra-Retinal Microvascular Abnormalities (IRMA), the presence of deep intra-retinal
haemorrhages termed Cluster Haemorrhages, > 5 Cotton Wool Spots and the development of
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venous changes. Venous changes are particularly pathognomic of severe retinal ischaemia and
are characterised by venous beading (irregular sausage-like irregularities of luminal diameter),
venous dilatation or venous reduplication.
3. Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy is characterised by the development of fragile new blood
vessels, formed in the environment of a severely ischaemic retina. These new vessels have a
propensity to bleed spontaneously to produce pre-retinal or vitreous haemorrhage, with the
subsequent risk of visual loss and retinal detachment.
4. End-Stage Diabetic Eye Disease
The most advanced stage of diabetic eye disease is characterised by Retinal Detachment, Vitreous
Heamorrhages, Neovascular Glaucoma and blindness.
4.6.2 Neuropathologies! Studies of Cerebral Microangiopathy
For many years the cerebral circulation was thought to be resistant to the development of diabetic
microangiopathy and to this day very little is known with respect to the histological effects of
Type 1 diabetes on the human brain. DeJong and colleagues had reported the presence of
multiple cerebral abnormalities, observed at post-mortem in a young patient with long-duration
Type 1 diabetes, which were not consistent with the pattern of hypoglycaemia-related
neuropathological damage previously described by Baker (1939) and Lawrence (1942), and
further explored by Lawrence in 1952 (DeJong, 1977;Reske-Nielsen and Lundbaek, 1963b). In
1963 Reske-Neilsen and colleagues reported the cerebral histological abnonnalities observed in
an autopsy study of three young patients with Type 1 diabetes. The same research group
thereafter perfonned a more detailed examination of the neuropathological consequences of
"juvenile-type diabetes" and its associated clinical complications in a larger post-mortem series of
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16 patients and observed gross pathological abnormalities affecting gray-matter, white-matter and
the lepto-meninges which were co-existent with multiple histopathological abnormalities. These
histological changes included changes in the structure of the cerebral microvessels where
hyalinosis of vessel walls, thickening of the capillary basement membrane and increased peri¬
vascular connective tissue was observed, in keeping with the microscopic findings associated
with diabetic microangiopathy in other tissues, inferring that the cerebral circulation may also be
vulnerable to microangiopathy in T1DM. However, in addition to advanced microangiopathic
complications the cohort evaluated by Reske-Nielsen had other extensive co-morbidity including
previous exposure to severe hypoglycaemia, hypertension, chronic renal failure and clinically
manifest psychiatric symptomatology. The post-mortem observations could not be directly
correlated to the presence of any particular clinical complications of Type 1 diabetes and Reske-
Nielsen and colleagues concluded that multiple different pathogenic factors may be responsible
for the gross changes described at autopsy (Reske-Nielsen and Lundbaek, 1963b). Since this
report, published in excess of 40 years ago, no other histo-pathological analysis of the effects of
Type 1 diabetes on the cerebral circulation has been published in the main stream medical
literature.
4.6.3 Neuroimaging Associations of Retinal Microangiopathy
In disease states other than diabetes, the presence of retinopathy, defined as pathological changes
in the vessels of the retinal microcirculation, is associated with the presence ofmicroangiopathy
of the cerebral circulation. Mitchell and colleagues evaluated the relationship between retinal
markers of microvascular disease, present as microaneurysms or retinal haemorrhages, in a non-
diabetic elderly cohort and reported an association with the incidence and mortality from
cerebrovascular disease (Mitchell et ah, 2005). This has been best described in essential
hypertension where the presence of hypertensive retinopathy is associated with the presence of
high-intensity white matter lesions and their rate of progression (Ikram et ah, 2006). In a study of
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elderly subjects, Longstreth and colleagues reported a higher incidence of white matter lesions
observed on MRI in those with retinal small vessel disease, interpreting the presence ofWML as
being indicative of cerebral microvascular disease (Longstreth, Jr. et al., 2007). Wong and
colleagues reported the neuroimaging associations of the presence of retinal microvascular
abnormalities in a middle-aged and elderly cohort of 1684 healthy individuals participating in the
Atherosclerosis Risk In Communities (ARIC) study: those with retinopathy exhibited greater
degrees of sulcal and ventricular atrophy (Wong et al., 2003) and also had a significantly higher
prevalence of high-intensity lesions of the cerebral white matter [(Wong et ah, 2002). The ARIC
study included some participants with diabetes, predominantly as Type 2 diabetes, but the
relationship between retinopathy and structural brain abnormalities persisted following statistical
adjustment for diabetes. Wong concluded that the presence of retinal microangiopathy was
indicative of microangiopathy of the brain, a conclusion supported by the higher incidence of
stroke subsequently observed in the prospective arm of the ARIC study in those who had
retinopathy at baseline (Wong et ah, 2002). In keeping with this observation, Inoue and
colleagues reported an independent association between the presence of retinopathy and lacunar
infarcts, in a middle-aged to elderly cohort some of whom had Type 2 diabetes (Inoue et ah,
1996). The Wisconsin Epidemiologic Study of Diabetic Complications reported an increased
incidence of cerebrovascular episodes in association with the presence of diabetic retinopathy in
the 996 participants with Type 1 diabetes: severity of retinopathy significantly predicted the
incidence of Stroke, with a significantly higher incidence reported in those with proliferative or
advanced background retinopathy. This association was strongly influenced by age, such that the
correlation reported between the severity of diabetic retinopathy and Stroke was only significant
in those aged more than 50 years, as a paucity of end-points was observed in younger participants
(Klein et ah, 2004)
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4.7 NEUROPSYCHOLOGICAL STUDIES AND MICROANGIOPATHY
4.7.1 Case Reports
In contrast to the literature that exists summarising the cognitive deficits observed in case reports
of the acute metabolic decompensations of Type 1 diabetes, as either severe hypoglycaemia or
diabetic keto-acidosis, there are no published case reports describing cognitive deficits in
association with microangiopathy. This may reflect the insidious and chronic progressive nature
ofmicroangiopathy per se which does not become clinically evident as acute neuropsychological
or neurological deterioration.
4.7.2 Cross-Sectional Studies
Relatively few studies have explored the relationship between the microvascular complications of
Type 1 diabetes, defined as retinopathy, peripheral neuropathy or nephropathy and their
association with cognitive performance. Rennick and colleagues (Rennick PM et al., 1968) first
reported relative cognitive disadvantage in association with diabetic microangiopathy. Rennick
evaluated the cognitive perfonnance of 30 adults with Type 1 diabetes utilising two validated
neuropsychological test batteries: the Wechsler Adult Intelligence Scale (WAIS) and the Halsted-
Reitan Neuropsychological Battery. The 15 participants with microangiopathy, present as
diabetic retinopathy, performed significantly more poorly on the sub-components of the test
batteries which appraised abstract reasoning skills and complex problem solving, relative to the
remaining participants who were free of microangiopathy. Performance on the other aspects of
cognitive ability evaluated appeared unaffected by microangiopathy (Rennick PM et al., 1968).
Skenazy and Biggler used the same neuropsychological test battery to study two groups, defined
as "less severe" and "more severe", according to the accumulation and severity of the
microangiopathic complications of Type 1 diabetes (Skenazy and Bigler, 1984). The "more
severe" group, which had the greater microvascular burden, demonstrated relative deficits in
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mental flexibility and psychomotor speed. The pattern of dysfunction observed by Skenazy and
Biggler in association with microangiopathy differed to that reported by Rennick et al, which may
reflect the diversity of the microangiopathic disease of those studied, or the psychometric tests
utilised. Dejgaard and colleagues described the neuropsychological, neurophysiological and
Magnetic Resonance neuroimaging correlated of the clinical complications of Type 1 diabetes in
three groups: a short-duration T1DM group free of microvascular complications (n=20); a long-
duration T1DM group with established microangiopathy (n=20) and age-matched healthy control
group (n=19) (Dejgaard ct al., 1991b). Cognitive performance, relative to that of a reference
population of 120 healthy controls, was significantly poorer in the long-duration T1DM group
who exhibited relative deficits in verbal learning, visual memory, fluid intelligence (WAIS
performance sub-tests) and frontal lobe and executive function, whereas visuo-motor speed and
visuo-spatial abilities appeared preserved (Dejgaard et al., 1991b). Ryan administered a battery
of neuropsychological tests to 75 adults with T1DM and a demographically matched non-diabetic
control group. Relative to control subjects, those with T1DM performed significantly more
poorly on measures of psychomotor efficiency and spatial information processing, whereas
performance with respect to verbal intelligence, learning, memory, problem solving and simple
motor speed were equivalent. Multiple regression analyses identified microvascular
complications, particularly the presence of distal symmetrical polyneuropathy, as an independent
determinant of psychomotor slowing, leading to the hypothesis that a "central neuropathy" may
also potentially complicate Type 1 diabetes (Ryan et al., 1992). In the largest study to date to
examine the cognitive associations of microangiopathy Ryan and colleagues thereafter examined
the performance of 142 subjects with T1DM and 100 age and ability-matched healthy controls on
measures of general intelligence, sustained attention, visual scanning and rapid decision making,
mental flexibility, memory and motor speed (Ryan et al., 1993). The 142 T1DM subjects had
been diagnosed with diabetes before their 17th birthday and had diabetes of long duration.
Independent determinants of cognitive performance were identified using regression techniques.
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Ryan identified the presence of distal symmetrical polyneuropathy as the most powerful disease-
related determinant of cognitive performance. The presence of neuropathy was disadvantageous
to all of the cognitive abilities examined with the exception ofmemory. The presence of diabetic
retinopathy also independently influenced motor speed, despite the presence of neuropathy and
retinopathy being moderately correlated (r2=0.39) and sharing pathogenic commonality. The
presence of microangiopathic complications of Type 1 diabetes was associated with poorer
performance on tests of sustained attention, visuospatial ability and psychomotor speed (Ryan et
al., 1993).
In contrast to the widely divergent findings previously described in studies evaluating the effects
of recurrent exposure to severe hypoglycaemia on cognitive abilities in T1DM, only a single
study has failed to report significant ability differences in association with microangiopathy.
Lawson and co-workers compared the performance of 40 subjects with T1DM complicated by
peripheral and autonomic neuropathy, relative to a control group and observed no between-group
differences in performance across a number of cognitive domains (Lawson ct al., 1984). Lawson
concluded that the presence of advanced microvascular complications of diabetes did not appear
harmful to cognitive performance. However, the T1DM and healthy control groups studied by
Lawson and colleagues were not matched for pre-morbid ability, which undermines the
interpretations and conclusions of this study, as the lack of differences observed may reflect
inherent differences in the crystallised intelligence of the study groups.
In summary, the presence of microvascular complications of Type 1 diabetes, particularly as
peripheral neuropathy, may be associated with a degree of cognitive disadvantage which appears
to affect perfonnance across a broad variety of cognitive domains.
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4.7.3 Prospective Studies
No prospective studies have examined the cognitive consequences of the development of
microvascular complications of Type 1 diabetes of adult onset. In particular, analyses of the
DCCT have not explored this research question to date, as all published analyses addressing
cognitive ability have been performed on an "intention to treat" basis, or in relation to summary
variable of exposure to severe hypoglycaemia. The most recent publication from the DCCT
investigators pertaining to the cognitive abilities of participants assessed after a mean total
duration of 18 years of follow up in the EDIC study has indicated that the vast majority of the
original DCCT participants now have established microangiopathy (Jacobson et ah, 2007). The
EDIC study is therefore not best placed to address the cognitive associations ofmicroangiopathy
in Type 1 diabetes.
4.7.4 Meta-Analyses
Formal meta-analysis techniques have not been applied to explore the relationship between the
microangiopathic complications of T1DM and cognitive ability, due to the relatively small
number of studies examining this hypothesis and their heterogeneity in terms of those studied and
the diversity of the neuropsychological instruments utilised.
4.8 NEUROIMAGING STUDIES AND MICROANGIOPATHY IN T1 DM
4.8.1 Case Reports
In stark contrast to the multiplicity of case reports which provided an outline to guide researchers
exploring the likely structural brain correlates of severe hypoglycaemia or diabetic keto-acidosis,
there are scant case reports published which describe the neuroimaging associations of
microangiopathic complications, apart from the single case report of Bellassoued and colleagues
(Bellassoued et al., 2001) which was discussed previously. This may reflect the chronic and
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insidious nature of microangiopathy relative to the clinically dramatic acute neurological
decompensations that can accompany the presentation of Severe Hypoglycaemia or Diabetic
Keto-Acidosis.
4.8.2 Cross-Sectional Studies
Dejgaard and colleagues (Dejgaard et al., 1991b) first explored the neuroimaging correlates of
microangiopathy in evaluating the MRI appearances of sixteen patients with long-duration Type 1
diabetes, complicated by diabetic retinopathy and peripheral neuropathy, relative the appearances
observed in non-diabetic healthy controls (n=40). The diabetes group had a substantial
microvascular burden: each had peripheral neuropathy and a degree of background or
proliferative retinopathy, with a proportion also having clinically apparent autonomic neuropathy
and overt diabetic nephropathy, yet none had previously experienced severe hypoglycaemia. The
MRI techniques utilised were commensurate with the year of study and relative to current
techniques could be considered relatively insensitive for detecting abnormalities of white matter.
Despite this caveat, high-intensity white matter lesions were observed in 69% of the diabetes
group, of whom 31% were also considered to have a degree of subjectively-rated cerebral
atrophy. The white matter lesions observed by Dejgaard were non-specific in their distribution,
being located throughout the cerebral hemispheres, cerebellar hemispheres and brain stem, were
small in size and infrequent in number in each subject. White-matter lesions (69%) were
significantly more common in the microangiopathic group relative to healthy age-matched
controls (12%) and no neuroimaging evaluation was performed in the short-duration Type 1
diabetes controls. Dejgaard et al interpreted the higher prevalence of white-matter lesions
observed in the microangiopathic group as being indicative of the presence of intra-cranial
microangiopathy, complicating Type 1 diabetes, or alternatively as being indicative of small foci
of ischaemia, known as leukoaraiosis (Pantoni and Garcia, 1995) as part of a subcortical
arteriosclerotic encephalopathy (Dejgaard et al., 1991b). Youssem and colleagues (Yousem et
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al., 1991) in a study published in the same year also hypothesised that the presence of
proliferative diabetic retinopathy may be associated with co-existent white-matter abnonnalities
of the brain visible on MRI as a neuroimaging indicator of intra-cranial microangiopathy.
Youssem compared the frequency of white-matter lesions in 25 adult patients with Type 1
diabetes complicated by proliferative diabetic retinopathy (severe retinopathy) relative to 10 age-
matched healthy control subjects using MRI techniques consisting of Tl-weighted and Proton
Density images. In contrast to the observations of Dejgaard, no white-matter lesions were
identified in any study participant and Youssem et al concluded that proliferative diabetic
retinopathy was not associated with white-matter pathology and that microangiopathy of the brain
was unlikely in T1DM. Advances in MRI technology in the intervening years since publication
have since revealed that the imaging sequences utilised by Youssem are unsuited for the
quantification ofwhite-matter changes, being unlikely to detect subtle differences.
In a small underpowered cross-sectional study Lunetta and co-workers examined a heterogeneous
group of ten patients with Type 1 diabetes, who had a relatively short median duration of
diabetes, variable hypoglycaemia exposure and differing degrees ofmicroangiopathy (Lunetta et
al., 1994). MRI brain appearances were compared to control subjects, of which little detail is
provided in the paper. The MRI sequences utilised included T1 and T2-weighted images and the
cerebro-ventricular index (CVI) was calculated as a surrogate measure of dilatation of the lateral
ventricles. Lunetta reported an increased CVI in 70% of the diabetes group, as well as a degree
of subjectively-rated cortical atrophy, interpreting these observations as being indicative brain
atrophy in the diabetes group relative to control subjects. No mention of white-matter
abnormalities were reported in the manuscript. The study was underpowered to address any of its
primary aims, the definition of an abnonnal CVI was suspect, the control group undefined and the
conclusions should be interpreted accordingly.
106
In summary, the limited neuroimaging data available suggest that the microangiopathic
complications of Type 1 diabetes may be associated with structural abnormalities of the central
nervous system, perhaps as high intensity white matter lesions and possibly cerebral atrophy.
However, the heterogeneous nature, small sample sizes and methodological flaws of some
published studies preclude definitive interpretation.
4.8.3 Prospective Studies
No prospective studies have examined the structural brain correlates of Type 1 diabetes and
associated microvascular complications.
4.9 APOLIPOPROTEIN-E POLYMORPHISMS AND THE BRAIN
Genetic factors have been identified as significant modulators of outcome in a variety of
neurological diseases (Wright, 2005) and could partly mediate the susceptibility towards the
development of cognitive impairment in Type 1 diabetes. The role of genetic factors as mediators
of cognitive dysfunction following severe hypoglycaemia, or chronic hyperglycaemia has not
been previously examined.
4.9.1 Genetic Polymorphisms and Cognitive Ageing
Genetic factors have been identified which appear to influence cognitive ageing and which may
additionally modify the rate of age-related decline in specific cognitive abilities. Genes identified
to date include the Apolipoprotein-E gene (APOE), the Brain Derived Neurotrophic Factor gene
(BDNF), the Catechol-O-Methyl Transferase gene (COMT) and the multiple genes coding for
subtypes of the Dopamine receptor (Savitz et al., 2006). Only the role of the APOE gene will be
discussed further.
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4.9.2 Neurobiology of Apolipoprotein-E (APOE)
Polymorphism of the gene for Apolipoprotein-E (APOE) is the most important single genetic
determinant of late-onset Alzheimer's disease (Corder et al., 1993). The APOE gene has three
common alleles (e2, s3, e4) coding for three corresponding protein isoforms, designated as E2,
E3 and E4 respectively, each of which vary in their biological activity. The APOE E4 isoform
has the least biological activity and the bioactivity of the protein isoform appears to be of clinical
importance. Apolipoprotein-E (APOE) mediates central nervous system cholesterol transport in
an isoform-specific manner and is an important determinant of neuronal repair and cytoskeletal
maintenance: the likelihood of neuronal recovery and survival following brain injury appears to
be mediated in an isoform-specific manner with the least active E4 isoform conferring a
disadvantage (Smith, 2000).
4.9.3 APOE Polymorphisms and Cerebral Glucose Metabolism
Small and colleagues first identified regional cerebral metabolic abnormalities in a small study of
healthy middle-aged relatives of patients with Alzheimer's disease which utilised PET and MRI
techniques: reduced parietal lobe metabolism and increased right-left hemisphere asymmetry was
observed only in those at risk relatives who had one or more e4 allele (Small et al., 2000).
Reiman et al further refined this observation by studying regional cerebral glucose metabolism in
healthy younger adults, aged 20-49 years, utilizing a combination of PET and MRI techniques.
Symmetrical reductions in regional cerebral glucose utilisation (CMRgiu) were observed in e4
hetcrozygotes in the posterior cingulate, parietal, temporal, and prefrontal cortex. The reduction
observed in CMRg!u was apparent decades before any clinical presentation of Alzheimer's disease
could reasonably be expected and was detectable in the absence of any measurable difference in
cognitive ability, as determined by a neuropsychological test battery (Reiman et al., 2001;Reiman
ct al., 2004;Reiman et al., 2005).
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4.9.4 APOE Polymorphisms and Healthy Ageing
Polymorphism of the APOE s4 allele appears to influence aspects of cognitive ageing, even in
apparently healthy individuals, although no negative consequences have been reported as yet in
childhood or adulthood. Children and young adults with an e4 allele appear not to exhibit any
cognitive disadvantage on tests of general intelligence (Turic et ah, 2001) and the relative
frequencies of APOE genotypes appears not to differ between high and low-IQ children (Plomin
et al., 1994). In another study of young Chinese women superior fluid intelligence was observed
in association with the 84 allele (Yu et ah, 2000). However, by middle-age possession of the e4
allele appears to confer disadvantage. Apparently healthy middle-aged adults possessing an s4
allele exhibit subtle deficits in learning and memory abilities relative to those with other
genotypes (Flory et ah, 2000). APOE genotypes also appear to influence the rate at which certain
cognitive abilities decline with normal ageing: healthy elderly subjects with an e4 allele have
poorer information processing speed and memory abilities (Staehelin et ah, 1999) but do not
appear to undergo a more rapid rate of loss of cognitive ability than that observed in those with no
e4 allele (Pendleton et ah, 2002;Staehelin et ah, 1999).
4.9.5 APOE Polymorphisms in Neurological Disease
Clinical research studies evaluating cognitive ability, morbidity and in some cases mortality
following a variety of central nervous system insults have consistently identified a significant
disadvantage in outcome in association with possession of an e4 allele in middle-aged and elderly
subjects (Smith, 2000). However, carriage of the e4 allele, and consequently the least
biologically-active E4 isoform, appears only to be disadvantageous when pathological processes
affect the central nervous system: measurable negative associations of the e4 allele are not
evident during childhood or young adult life (Plomin et ah, 1994;Turic et ah, 2001 ;Yu et ah,
109
2000). This observation infers that the negative consequences associated with possession of the
e4 allele are not mediated through a neuro-developmental mechanism, only becoming manifest
when age-related decline or detrimental pathological processes affect the central nervous system.
An association between polymorphism of the APOE gene and outcome differences has been
reported following a broad spectrum of brain injuries. The APOE e4 allele has been associated
with poorer cognitive and neurological outcome in head injury (Crawford et al., 2002;Teasdale et
ah, 1997), rapidity of disease progression, white-matter lesion burden, mortality and disability in
multiple sclerosis (Pinholt et ah, 2006); reduced verbal fluency following sub-arachnoid
hemorrhage and cardio-pulmonary bypass surgery (Louko et ah, 2006); poorer general cognitive
function in ex-professional Boxers (Jordan et ah, 1997); impaired attention, information
processing speed and general cognitive ability in ex-US Football players (Kutner et ah, 2000);
and a higher incidence of dementia following Stroke (Sudlow et ah, 2006).
In summary, carriage of the APOE e4 allele may influence glucose utilisation in certain brain
regions, appears to be disadvantageous to the normal cognitive ageing process and may
significantly increase the risk of subsequent cognitive impairment, death or morbidity following a







5.1 Influence of Diabetes Specific Factors on Cerebral Structure and Function in
Type 1 Diabetes
The present study was designed to ascertain the neuroimaging and cognitive associations of the
clinical complications and disease-specific factors unique to Type l diabetes. In particular, the
relationship between the neuropsychological performance and neuroimaging correlates of
preceding exposure to recurrent severe hypoglycacmia, the presence ofmicrovascular disease (as
retinopathy), the duration of diabetes and the age of onset of diabetes were of particular interest.
A body of evidence exists which suggests that each of these diabetes-related factors may be
disadvantageous to the brain. The present study was not designed to examine the effects of
diabetes per se on cognitive function, rather was focused on determining the consequences of
diabetes-specific disease factors on the neuropsychological and neuroimaging outcomes of
interest. The hypotheses were:
1. Preceding exposure to recurrent severe hypoglycaemia may be associated with
differences in cognitive ability and brain structure, particularly changes affecting gray matter
structures in the cerebral cortex and deep gray matter.
2. Diabetic retinopathy may be a surrogate marker for microangiopathy elsewhere within
the brain, apparent as high-intensity white matter lesions.
3. The onset of Type 1 diabetes during early childhood ncurodevelopment may be
disadvantageous and if associated with measurable differences in brain structure then an organic
pathogenesis would be likely.
To test these hypotheses 71 young people with Type 1 diabetes of relatively long duration, who
had developed the disorder during childhood or adolescence, and as a consequence may therefore
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be more vulnerable to the development of cognitive impairment (Northam et al., 2001;Ryan and
Becker, 1999) were recruited for study.
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5.2 Influence of Diabetes-Specific Factors on Objectively Rated Structural Brain
Abnormalities in Type 1 Diabetes
The neuroimaging associations of Type 1 diabetes remain under explored. Several diabetes-
specific factors have been reported in the literature as being associated with the presence of
structural brain abnormalities in case reports and small case-control studies. These diabetes-
specific factors include exposure to protracted and profound degrees of severe hypoglycaemia,
the development of Diabetic Keto-Acidosis in children and adolescents, and the development of
microvascular complications as a consequence of chronic exposure to hyperglycaemia.
The present study examined a group of 133 adults with Type 1 diabetes of relatively long
duration: a subgroup had developed the disorder during childhood or adolescence, and as a
consequence were exposed to the potential negative consequences of diabetes during
neurodevelopment and a second subgroup in which the onset of diabetes had occurred after
neurodevelopment was largely complete. The present study was designed to achieve a number of
aims:
1. To determine the prevalence of structural brain abnormalities, as high-intensity white
matter lesions and cerebral atrophy, in a population ofyoung adults with T1DM.
2. To determine whether structural brain abnormalities, such as white matter lesions or
cerebral atrophy, were related to cognitive ability in T1DM.
3. To explore whether exposure to the clinical complications of Type 1 diabetes, as severe
hypoglycaemia and microangiopathy, or an early childhood onset of Type 1 diabetes
independently influenced the presence of any structural brain abnonnalities.
As no healthy age-matched control group was included, the aims were not to examine the effects
of Type 1 diabetes per se on brain structural outcome measures, rather concentrated on
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determining the consequences of the diabetes-specific disease factors of interest on macroscopic
neuroimaging outcomes of interest.
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5.3 APOE Genotype and Cognitive Function in Type 1 Diabetes
As summarised in Chapter 4 (Section 4.7), polymorphism of the Apolipoprotein-E (APOE) gene
appears to be a moderator of successful cognitive ageing from middle-age in apparently healthy
adults, such that those with one or more copies of the APOE e4 allele appear disadvantaged and
may undergo more rapid cognitive decline. In addition to a role in mediating successful cognitive
ageing, polymorphism of the APOE gene appears to influence the recovery of the human brain
following a variety of cerebral insults, including head injury, vascular insults, demyelination and
other pathologies. Type 1 diabetes can affect cerebral function, most notably through the
development of intermittent hypoglycaemia. The relationship between APOE genotype and
cognitive function in patients with Type 1 diabetes is unknown. The primary hypothesis of the
present study was that possession of an APOE e4 allele would associated with measurable
cognitive disadvantage in a group of adults who had Type 1 diabetes of long duration, sufficient
to accrue some clinical complications of the disorder. The secondary hypothesis was that severe
hypoglycaemia exposure may modify any differences observed in neuropsychological
performance, such that those with an APOE e4 allele who had been previously exposed to severe







The clinical characteristics and individual study inclusion and exclusion criteria are explained in
detail in the individual chapters.
6.2 ETHICAL PERMISSION
Ethical permission was granted for each of the studies comprising this thesis by the Lothian
Health Board Medical Research Ethics Subcommittee for Medicine and Clinical Oncology.
Following a detailed explanation of the nature of the studies written informed consent was
obtained from all subjects. All studies comprising this thesis were performed in accordance with
the Declaration of Helsinki.
6.3 ASSESSMENT OF CLINICAL COMPLICATIONS OF DIABETES
Type 1 diabetes may be complicated by the development of acute and chronic metabolic
complications.
Acute metabolic complications of Type 1 diabetes
The acute metabolic complications of type 1 diabetes include transient episodes of
hypoglycaemia, and hyperglycaemic decompensation in the form of diabetic keto-acidosis
(DKA).
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Chronic complications of Type 1 diabetes
Chronic long-term complications of type 1 diabetes include the development of microvascular
disease (microangiopathy), which may be manifest as retinopathy, neuropathy or nephropathy;
premature macrovascular disease (as ischaemic heart disease, cerebro-vascular disease, peripheral
vascular disease and reno-vascular disease), and recurrent exposure to severe hypoglycaemia. As
the aim of the present series of studies was to determine whether any cumulative effects were
present as a consequence of exposure to either recurrent exposure to severe hypoglycaemia or
microangiopathy on the structure and function of the brain, only the presence of these clinical
complications were assessed.
6.3.1 Assessment of preceding exposure to severe hypoglycaemia
Severe hypoglycaemia was defined in a manner consistent with the criteria of the Diabetes
Control and Complications Trial (DCCT), as an episode of hypoglycaemia sufficient in severity
such that external assistance was necessary to facilitate recovery (The DCCT Research Group,
1997). In addition to this clinical definition, the blood glucose concentration had to be
documented at less than 2.8 mmol/1 and/or the clinical manifestations had to have been reversed
with oral carbohydrate, intramuscular glucagon, or intravenous glucose (The DCCT Research
Group, 1997). These definitions encompass episodes of severe hypoglycaemia of varying
severity; from episodes during which the patient retains consciousness but lacks the insight and
volition to reverse the episode with oral carbohydrate, through to more profound degrees of
hypoglycaemia sufficient to render the patient unconscious or result in a seizure secondary to
neuroglycopenia.
In the present series of studies the severe hypoglycaemia exposure of participants was
retrospectively assessed using a validated and formatted hypoglycaemia questionnaire (Deary et
al., 1993). Using this questionnaire Deary et al have previously demonstrated a high degree of
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correlation between the prospective assessment of the frequency of severe hypoglycaemia and
patients self-reported estimates of their severe hypoglycaemia exposure obtained 18 months later.
To further improve the accuracy of estimates of severe hypoglycaemia exposure participants in
the present series of studies were requested to discuss their severe hypoglycaemia history with
relatives or friends before completing questionnaires. Estimates were corroborated with case
records where possible. Details were recorded of the total lifetime number of episodes, the
frequency of occurrence of episodes, the total number of episodes requiring glucagon or medical
assistance for recovery, and the total lifetime number of episodes of coma and hypoglycaemia-
associated seizure. However, using this retrospective method of exposure it was not possible to
precisely document the exact number of episodes to which participants had been exposed, neither
was it possible to definitively state with exactitude the age at which the exposure to severe
hypoglycaemia had occurred. The retrospective ascertainment of severe hypoglycaemia utilised
in the series of studies comprising this thesis is a methodological weakness relative to the gold-
standard methodology of prospective ascertainment, although is sufficient to determine with a
degree of accuracy those naive to and those previously exposed to severe hypoglycaemia. To
overcome this relative methodological deficit would take decades of meticulous prospective
evaluation, which is neither practical or easily funded.
6.3.2 Assessment of microangiopathy
The presence or absence of the microvascular complications of diabetes was determined in all
subjects. Details of the assessment of the presence or absence of degrees of diabetic retinopathy,
diabetic peripheral neuropathy and diabetic nephropathy are summarised below.
Assessment of Diabetic Retinopathy
Subjects were examined for clinical evidence of diabetic retinopathy using a composite of two
separate diagnostic techniques. Two techniques were used, direct ophthalmoscopy and digital
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retinal photography, as their combination has been demonstrated to increase the sensitivity and
specificity of determinations of the degree of diabetic retinopathy (Aldington et ah, 1995). Direct
ophthalmopathy was performed following mydriasis with 1 % Pilocarpine. The sensitivity of this
technique when used in isolation for the detection ofminimal changes of diabetic retinopathy is
relatively poor, and varies according to the clinical experience of the operator. Sensitivities have
been reported between 35% for general practitioners to greater than 85% for consultant
ophthalmologists. For this reason the examination by indirect ophthalmoscope was
complemented by digital retinal photography. Digital retinal photography was performed after
mydriasis (1% Pilocarpine) using a Sony® video camera within a Topcon® digital fundus
photography system. A single 45° field centred on the macula and with a resolution of
1200x1600 pixels was obtained. This single field assessment, which was the clinical standard at
the time that the present series of studies were designed, has been subsequently demonstrated to
have the potential to miss early diabetic retinopathy in the peripheral retina. Accordingly, it is
now standard clinical practice to obtain two digital retinal images per fundus. As such, the
techniques employed in the present studies could potentially misclassify those individuals as with
minor degrees of diabetic retinopathy in the peripheral retina, but not apparent within the central
retina. Technical failures can result in images which are inadequate for the grading of diabetic
retinopathy. However, in the young adult population examined by the present series of studies no
such technical failures were encountered. Digital retinal images were examined and scored
according to criteria of the modified Airlie House grading system (Early Treatment Diabetic
Retinopathy Screening Group, 1991). Digital retinal photography has a greater sensitivity than
ophthalmoscopy alone for the detection of diabetic retinopathy, and the combination of both
techniques when utilised together improves the sensitivity and specificity for the detection of
diabetic retinopathy to approximately 85-95% and 80-90% respectively (Aldington et al., 1995).
As the majority of the cognitive and intelligence tests performed in the present series of studies
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were presented visually, only individuals who had no clinical evidence of diabetic retinopathy or
who had minor degrees of diabetic retinopathy only (background diabetic retinopathy, Airlie
House grades la-lc) which are not thought to interfere with visual function were selected for
study. Greater degrees of diabetic retinopathy have the potential to interfere with visual function
and may therefore confound the interpretation of tests of intelligence and cognitive ability.
Assessment of Diabetic Nephropathy
Each participant was screened for the presence of diabetic nephropathy. Screening was
performed through the analysis of first morning specimen of urine. The concentration of albumin
and creatinine in first morning specimens were determined and the ratio of urinary albumin to
urinary creatinine calculated. Subjects who had urinary Albumin:Creatinine ratio (ACR) in
excess of 3.5 were further examined for the presence of microalbuminuria, the earliest clinically
detectable phase of diabetic nephropathy. Microalbuminuria was defined as albuminuria in
excess of 30 mg/24 hours but less than 300 mg/24 hours. Macroproteinuria, or overt diabetic
nephropathy, was defined as a 24 hour protein excretion in excess of 300 mg. Subjects in whom
the initial urinary ACR was elevated supplied three further early morning specimens for
confirmatory analysis. Subjects were requested not to consume alcohol of perform physical
exercise on the day preceding the collection of these three further specimens, as alcohol and
exercise both increase glomerular permeability and may transiently induce low-grade proteinuria
within the microalbuminuric range. In those in whom the urinary ACR remained in excess of 2.5
(males) or 3.5 (females) despite the above precautions, and in whom a suspicion of persistent
microalbuminuria remained, were not invited to participate. These exclusion criteria were
applied as microalbuminuria and overt nephropathy are closely associated with the development
of hypertension, a condition which is known to directly influence performance on cognitive
ability tests and impact directly on the structure of the brain.
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Assessment of Blood Pressure
Blood pressure was measured at the brachial artery using an appropriately sized cuff for the
individual. A calibrated mercury sphygmomanometer was used for all measurements.
Measurements were perfonned in the sitting position, after the subject had been seated for at least
five minutes. An office blood pressure in excess of 140/90 mmHg was used to define the
presence of hypertension.
Assessment ofPeripheral Neuropathy
The presence of Peripheral Neuropathy was defined as an inability to detect the pressure applied
by a lOg monofilament on the sole of the foot. Those with a history of previous foot ulceration,
which infers the presence of peripheral neuropathy, peripheral vascular disease, or both
processes, were not invited to participate. In addition, those with peripheral neuropathic
symptoms were excluded from participation, even in the absence of objective clinical signs of
peripheral neuropathy. Other more sensitive techniques, particularly the use of
electrophysiological techniques, which can quantitatively measure nerve conduction velocity,
were not employed due to restraints on time. However, despite this relative limitation it was
unlikely that participants with significant degrees of diabetic peripheral neuropathy were
recruited for study as a considerably greater cumulative glycaemic burden is required for the
development of clinically apparent neuropathy than early degrees of diabetic retinopathy
(Orchard et al, 1990).
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6.4 ASSESSMENT OF INTELLIGENCE AND COGNITIVE ABILITY
A battery of tests was utilised to evaluate the intelligence and a range of cognitive abilities for
each subject. Tests were administered by trained assessors and delivered in a standardised pre¬
determined manner. Assessors were blind to the diabetes-specific characteristics of those
undergoing study to minimise investigator bias. Assessments included measures of pre-morbid
intellectual ability, current intellectual performance, information processing ability and abilities
spanning a number of other pre-specified cognitive domains. The battery of tests administered
were selected on the basis of prior studies within the field (Langan et al., 1991;Perros and Frier,
1997) and weighted towards the assessment of pre-morbid intelligence, fluid intelligence and
information processing ability. The specific tests utilised to measure these abilities are described
in the following section.
6.4.1 National Adult Reading Test
The National Adult Reading Test (NART) is a test of word pronunciation ability and evaluates
the ability of the individual to pronounce 50 irregularly spelled words (e.g. demesne, chord,
prelate and campanile) (Nelson and Willison, 1991). Subjects are marked by trained raters on
their ability to correctly pronounce the words, according to a standardised scoring system. NART
scores are reliable and consistent provided the test is administered by pre-trained raters (Alcott et
al., 1999;0'Carroll, 1987). NART scores remain stable over many decades of life in healthy
ageing populations (Crawford et al., 2001) and in mild-to-modcrate organic brain disease of
differing aetiology. Scoring on the NART correlates closely with the lifetime peak intelligence
quotient (IQ) of an individual and measures a type of intelligence known as "crystallised
intelligence" due to its stability over time and resistance to the detrimental effects of ageing,
neurological and psychiatric diseases. However, the reliability of NART scores as an estimate of
pre-morbid IQ can be negatively affected by several factors. These include the technical training
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of the assessor performing the test (Alcott et al., 1999) and the potential confounding effects of
more severe degrees of organic brain disease (Cockburn et al., 2000) in which NART scores
decline, providing a less robust estimate of pre-morbid IQ. NART scores can therefore be used to
estimate the maximum intellectual ability of an individual prior to any deterioration in intellectual
ability through the processes of ageing or organic disease, within the above caveats. As the series
of studies presented in this thesis evaluated apparently healthy normal adults these specific
deficiencies should not detract from the validity of NART scores as a reliable surrogate of pre¬
morbid IQ. The estimate of pre-morbid IQ from NART scores is superior to estimates derived
from socio-economic factors, such as degree of education or measures of social deprivation, and
for this reason the NART has been used as the estimate of 'best ever' intellectual ability in the
present series of cross-sectional studies, within the limitations as summarised above.
6.4.2 Wechsler Adult Intelligence Scale - Revised
The Wechsler Adult Intelligence Scale-Revised (WAIS-R) is a tool for the assessment of current
intellectual performance, validated across an age range spanning 16 years to 74 years and 11
months. The WAIS was first introduced in 1955 but subsequently modified and updated to the
WAIS-R in 1981 to remove ambiguous tests and replace those with little or no discriminatory
value. The full WAIS-R comprises eleven tests: six Verbal sub-tests (Infonnation, Digit span,
Vocabulary, Arithmetic, Comprehension and Similarities) and five non-verbal Performance sub¬
tests (Picture Completion, Picture Arrangement, Block Design, Object Assembly and Digit
Symbol). Summation of individual test scores yields separate Verbal, Perfonnance and combined
Full-Scale scores which are converted to scaled-scores from which Verbal IQ, Perfonnance IQ
and Full-Scale IQ scores are derived (Wechsler, 1981). The IQ score for each sub-component
can be compared with standardised reference populations, each ofwhich exhibits a mean IQ score
of 100 with a standard deviation of 15 points. In contrast to scoring on the NART, pcrfonnance
on the WAIS-R is extremely sensitive to the detrimental effects of ageing and can identify
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deficits consequent upon subtle degrees of organic brain disease. Individual sub-tests which
comprise the WAIS-R differ in their relative sensitivity to the detrimental effects of organic brain
disease and normal human ageing. In general, performance on the Verbal sub-tests appears
comparatively more resilient than on the Performance sub-tests. The WAIS-R provides a
measure of the current intellectual performance of an individual, termed as their "fluid
intelligence", due to its propensity to change with age and organic brain disease. For the series of
studies presented in this thesis only the five Performance IQ sub-tests of the WAIS-R were
utilised. These sub-tests were the Picture Completion, Block Design, Object Assembly and Digit
Symbol tests. Performance on some of these specific tests has been previously demonstrated to
be negatively affected by the development of the clinical complications of Type 1 Diabetes
Mellitus.
Picture Completion
Subjects are shown a consecutive series of 20 picture cards of everyday objects or situations.
From each picture an essential item is missing e.g. a car with missing door handles, a pair of
spectacles where the nosepiece is missing. Subjects are given 20 seconds to identify the specific
item missing from each test card, and the total number of correct responses is recorded from a
potential maximum score of 20 points. The Picture Completion task is said to provide a measure
of visual perception and long-term visual memory. Performance on the Picture Completion task
is relatively resilient to ageing, certainly into the 8th decade of life in healthy populations,
relatively unaffected by brain damage and is the least sensitive of the Performance IQ sub-tests
(Lezak, 2004;Wechsler, 1981).
Block Design
Subjects are required to orientate a set of nine identical blocks (coloured red on two-sides, white
on two-sides, with two-sides diagonal red/white) to exactly reproduce a series of ten two-
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dimensional patterns displayed by the examiner on a printed card. The ten patterns presented are
of ascending difficulty and subjects are required to complete each task in as short a time as
possible. Marks are awarded on a structured scoring system which is dependent on the time taken
to correctly complete each pattern. A maximum score of 51 may be attained. The Block design
sub-test is a speed-based test which is said to provide a measure of visuo-spatial constructional
ability and has been described by some researchers as providing a robust measure of current
"fluid intelligence" (Lezak, 2004). Perfonnance on the Block Design test is negatively affected
by subtle degrees of brain damage, grossly affected by Alzheimer's disease and Alcohol-related
brain injuries, and impaired in demyclination and other sub-cortical neuropathologies (Lezak,
2004). Scoring on the Block Design sub-test is most strongly affected by non-dominant
hemisphere lesions, typically those involving the posterior aspects of the parietal lobe.
Object Assembly
Subjects are presented with a series of eccentrically cut jigsaw pieces which are presented in a
pre-determined manner by the examiner and which are required to be assembled to create a
recognisable object e.g. a profde, an elephant; a hand. For each of the four sets of jigsaw pieces
presented, subjects are asked to assemble the object within a pre-defined time limit. Scores are
allocated for the number of jigsaw pieces correctly aligned and perfect performance accrues a
score of 41 points. The Object Assembly sub-test is said to measure visual constructional
abilities. Scoring on this sub-test declines progressively with age and is particularly sensitive to
lesions affecting the occipital lobes, particularly on the non-dominant side (Lezak, 2004).
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Digit Symbol
The digits one through nine are represented by corresponding symbols. Subjects are required to
write down the symbol corresponding to the given number for each in a standardised pre¬
determined array of 93 numbers. A maximum of 93 points can be attained according to the
number of accurate responses, completed in sequential order, within the 90 seconds allocated for
the task. The Digit Symbol test measures psychomotor speed, visual-motor speed and short-term
visual memory(Lezak, 2004). Scoring on the Digit Symbol test declines with age, from the age
of 30 years onwards, with scores exhibiting a more rapid decline after the age of sixty. Scoring is
sensitive to subtle degrees of brain damage and is impaired by a broad variety of pathological
processes affecting the central nervous system (Lezak, 2004).
WAIS-R Performance Score
The raw test scores for each of the WAIS-R Performance sub-tests were added together with total
test scores converted into 'scaled scores' according to the criteria of the WAIS-R test manual
(Wechsler, 1981). Scaled scores were used to calculate the Performance IQ for each subject. The
Performance IQ score is a representative measure of the current "fluid intelligence" of an
individual (Lezak, 2004).
6.4.3 Assessment of Information Processing and Cognitive Ability
Psychometric tests were utilised to evaluate other aspects of cognitive ability not captured by the
use of the WAIS-R. The psychometric test battery utilised was selected on the basis of previous
observations from studies of patients with Type 1 Diabetes Mellitus (Langan et ah, 1991;Pcrros et
al., 1997), weighted towards the assessment of information processing abilities and designed to be
capable of identifying subtle ability differences. Through limitations of time, the assessment did
not encompass all aspects of cognitive ability. In particular, frontal and executive functions were
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not assessed in any depth, and memory and learning ability were not evaluated to any extent in
the series of studies presented in this thesis.
6.4.3.1 Assessment of Early Visual Information Processing Ability
Inspection Time (IT) was used to assess visual perceptual speed, a component of infonnation
processing ability representing the early stages of visual infonnation processing (McCrimmon et
al., 1996). Participants discriminated between the spatial position (left or right) of two briefly-
presented vertical lines of different lengths. The stimuli were backward-masked and the duration
of presentation altered according to an adaptive staircase algorithm, such that the presentation
time (in milliseconds) was progressively shortened until the threshold required by each subject to
achieve an 85% response accuracy was reached. The duration of stimulus presentation required
to reliably distinguish the stimulus (85% correct) was termed the subjects 'Inspection Time'.
6.4.3.2 Assessment of Psychomotor Speed: Choice Reaction Time
A Hick-type reaction time device was utilised to measure reaction time (Jensen, 1987). Reaction
time provides a measure of the speed of information processing at the cognitive-experimental
level. Reaction times consist of two separate components; termed 'decision time' and 'movement
time' respectively. The device used to measure reaction time consists of a 'home' button and
eight 'response' buttons equidistantly spaced from the home button. The subject is asked to
maintain the 'home' button depressed with the dominant hand until one of the 'response' buttons
is lit; the decision time is calculated from the time that the 'response' button is lit until the
subject's hand leaves the home button. Movement time represents the time between the subject's
hand leaving the 'home' button and depressing the correct 'response' button. In the present
studies, measures were made of simple reaction time and 2-, 4- and 8-choice reaction times and
thereafter 8- , 4-, and 2-choice reaction time and simple reaction time. Twenty trials were
attempted at each level and the median Decision Time (DT) and median Movement Time (MT) in
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milliseconds was recorded. Median values of the components of reaction time were recorded
because multiple reaction time trials typically demonstrate a skewed distribution (Jensen, 1987).
Decision Time
Decision times lengthen with increasing complexity of the choice reaction task as additional
'response' buttons are added. This effect is known as the Hick Paradigm. The 'decision time'
provides a measure of "psychomotor speed" or speed of information processing by the brain
(Jensen, 1987).
Movement Time
Movement times are influenced by increasing the complexity of the task to a lesser extent than
decision times and are more representative ofmotor speed rather than being a measure of cerebral
information processing (psychomotor speed).
6.4.4 Borkowski Verbal Fluency Task
The Borkowski Verbal Fluency task is thought to assess frontal lobe and executive functions and
scoring on the Borkowski Verbal Fluency task has been demonstrated to be sensitive to disruption
by mild head injury (Borkowski and Benton, 1967). During the Verbal Fluency Task subjects are
given one minute to state as many words as possible, beginning with a letter of the alphabet
specified by the examiner. In the present series of studies the letters of the alphabet 'J', 'S', 'U' and
'M' were used. The total number of novel words stated for each letter was noted and a summation
of all four recorded as the Verbal Fluency Score. Verbal fluency scoring remains stable into the
8th decade of life in healthy individuals and is sensitive to decrements in frontal lobe pathology.
Verbal fluency performance is said to provide a measure of frontal lobe and executive functions
(Lezak, 2004).
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6.4.5 Paced Auditory Serial Addition Test (PASAT)
Performance on the PASAT provides an assessment of the ability to sustain attention and
concentration and provides a measure of auditory information processing speed and flexibility
(Deary I.J. et al., 1991). Subjects listen to a list of numbers which they are required to add
together according to a given rule: 'add each number that you hear, to the number that preceded
if. After practice, two trials of 61 consecutive numbers are performed, the first with an interval
of 4-seconds between numbers and the second with 2-seconds between successive digits,
respectively. Performance on the 4-second test is associated with short-term memory ability,
whereas performance on the 2-second test more closely relates to perceptual processing speed.
The total number of correct responses for each test is recorded from a maximum score of 60.
6.5 ASSESSMENT OF MOOD AND ANXIETY
The Hospital Anxiety and Depression Scale (HAD) is a self-rating scale which provides a
validated measure of mood and anxiety states for a subject in the week prior to testing (Zigmond
and Snaith, 1983). Subjects are requested to answer 14 statements relating to mood and anxiety
(e.g. 'I feel tense or wound up') and arc instructed to complete the statements, on the basis of their
mood state in the preceding week, from four potential alternative statements which best describe
their present mood state. Individual responses are scored on a four-point scale from zero (not
present) to three (considerable), and maximum summated anxiety and depression scores of 21 are
obtainable (the minimum score is 0). Seven statements assess anxiety levels, and seven assess
depression levels. Higher scores are indicative of greater levels of anxiety or depression. To
determine whether a significant neurotic disorder is likely to be present, scores on the seven
statements are each summated to provide sub-scale scores on the HADS-A and the HADS-D
from zero to 21. In this study valid HADS subscale scores were defined as having answered at
least five of seven items on both the HADS-A and the HADS-D. In order to be valid in patients
with somatic problems, the HADS items were based on the psychological aspects of anxiety and
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depression. The anxiety items were concentrated on general anxiety, with five of the items close
to the diagnostic criteria of Generalised Anxiety Disorder. The depression items included in the
questionnaire are based on anhedonia, which is considered to an essential criterion of depression
(Lezak, 2004).
6.6 MAGNETIC RESONANCE NEUROIMAGING PROTOCOL
Brain magnetic resonance imaging was performed at the Department of Medical Radiology,
University of Edinburgh and subsequent analysis of data was performed at the Department of
Clinical Neurosciences, University of Edinburgh.
6.6.1 Magnetic Resonance Neuroimaging Protocol
Fundamentals ofMagnetic Resonance Imaging
Magnetic resonance (MR) imaging generates images by applying a varying magnetic field to the
body, which aligns the hydrogen atoms of the tissue under evaluation in accordance with the
polarity of the applied magnetic field. When the field is released, radio waves are generated as
the polarised hydrogen atoms return to their resting state. The frequency of the emitted radio
waves is related to the chemical environment of the atoms as well as to their location. With
computer analysis of these data, MR images can be generated.
Magnetic Resonance imaging systems are formed from several key components. These include a
large magnet supplemented by shim coils to generate a sufficiently uniform powerful magnetic
field. A radiofrcquency (RF) coil is used to transmit controlled radio signals into the body tissue
under evaluation. The characteristics of the transmitted radio signals are altered as they penetrate
tissues, according to the properties of each specific tissue, and such alterations are detected by the
receiver coil. Additional gradient coils assist in delineating the spatial localisation of the
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returning radio signals, which are then computer integrated to generate reconstructed images for
interpretation by a radiologist. A major advantage ofMR techniques is the ability to alter radio
signal settings to selectively enhance and delineate intra-cranial tissues. With the notable
exception of bony structures most tissues within the skull vault can be outlined. This allows the
accurate definition of white matter, gray matter, cerebrospinal fluid, adipose tissue and their
interfaces, which facilitates volumetric analysis of specific tissue types. Alteration of the plane of
imaging can also be manipulated to the specific anatomical brain area being studied, allowing
regional brain areas to be outlined with a greater degree of accuracy than that permitted by
previous neuroimaging techniques.
Alteration of Radio Signal Intensity and MR Images
Different image contrasts can be achieved by using specific RF pulse sequences and imaging
parameters. The basic signal intensity parameters that can influence imaging are:
(1) Proton Density
The proton density (PD) of a tissue reflects the concentration of protons in the tissue, in the form
ofwater and contained within macromolecules.
(2) T1 Relaxation Time
The T1 relaxation time reflects the longitudinal relaxation time taken by protons to revert back to
their resting states after exposure to an RF pulse.
(3) T2 Relaxation Time
The T2 relaxation time reflects the transverse relaxation time taken by protons to revert back to
their resting states after exposure to an RF pulse.
(4) Blood Flow
Blood flow can affect signal acquisition as rapidly flowing arterial blood produces deficits in
signal. Exploitation of this characteristic underlies the development of specific sequences that
facilitate MR angiography techniques.
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The contrast on MR images can be manipulated by changing the parameters which characterise a
pulse sequence. A pulse sequence defines the specific strength, number, timing and gradient of
the RF pulses applied to the body tissue under evaluation. The two most important parameters
are the repetition time (TR) and the echo time (TE). The TR is the time between consecutive 90
degree RF pulses. The TE is the time between the initial 90 degree RF pulse and the echo. Tl-
weighted sequences use a short TR and short TE (TR < 1000msec, TE < 30msec). T2-weighted
sequences use a long TR and long TE (TR > 2000msec, TE > 80msec). T2-weighted sequences
can be employed as a dual echo sequence to further enhance the contrast between tissues of
interest. The first or shorter echo (TE < 30msec) is proton density-weighted, or a mixture of T1
and T2-weighted images. This image is very helpful for evaluating changes in the peri¬
ventricular white matter, such as those observed in demyelination or cerebral microangiopathy,
because hyperintense white matter lesions are contrasted against the lower signal observed in the
CSF. FLAIR (Fluid Attenuated Inversion Recovery) sequences are a further enhancement of the
basic PD imaging sequence. FLAIR images are a special inversion recovery sequence in which
the TI time is adjusted to match the relaxation time of the tissue whose image should be
suppressed. This sequence is an important technique used to differentiate lesion type within the
central nervous system.
Magnetic resonance (MR) imaging is an ideal modality for the imaging of brain structure, and has
several advantages over X-ray dependent technologies such as CT scanning. The advantages of
MR imaging include:
1. MR imaging does not involve the delivery of a dose of ionising radiation;
2. The imaging study can be tailored to the brain region of interest and to the disease process
being studied. Radio signal intensities observed on T-l, T-2, and proton density-weighted images
relate to specific characteristics of the tissues being evaluated.
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Due to its high sensitivity for brain water, MR is generally more sensitive for detecting subtle
brain abnonnalities, during the early stages of disease, than CT based techniques. In addition,
MR imaging is exquisitely sensitive for the detection of white matter changes, such as those
caused by demyelination and cerebral microvascular disease. Patients with substantial white
matter abnonnalities on MR imaging may have an apparently normal CT scan.
6.6.2 MRI Protocol
Neuroimaging was performed using a 1.0T SPE Magnetom scanner (Siemens, Erlangen,
Germany). Following midline localization, two sequences were used to image the entire brain
(Lawrie et al., 1999). The first scan was a double spin-echo sequence giving simultaneous
proton-density and T2-weighted images (TR=3565ms, TE=20ms and 90ms, 31 contiguous 5mm
slices acquired in the Talairach plane, FOV 250mm) that were used to calculate whole brain and
cerebrospinal fluid volumes using a supervised cluster analysis package (ANALYZE, Mayo
Foundation, Rochester, MN, USA). The second scan, for the regional volumetric analysis, was a
three dimensional magnetization prepared for rapid-acquisition gradient echo sequence consisting
of an 180 inversion pulse followed by a fast low-angle shot collection (Flip angle 12, TR=10 ms,
TE=4 ms, TI=200 ms, relaxation time delay time 500 ms, FOV 250mm) giving 128 contiguous
1.88mm thick slices in the coronal plane orthogonal to the Talairach plane. Inhomogeneity
corrections were performed using a flood phantom.
6.7 OBJECTIVE ASSESSMENT OF IMAGING ABNORMALITIES
The MRI brain scans of all participants were reviewed by an experienced neuroradiologist
(Professor Joanna Wardlaw, Department of Clinical Neurosciences, University of Edinburgh)
who scored each scan for the presence of abnormalities, in particular the presence of high-
intensity white matter lesions (Leukoaraiosis) (Breteler et al., 1994a;Breteler et al.,
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1994b;Longstreth, Jr. et al., 1996;Mirsen TR et al., 1991;Shimada et al., 1990;Van Swicten et al.,
1990;Wahlund et al., 1990) and cerebral atrophy(Breteler et al., 1994a;Breteler et al.,
1994b;Longstreth, Jr. et al., 1996;Mirsen TR et al., 1991;Van Swieten et al., 1990;Wahlund et al.,
1990). Professor Wardlaw assessed scans independently, and was blinded to the diabetes-specific
factors of participants.
6.7.1 Cerebral Atrophy
Cerebral atrophy was defined on the basis of which area of the brain appeared to have undergone
a relative loss of tissue volume. In the present series of studies scans were rated for the presence
of two distinct types of cerebral atrophy: "Ventricular atrophy" (i.e. with enlargement of the
ventricles) and "Sulcal atrophy" (i.e. with enlargement of the sulci). Professor Joanna Wardlaw
independently assessed all of the MRI neuroimaging studies included in this thesis and was
blinded to the diabetes-specific characteristics of each participant. The degree of cerebral atrophy
observed within each brain area was rated on a subjective rating scale of 0-3, with the grading
indicating the severity of atrophy:
Grade 0. No atrophy
Grade 1. Mild atrophy
Grade 2. Moderate atrophy
Grade 3. Severe atrophy
Using the above rating scale, the degree of cerebral atrophy observed on each MRl scan was
scored separately for the presence of Ventricular atrophy and Cortical atrophy.
6.7.2 High-Intensity White Matter Lesions (Leukoaraiosis)
High-intensity white-matter lesions (Leukoaraiosis) are abnonualities detected within the
cerebral-white matter on T2-weighted magnetic resonance images. White matter lesions (WML)
are thought to represent focal areas of increased water content, gliosis and demyelination within
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the white-matter, and are thought to signify foci of ischaemia, perhaps relating to microvascular
disease of the cerebral circulation (Pantoni and Garcia, 1995). The presence and degree of
Leukoaraiosis was independently evaluated by an experienced neuroradiologist (Professor Joanna
Wardlaw) who was unaware of the clinical and diabetes-specific characteristics of participants.
Several validated scoring systems were used to capture the intensity, distribution and appearance
ofWML as no single scale was judged by the rater to be an adequate summary of the type and
distribution of the white matter abnormalities observed in those evaluated. Rating scales used to
determine the degree of white matter changes differ in their relative sensitivity in scoring the
presence ofWML (Mantyla et al., 1997) and the majority of rating scales have been developed to
assess WML load in elderly subjects in whom changes were often marked and advanced.
Relatively few validated methodologies exist for the assessment of younger patient groups in
whom the white matter pathology observed could reasonably be expected to be more subtle. The
rating scales used to objectively determine the presence of white matter changes in the present
series of studies were:
(1) Fazekas et al (Fazekas et al., 1987)
White matter lesions within the peri-ventricular white matter (PVH) are scored separately, on
a scale of 0-3:
0. Absent
1. Caps or pencil-thin lining around ventricles
2. Smooth halo around ventricles
3. Irregular PVH extending into the deep white matter.
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Lesions located within the deep white matter (DWMH) are scored on a scale of 0-3:
0. Absent
1. One punctate focal lesion
2. Early confluence ofDWMH
3. Large areas of confluent DWMH.
(2) Shimada et al (Shimada et ah, 1990)
The presence ofWML was evaluated from three pre-determined slices and PVH and DWMH
were considered together. The slices utilised were through the (a) Foramen of Munro; (b)
body of lateral ventricle; (c) superior slice through the lateral ventricle. Scores were allocated
on a scale of 1 -4:
1. Absent or minimal PVH
2. Anterior and posterior caps or > 1 focal PVH
3. Multiple PVH and early confluence of foci
4. Multiple confluent patches.
(3) Wahlund et al (Wahlund et al., 1990)
PVH and DWMH are considered together and rated on a scale of 0-3:
1. Absent
1.5 Small solitary white matter changes
2 Multiple discrete or large solitary white matter changes
2.5 Multiple partly confluent white matter changes
3 Multiple large confluent white matter changes.
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(4) Van Swieten et al (Van Swieten et al., 1990)
White matter changes are assessed from three predetermined slices and PVH and DWMH are
considered together. Anterior and posterior changes are assessed separately and rated on a
scale of 0-3:
0. PVH absent or single lesion
1. Multiple focal lesions
2. Multiple confluent lesions throughout white matter.
(5) Mirsen et al (Mirsen TR et al., 1991)
PVH and DWMH are considered separately.
DWMH are rated on a scale of 0-4:
0. PVH absent
1. One or two focal lesions
2. Three to five lesions
3. >5 lesions
4. Confluent lesions.
PVH are rated as either absent or present.
(6) Breteler et al (Breteler et al., 1994a)
PVH and DWMH are considered together and rated on a scale of 0-3:
1. PVH absent or mild - small caps or lining, <5 lesions
2. Moderate PVH - regular shaped caps on both anterior and posterior of horns of the lateral
ventricles; > 5 punctate lesions; no confluence of lesions
3. Severe PVH - irregular outlines penetrating the deep matter at the homs of the lateral
ventricles, or marked areas ofWML surrounding the ventricles.
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(7) Longstreth et al (Longstreth, Jr. et al., 1996)
PVH and DWMH are considered together and scored from a single slice through the lateral
ventricles on a scale of 0-8:
0. Absent
1. Discontinuous PVH rim with minimal dots of sub-cortical disease
2. Thin continuous PVH rim with a few patches of sub-cortical disease
3. Thicker PVH with scattered patches of sub-cortical disease
4. More irregular PVH rim with mild sub-cortical disease
5. Mild PVH confluence surrounding the frontal and occipital homs
6. Moderate PVH confluence surrounding the frontal and occipital homs
7. Peri-ventricular confluence with moderate involvement of the centrum semi-ovale
8. Peri-ventricular confluence involving most of the centrum semi-ovale.
6.7.3 Small Punctate White Matter Lesions (SPWML)
MRI scans were also objectively scored for the presence of small punctate white-matter lesions
(SPWML), representing enlarged peri-vascular spaces (typically < 1mm diameter), that were
frequently observed in subjects but not accounted for by the rating scales described above that
were used to evaluate white matter changes. Using the most affected hemisphere, small
punctuate white matter lesions were rated on a scale of 0-3:
0. Absent
1. Mild -<10 lesions
2. Moderate - 10-20 lesions
3. Severe - >20 lesions.
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6.8 VOLUMETRIC ANALYSIS OF MAGNETIC RESONANCE IMAGES
Volumetric analysis was performed by an experienced technician (Annette Blain) from the
Department of Medical Radiology, University of Edinburgh. The technician performing the
volumetric analysis was blind to the clinical and diabetes-specific characteristics of all
participants. Regions of interest analysis was performed on a Sun Microsystem (Sun
Microsystems, CA, USA) workstation using a supervised cluster analysis package (ANALYZE®,
MAYO Foundation, Rochester, USA). Regions of interest were outlined and their volumes






6.9 DETERMINATION OF APOE GENOTYPE
DNA was extracted from venous blood from all participants in the sub-study which explored the
effects of APOE Genotype on cognitive ability in Type 1 diabetes. The APOE genotype was
determined using the standard methodology developed by Wenham et al (Wenham et al., 1991).
This technique utilises a single stage PCR-RFLP assay to accurately determine the APOE
genotype and provides a greater degree of accuracy when compared to previous methodologies
which were reliant upon isoelectric focusing of plasma APOE isoforms.
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CHAPTER 7
INFLUENCE OF DIABETES-SPECIFIC FACTORS ON CEREBRAL
STRUCTURE AND FUNCTION IN TYPE 1 DIABETES
7. INFLUENCE OF DIABETES-SPECIFIC FACTORS ON CEREBRAL
STRUCTURE AND FUNCTION IN TYPE 1 DIABETES
7.1 INTRODUCTION
Protracted severe hypoglycaemia is an uncommon complication of Type 1 diabetes but anecdotal
reports have described permanent neurological and cognitive deficits following protracted severe
hypoglycacmia that were associated with localised neuro-imaging abnonnalities (Bakshi et al.,
2000;Boeve et ah, 1995;Chalmers et ah, 1991;Chan et ah, 2003;Finelli, 2001;Gold and Marshall,
1996;Holemans et ah, 2001;Koppel and Daras, 1993;Maekawa et ah, 2006;Perros et ah,
1994;Rajbhandari et ah, 1998;Richardson et ah, 1981;Yoneda and Yamamoto, 2005). The neuro-
radiological abnormalities described in these case reports predominantly affected the cortical gray
matter and sub-cortical gray matter structures, particularly the hippocampus and basal ganglia,
which appear more susceptible to hypoglycaemia-induced damage (Auer and Siesjo, 1993), but
abnormalities of white matter have also been reported. It remains unresolved whether recurrent
episodes of severe hypoglycaemia, in the absence of protracted coma, can have long-term
deleterious effects on intellectual function in adults. Intensified insulin therapy, which can
achieve strict glycaemic control and can substantially reduce the risk of developing diabetic
microangiopathy and its associated morbidity, is associated with a three-fold higher incidence of
severe hypoglycaemia (1997). Current treatment goals for those with Type 1 diabetes advocate
the attainment of strict glycaemic control to reduce future microvascular morbidity and as such
will increase the cumulative exposure to severe hypoglycaemia. The human brain depends on a
continuous glucose supply and rapidly malfunctions during hypoglycaemia, but appears to
recover rapidly; a single acute episode of hypoglycaemic coma temporarily impairs intellectual
function but no permanent effects on cognitive ability are evident 36 hours later (Strachan et al.,
2000). Prospective studies have found no adverse effect of recurrent episodes of severe
hypoglycaemia on cognitive function in young people with type 1 diabetes (1996;Austin and
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Deary, 1999;Reichard et al., 1991). However, cross-sectional studies in older adults in whom
type 1 diabetes had commenced after adolescence, and in whom the duration of diabetes was
longer, have demonstrated a modest, but significant cognitive decrement associated with the
frequency of preceding severe hypoglycaemia (Langan et al., 1991;Lincoln et al., 1996;Sachon et
al., 1992;Wredling et al., 1990). A study of a small sub-group of the subjects previously
examined by Langan et al (Langan et al., 1991) were re-examined by Perros et al who used
magnetic resonance imaging (MRI) of the brain to delineate the neuroimaging associations of
severe hypoglycaemia exposure in this cohort. Perros et al reported that cortical atrophy was
more prevalent in those with a history of frequent exposure to severe hypoglycaemia (n=ll)
relative to those who were severe hypoglycaemia naive (n=ll) (Perros et al., 1997). This small
study is the only to date to examine the neuro-radiological associations of severe hypoglycaemia
exposure in a structured manner.
The incidence of cerebral macrovascular disease is increased in Type 1 diabetes (Grunnet, 1963)
and increases with age (Laing et al., 2003) but is rare below the age of 45 years (The DCCT
Investigators, 1995;Klein et al., 2004;Nathan et al., 2005;Stettler et al., 2006). Multiple
ncuropathological abnonnalities have been described in post-mortem brains of individuals with
type 1 diabetes who had end-stage microangiopathy (Reske-Nielsen and Lundbaek, 1963),
although changes could not be attributed exclusively to diabetic microangiopathy due to the
confounding presence of co-existent macrovascular disease, hypertension and uremia. It remains
uncertain whether diabetes per se is associated with the development of cerebral microangiopathy
remains speculative. The concept of a "diabetic encephalopathy" has been mooted for in excess
of 50 years and was revisited more recently by Dejgaard and colleagues (Dejgaard et al., 1991)
who suggested along with others (McCall, 1992) that multiple factors would be likely
contributors to the development of a diabetic microangiopathy, including metabolic derangements
such as severe hypoglycaemia and diabetic kcto-acidosis as well as hypertension. The potential
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relationships between diabetic microangiopathy, cognitive performance and brain structure have
only been explored in a limited manner: a few small underpowered studies confounded by co¬
morbidity (Dejgaard et al., 1991;Lunetta et ah, 1994;Yousem et ah, 1991) and limited by the
deficiencies and relative insensitivity of the neuroimaging technology available at the time have
been published. Results to date have been conflicting. High-intensity lesions of the cerebral
white matter (Leukoaraiosis), abnormalities that are thought to represent foci of ischemia and
gliosis (Pantoni and Garcia, 1995), were observed more frequently in a small cohort with long
duration type 1 diabetes who had microangiopathy, hypertension and uremia (Dejgaard et ah,
1991), whereas no abnormalities were evident on cerebral MRI in another study of subjects who
had advanced diabetic retinopathy (Yousem et ah, 1991). A further neuroimaging study observed
cerebral atrophy more frequently in people with type 1 diabetes but was too small to give clues as
to causality and utilised questionable techniques to determine the presence of cerebral atrophy
(Lunetta et ah, 1994).
Optimal intellectual development may be compromised by the onset of type 1 diabetes during
early childhood. The diabetes-related factor most consistently related to measurements of
cognitive ability and intelligence in later life is the onset age of type 1 diabetes; children
developing the disorder in early childhood are more likely to score relatively poorly on cognitive
tests, independently of their diabetes duration. Ack et al first identified an association between an
early childhood onset of Type 1 diabetes and comparatively lower scores on a test of general
intelligence; children whose onset of diabetes was before their 5th birthday scored on average 10
IQ points lower than their siblings (Ack et ah, 1961). Subsequent studies identified small-to-
moderate permanent differences in non-verbal intelligence (fluid intelligence) (Holmes and
Richman, 1985;Northam et ah, 1999;Rovet et ah, 1988;Ryan et ah, 1985a;Ryan et ah, 1985a),
verbal intelligence (Alvarez and Rovet, 1997;Ryan et ah, 1985a;Schocnle et ah, 2002),
information processing (Bjorgaas et ah, 1997;Northam ct ah, 2001;Ryan et ah, 1985a;Northam et
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al., 2001;Northam et al., 2001), visuo-spatial ability (Northam et al., 1999;Rovet et al.,
1988;Ryan et al., 1985a;Northam et al., 1999), attention (Alvarez and Rovet, 1997;Bjorgaas et al.,
1997;Chabriat et al., 1994;Northam et al., 2001;Service, 1995;Wysocki et al., 2003;Alvarez and
Rovet, 1997), executive function (Northam et al., 2001;Service, 1995), and learning and memory
ability (Hershey et al., 2003;Hershey et al., 2005;Holmes and Richman, 1985;Ryan et al.,
1985a;Service, 1995;Holmes and Richman, 1985). Prospective evaluation has confirmed that an
early childhood onset of T1DM independently influences verbal (Northam et al., 2001;Rovet and
Ehrlich, 1999) and non-verbal intelligence (Schoenle et al., 2002), attention (Northam et al.,
2001;Rovet and Ehrlich, 1999), psychomotor speed (Northam et al., 1998) and executive
functions (Northam et al., 2001;Schoenle et al., 2002). Experts have suggested that the
differences in ability observed in association with an early childhood onset of T1 DM may reflect
chronic hyperglycemia, severe hypoglycaemia or other diabetes-related organic factors, whereas
others have proposed psychosocial factors, relating to school attendance (Ryan et al., 1985b) and
behaviour (Rovet et al., 1993) as causative. However, the pathogenesis of differences in
intellectual ability associated with an early childhood onset of T1DM remains uncertain.
7.2 AIMS
The present study examined a group of young people with type 1 diabetes of relatively long
duration, who had developed the disorder during childhood or adolescence, and as a consequence
may therefore be more vulnerable to the development of cognitive impairment (Northam et al.,
2001;Ryan and Becker, 1999) than those in whom the onset of diabetes occurred after the full
development and maturation of the central nervous system. The present study was designed to
ascertain the neuroimaging and cognitive associations of the clinical complications and disease-
specific factors unique to Type 1 diabetes. In particular, the neuroimaging correlates of preceding
exposure to recurrent severe hypoglycaemia, the presence of microvascular disease (as
retinopathy), the duration of diabetes and the age of onset of diabetes were of particular interest.
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The present study was not designed to examine the effects of diabetes per se on cognitive
function, rather was focused on detennining the consequences of diabetes-specific disease factors
on the neuropsychological and neuroimaging outcomes of interest.
7.3 SUBJECTS AND METHODS
7.3.1 Study Design
The study was cross-sectional in design and the study protocol was completed in sequential order:
1. detailed Magnetic Resonance Imaging (MR1) of the brain;
2. neuropsychological test battery;
3. retinal examination;
4. assessment of preceding severe hypoglycaemia;
Each component was evaluated and scored blind to all other information.
7.3.2 Subjects
Recruitment criteria were selected with the explicit aim of obtaining a cohort with a long duration
of diabetes (> 10 years), sufficient to ensure exposure to the metabolic consequences of interest
(severe hypoglycaemia, diabetic retinopathy, disease duration), but without other significant co¬
morbidity which may confound the interpretation of findings. Subjects were recruited who had
developed type 1 diabetes in childhood or adolescence (age at diagnosis <18 years) and who had
attained full intellectual development (age > 20 years) at the time of study. An upper age limit of
45 years was applied to minimise the potential confounding effects of ageing on cognitive ability
and brain structure, but also to minimise the likelihood of recruiting subjects with silent
macrovascular disease of the cerebral circulation. Those invited to participate either had no
clinical evidence of diabetic microvascular complications or had early microangiopathy, manifest
as background retinopathy alone. As many of the cognitive ability tests utilised were highly
dependent on visual function, those with more advanced degrees of diabetic retinopathy (Airlie
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House grading > 2) including diabetic maculopathy, pre-proliferative retinopathy, proliferative
retinopathy or those who had previously received laser treatment for diabetic retinopathy were
excluded from participation (The Diabetes Control and Complications Trial Group, 1991). The
presence of any clinically apparent degree of diabetic neuropathy, the presence of
microalbuminuria, or overt proteinuria were also exclusion criteria. Other exclusions included
essential hypertension (defined as BP > 140/90 mmHg), any previous central nervous system
pathology, previous alcohol or drug misuse, or other multi-system disease known to affect the
central nervous system. The aim was to recruit only those in whom diabetes-related factors were
likely to account for any differences observed in their cognitive performance or brain structure.
The application of the above exclusion and inclusion criteria resulted in the recruitment of a
group of people who had Type 1 diabetes of long duration, yet had a comparatively lower
microvascular disease burden relative to the general population of individuals with similar disease
duration. This caveat should be borne in mind when interpreting the study findings.
Seventy-four individuals with type 1 diabetes were recruited. Seventy-one participants completed
the study protocol, with three participants failing to return to complete the cognitive assessment.
The data from the 71 participants who completed the full study protocol are presented. The
clinical characteristics of those studied are summarised in Table 1. Twenty-five subjects (35%)
had background diabetic retinopathy, identified by digital retinal imaging and direct
ophthalmoscopy. Background diabetic retinopathy was defined by the presence of at least two or
more microaneurysms in one eye (Airlie House Gradings la-lc). Exposure to severe
hypoglycaemia was assessed retrospectively using a validated formatted hypoglycaemia
questionnaire (Deary et al., 1993). Participants were requested to discuss their severe
hypoglycaemia history with relatives or friends before completing questionnaires, to improve the
accuracy of estimates. Details were recorded of the lifetime total number of episodes, the
frequency of occurrence of episodes, and the total number of episodes of convulsions, coma, and
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other episodes requiring medical assistance to treat the hypoglycaemia. Severe hypoglycaemia
was defined as any episode of hypoglycaemia sufficient in severity to require external assistance
to facilitate recovery, similar to the definition used in the Diabetes Control and Complications
Trial criteria [(The Diabetes Control and Complications Trial Group, 1997). Using this
definition, twenty subjects (28%) had never experienced severe hypoglycaemia, while 21 (30%)
had experienced ten or more previous episodes. Subdivision of the cohort by the presence of
background retinopathy showed a similar level of exposure to severe hypoglycaemia in the two
subgroups, with a slight excess of preceding severe hypoglycaemia in the sub-group who had no
diabetic retinopathy. The participants who had established retinopathy were slightly older and
tended to have had diabetes of longer duration, although the onset of diabetes occurred at a
similar age. The subgroups with or without retinopathy were very similar in their duration of
education and estimated pre-morbid cognitive ability.
149






Age (years) 26.4 ±4.6 (26, 20 to 36) 31.5 ±6.0 (32,21 to 44) 0.23
Sex (male/female) 23:23 14:11 0.63
Secondary Education (years) 6.9 ±2.3 (6, 4 to 11) 7.3 ±2.4 (8, 4 to 11) 0.95
NART (pre-morbid ability) 31.9 ±6.0 (32, 15 to 42) 32.5 ±6.6 (33, 16 to 41) 0.94
HbAlc at time of Study (5.0 - 6.5%) 8.4 ±1.2 8.9 ± 1.3 0.83
Blood Pressure (mmHg) 123/73 ± 14/10 121/74 ± 12/11 0.56
Age at Diagnosis ofT1DM (years) 9.5 ±4.4 (9, 1 to 16) 9.9 ±4.0 (10, 1 to 17) 0.67
Duration ofDiabetes (years) 17.0 ±4.6 (16, 10 to 30) 21.6 ±5.9 (22, 10 to 31) 0.052
Severe Hypoglycaemia
Total lifetime episodes (median, range) 6.0 (0 to 200) 4.0 (0 to 45) 0.86
No previous episodes (% participants) 26.1 32.0 -
1-4 episodes (% participants) 19.6 28.0 -
5-10 episodes (% participants) 23.9 12.0 -
>10 episodes (% participants) 30.4 28.0 -
Data are means ± SD with median and range bracketed.
NART = National Adult Reading Test.
HbAic = Glycated Haemoglobin, non-diabetic range 5.0-6.5% (by HPLC).
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Table 7.2. Characteristics of participants grouped by Diabetes Onset Age.
Onset < 7 Years
(n=26)
Onset > 7 Years
(n=45)
p-value
Age (years) 25.2 ±4.6 (23, 20-36) 29.9 ±5.6 (30, 20-44) <0.0001
Sex (male/female) 13:13 24:21 0.79
Secondary Education (years) 7.0 ±2.0 (6, 4-10) 7.1 ±2.5 (6,4-11) 0.82
NART (pre-morbid ability) 32.8 ±5.4 (33,21-41) 31.8 ±6.6 (32, 15-42) 0.52
HbAlc at time of study (%) 8.3 ±1.1 8.7 ± 1.3 0.20
Blood Pressure (mmHg) 122/72 ± 11/10 122/74 ± 14/10 0.94
Age at Diagnosis ofT1DM (years) 5.0 ±2.3 (5.5, 1-7) 12.2 ±2.4 (12, 8-17) <0.0001
Duration ofDiabetes (years) 20.1 ±5.2(18.5, 13-31) 17.7 ±5.5 (16, 10-29) 0.07
Background Retinopathy (%) 23% 42% 0.10
Severe Hypoglycaemia
Median Total Episodes (% exposed, range) 7.0 (77%, 0 to 200) 4.0 (69%, 0 to 100) 0.48
Median Total Coma (% exposed, range) 2.0 (65%, 0 to 40) 0.0 (49%, 0 to 9) 0.26
Median Total Seizures (% exposed, range) 0.0 (46%, 0 to 30) 0.0 (33%, 0 to 6) 0.25
Data are means ± SD with median and range bracketed.
NART = National Adult Reading Test.
HbAic = Glycated Haemoglobin, non-diabetic range 5.0-6.5% (by HPLC).
7.3.3 Methods
An outline of the methods utilised for ncuro-imaging, the assessment of intelligence and cognitive
ability are provided in this section. Detailed descriptions of the neuro-imaging techniques, the
characteristics of the neuropsychological test battery and the manner in which the clinical
complications of Type 1 diabetes were evaluated are provided in the Methods Chapter.
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Magnetic Resonance Imaging Protocol
MRI examinations of the brain were performed using a 1,0T SPE Magnetom scanner (Siemens,
Erlangen, Germany). Following midline localization, two sequences were used to image the
whole brain (Lawrie et al., 1999). The first scan provided simultaneous proton-density and T2-
weighted images (TR=3565ms, TE=20ms and 90ms, 31 contiguous 5mm slices acquired in the
Talairach plane, FOV 250mm) that were used to calculate whole brain and cerebrospinal fluid
volumes using a supervised cluster analysis package (ANALYZE, Mayo Foundation, Rochester,
MN, USA). The second scan, for the regional volumetric analysis, was a three dimensional
magnetization prepared for rapid-acquisition gradient echo sequence consisting of an 180
inversion pulse followed by a fast low-angle shot collection (Flip angle 12, TR=10 ms, TE=4 ms,
TI=200 ms, relaxation time delay time 500 ms, FOV 250mm) giving 128 contiguous 1.88mm
thick slices in the coronal plane orthogonal to the Talairach plane. Inhomogeneity corrections
were performed on Sun Microsystem workstations using ANALYZE to outline neuroanatomical
structures. The temporal lobe and amygdala-hippocampal complex were identified and their
areas outlined and volumes calculated by summing voxels in the regions of interest.
Assessment ofHigh-Intensity White Matter Lesion Burden
Each MRI scan was reviewed by an experienced Neuroradiologist (JW) and scored
independently, and blinded to clinical factors, for the presence of high-intensity white matter
lesions (leukoaraiosis) (Breteler et al., 1994a;Breteler et al., 1994b;Fazekas et al.,
1987;Longstreth, Jr. et al., 1996;Mirsen TR et al., 1991;Shimada et al., 1990;Van Swieten et al.,
1990;Breteler et al., 1994a). Several scoring systems were used to capture the intensity,
distribution and appearance of white-matter lesions as no single scale was judged to be an
adequate summary (Mantyla et al., 1997). An example of a high-intensity white matter lesion
(Leukoaraiosis) from a participant of the present study is illustrated in Figure 7.1.
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Figure 7.1. High-Intensity White Matter Lesion in deep white matter (arrowhead).
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MRI scans were also scored for the presence of a distinctly different type of white matter
abnormality, the small punctate white-matter lesion (SPWML), which was frequently observed
but not accounted for by any of the above rating scales (Figure 7.2). A scale of 0-3 was utilised
to quantify the presence of SPWML:
0. No SPWML;
1. Mild SPWML with total number not exceeding 10 lesions,
2. Moderate SPWML with total number of 10-20 lesions,
3. Severe SPWML with greater than 20 lesions observed.
This scale was used to quantify the presence of SPWML, indicating enlarged peri-vascular
spaces, in three distinct brain regions (hippocampus, basal ganglia, centrum semi-ovale) using the
most affected hemisphere. Examples of an MRI scan where small punctuate white matter lesions
were observed in participant of the present study is illustrated in Figures 7.2(a) and 2(b).
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Figure 7.2 (a) Small Punctate White Matter Lesions (arrowheads) in the region of the
Hippocampus.
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Figure 7.2 (b) Magnified version of the same Hippocampal SPWML (arrowheads).
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Assessment of the Presence and Degree of Cerebral Atrophy
The presence or absence of cerebral atrophy was subjectively determined by an experienced
Neuroradiologist. The severity of atrophy was rated on a subjective scale of 0-3:
0. No cerebral atrophy;
1. Mild cerebral atrophy;
2. Moderate cerebral atrophy;
3. Severe cerebral atrophy.
When present, cerebral atrophy was defined as being either "Ventricular" or "Sulcal".
Ventricular atrophy, also known as central brain atrophy, reflects enlargement of the cerebral
ventricles. Sulcal atrophy, also known as gyral or cortical atrophy, reflects enlargement of the
cerebral sulci and infers loss of cortical gray matter. An example of ventricular atrophy from the
MRI scan of a participant of the present study is illustrated in Figure 7.3. An example of sulcal
atrophy has not been provided due to the scarcity and mild nature of this neuroimaging
abnormality that was observed in the present cohort.
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Figure 7.3. Ventricular Atrophy from a participant of the present study (arrowheads). The
arrowhead indicates enlargement of the cavity of the body of the Lateral Ventricle.
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Assessment ofNeuropsychological Function
The neuropsychological test battery was chosen to be sensitive to mild-to-moderate cognitive
decrements and to provide an assessment of some major cognitive domains. Trained assessors,
blinded to the diabetes characteristics of participants, administered neuropsychological tests in a
standardised manner. The capillary glucose concentration was measured before the cognitive
assessment to exclude prevailing hypoglycaemia. The neuropsychological session was
rescheduled if hypoglycaemia was present or if antecedent hypoglycaemia had occurred within
the preceding 24 hours.
The neuropsychological tests utilised were:
Hospital Anxiety andDepression Scale (Zigmond and Snaith, 1983)
The potential confounding effects that affective disorders can have on cognitive ability were
assessed.
Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981)
The Performance IQ subtests of the WAIS-R are sensitive to disruption by organic brain disease
and measure current intellectual performance (fluid intelligence). The Picture Completion,
Object Assembly, Block Design, Digit Symbol tests were utilised.
National Adult Reading Test (NART) (Nelson and Willison, 1991)
Performance on the NART is relatively resistant to the effects of organic brain disease and
performance on this test correlates more closely with pre-morbid IQ than estimates obtained from
socio-economic or demographic variables. NART performance is representative of 'best ever'
global cognitive performance (irrespective of age, disease or time) and in the present study was
used as the estimate of pre-morbid intellectual ability (pre-morbid IQ, crystallized intelligence) of
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each participant. Pre-morbid ability is generally the most powerful determinant of performance
on many neuropsychological tests.
Inspection Time (IT) (McCrimmon et al., 1996)
Inspection Time, a sub-component of information processing ability, was used to provide a
measure of early visual infonnation processing ability. Participants were asked to discriminate
between the spatial position (left or right) of two briefly-presented vertical lines of different
lengths. The stimuli were backward-masked, the presentation duration was varied, and the
duration of time required to reliably distinguish the stimulus (85% correct) was termed the
participant's 'inspection time'.
Choice Reaction Time (CRT) (Jensen, 1987)
Choice reaction time was utilised as a measure of psychomotor speed and complemented
inspection time in assessing information processing ability. Tests measuring 1,2,4,8 and 8,4,2,1-
choice reaction times were used. Decision and movement times were measured.
Borkowski Verbal Fluency Test (controlled association) (Borkowski and Benton, 1967)
The Borkowski Verbal Fluency Test is thought to provide an assessment of frontal lobe and
executive functions. In this test participants have 60 seconds to state as many words as possible,
beginning with letters of the alphabet pre-specified by the tester.
Paced Auditory Serial Addition Task (PASAT) (Deary I.J. et al., 1991)
The PASAT was used to assess the ability of participants to sustain attention and concentration.
Participants listened to a numbers list, which they were required to add together according to a
given rule. After practice, two consecutive trials of 61 numbers were performed with 4s and 2s
between successive digits respectively.
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7.3.4 Statistical Analyses
Statistical analysis was performed using SPSS vlO.O (®SPSS Inc, Chicago, USA). The
relationship between demographic variables, neuropsychological performance, brain volumes and
MRI outcomes (cerebral atrophy, high-intensity white matter lesions, coded numerically) was
examined initially using bi-variate correlation (Speannan's rho). Neuropsychological
perfonnance was analysed by domain to reduce the possibility of Type 1 error, before sub-
analysis of individual tests was attempted. Sub-analysis was not perfonned if the multivariate
statistic (F-value) was non-significant. Parameters were entered into multivariate linear models
(MANCOVA) on the basis of prior hypotheses and correlates between demographic variables,
neuropsychological performance and brain volumes. This technique was utilised to determine
whether Diabetes Onset Age, Diabetic Retinopathy status, Severe hypoglycaemia exposure, or
Duration of Diabetes influenced neuropsychological performance or brain volumes and to
estimate the magnitude of their influence (Eta2). Specific models were constructed for the
analysis of neuropsychological performance and brain volumes. The neuropsychological model
included Gender, Diabetic Retinopathy status (coded as present/absent) and the Diabetes Onset
Age (coded as EOD < 7 years, LOD > 7 years) as between-subjects variables. Pre-morbid IQ
(NART), Age, Duration of Diabetes and Severe Hypoglycaemia exposure (as log transformed
total number of lifetime episodes due to skewed distribution) were entered as co-variates. The
brain volume model included Gender, Diabetic Retinopathy status (coded as present/absent) and
Diabetes Onset Age (coded as EOD < 7 years, or LOD > 7 years) as between-subjects factors,
with Age, Diabetes Duration, Severe Hypoglycaemia exposure (as log transformed total number
of lifetime episodes) and Intracranial Volume as co-variates. The relationship between the
diabetes variables of interest and subjectively-rated cerebral atrophy (coded as present/absent) or
the presence of white-matter lesions (coded as present/absent) was analysed by multiple logistic
regression, using Gender (male/female), Diabetes Onset Age (coded as EOD/LOD) and Diabetic
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Retinopathy status (coded as present/absent), Severe Hypoglycaemia exposure (coded as
naive/exposed) as factors. Age and Diabetes Duration were included as co-variates. Co-variates
and factors were entered into the multiple logistic regression models using a forward conditional
stepwise approach, such that non-significant variables were ejected from the final model.
7.4 RESULTS
7.4.1 Independent Predictors of Cognitive Ability (MANCOVA)
General linear modeling (MANCOVA) identified the following variables, listed in descending
order ofmagnitude of influence, as statistically significant independent predictors of performance
on the entire battery of neuropsychological tests:
1. Pre-morbid intellectual ability (NART, F=7.9, p<0.0001, Eta2=0.38);
2. Diabetic Retinopathy (F=6.3, p<0.0001, Eta2=0.33);
3. Gender (F=3.8, p<0.01, Eta2=0.23);
4. Diabetes Onset Age Group (F=3.0, p=0.03, Eta2=0.19).
Other factors of interest that were included in the multi-variate model but which did not appear to
exert a statistically significant influence on neuropsychological performance included:
1. Severe Hypoglycaemia exposure (F=0.64, p=0.64, Eta2=0.05);
2. Duration ofDiabetes (F=1.0, p=0.41, Eta2=0.07).
3. Age (F=T.34, p=0.26, Eta2=0.13).
7.4.2 Severe Hypoglycaemia and Neuropsychological Performance
A wide range of previous exposure to severe hypoglycaemia was recorded within the cohort,
allowing examination of possible neuropsychological consequences associated with cumulative
exposure to severe hypoglycacmia (Table 7.1). Approximately one-third of participants were
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naive to severe hypoglycaemia with a further third having experienced in excess of ten lifetime
episodes. Despite a wide spread of cumulative exposure to severe hypoglycaemia within the
study cohort no summary measure of preceding severe hypoglycaemia was significantly
correlated with neuropsychological performance. The correlation co-efficients (Spcannan's Rho)
between estimates of preceding severe hypoglycaemia and neuropsychological performance are
shown in Table 7.3.
Table 7.3. Correlation co-efficients between measures of exposure to severe hypoglycaemia and
neuropsychological function (Spcannan's rho).
Performance IQ Frontal & Executive Visual Information Psychomotor Speed Attention &
(WAIS-R) Function (Borkowski) Processing (IT) (Choice Reaction Time) Concentration (PASAT)
Lifetime episodes -0.009 0.068 -0.068 0.012 -0.129
Frequency of episodes -0.013 0.063 -0.048 0.011 -0.085
Episodes requiring glucagon -0.061 0.069 -0.121 0.032 -0.038
Episodes of coma 0.021 0.121 -0.066 -0.044 -0.089
Episodes of convulsion -0.023 0.008 -0.086 -0.080 0.044
All correlations p>0.05.
7.4.3 Background Retinopathy and Neuropsychological Performance
The relative neuropsychological performance of those with and without Background Diabetic
Retinopathy is summarised in Table 7.4, along with the estimated effect size (Eta2) of
Background Retinopathy and pre-morbid IQ (NART) on cognitive ability. Any cognitive
difference observed between the two sub-groups fonned by the presence/absence of Diabetic
Retinopathy is not consequent upon differences in the degree of education or prior intellectual
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ability, firstly because the two groups are very similar on these variables (Table 7.1) and secondly
as pre-morbid IQ was entered as a co-variate in the analyses.
Those subjects who had background retinopathy performed less well across most, but not all, of
the cognitive domains examined. The presence of Diabetic Retinopathy was associated with a
relative disadvantage in current intellectual performance (WAIS-R performance IQ, p=0.008) of
moderate effect size (Eta2=0.14). Information processing ability (sum of Z-scores for Choice
Reaction Time and Inspection Time) was poorer in those with Retinopathy (p=0.001) and the
effect size was moderate-to-large (Eta2=0.22). Both components of the tests which comprised the
information processing domain were affected: performance disadvantage was observed in Choice
Reaction times (4 Choice Reaction Time decision time component, p=0.003, Eta2=0.17) and early
visual information processing (p=0.03, Eta2=0.09). The ability to sustain attention and
concentration (PASAT) was also poorer in those who had Retinopathy (p=0.03, Eta2=0.09).
However, the presence of Diabetic Retinopathy was not associated with a performance
disadvantage on the Borkowski Verbal Fluency Test, a test that is thought to examine frontal lobe
and executive functions.
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7.4.4 Interaction Between Diabetic Retinopathy and Severe Hypoglycaemia
The co-existence of Diabetic Retinopathy and preceding exposure to Severe Hypoglycaemia did
not result in any additional cognitive disadvantage over and above that associated with the
presence of Diabetic Retinopathy alone: Retinopathy x Severe Hypoglycaemia interaction
F=0.52, p=0.76, Eta2=0.05. However, the size of the sub-groups for this sub-analysis were small
[Diabetic Retinopathy alone (n=8) vs. Severe Hypoglycaemia and Retinopathy (n=17)], which
makes definitive conclusions inappropriate through limitations in statistical power. However, this
analysis does infer that if any detrimental interaction does exist between Retinopathy and Severe
Hypoglycaemia it is likely to be of small magnitude and may be of little practical consequence.
7.4.5 Early Onset Age of Diabetes and Neuropsychological Performance
The neuropsychological performance of those with an Early Onset Diabetes (EOD < 7 years of
age) relative to those with a Later Onset Diabetes (LOD > 7 years of age) is summarised in Table
7.5. The statistical significance and estimated magnitude of effect (Eta2) of the Diabetes Onset
Age grouping are provided. An EOD was associated with a performance disadvantage across a
number of ability domains. Those with an EOD exhibited poorer fluid intelligence ability
(WAIS-R performance IQ, p=0.03) of small-to-moderate magnitude (Eta2=0.09), a difference
largely accounted for by performance on the Block Design and Digit Symbol Substitution
subtests, tests which assess spatial ability and psychomotor speed respectively. Information
processing ability (sum of Z-scores for Choice Reaction Time and Inspection Time) was
significantly poorer in those with an EOD (p=0.006) and the disadvantage was of moderate
magnitude (Eta2=0.13). The disadvantage in information processing performance associated with
EOD was limited to performance on tests of Simple Reaction Time (p=0.04, Eta2=0.07, decision
time component) and Choice Reaction Time (2, 4 and 8-Choice Reaction Time decision time
component (p=0.006-0.06, Eta2=0.06-0.I2). An EOD was not associated with poorer
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performance on tests of early visual information processing ability (Inspection time), sustained
attention and concentration (PASAT) or frontal lobe and executive functions (Borkowski Verbal
Fluency Test), indicating that the cognitive disadvantage associated with EOD was selective. No
statistically significant interaction was observed between an EOD and other diabetes-specific
factors. In particular, the presence of Diabetic Retinopathy and an EOD did not interact to
statistically influence cognitive ability on multi-variate testing (F=0.71, p=0.59, Eta2=0.05),
although those individuals in whom an EOD and Diabetic Retinopathy were co-existent
performed the most poorly.
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7.4.6 Neuroimaging Abnormalities
Abnormalities detected on the MRI scans of participants were generally mild and subtle. High-
intensity peri-ventricular white matter lesions particularly as peri-ventricular caps, or pencil-thin
rims, were common and present in one-third of scans. Deep white matter lesions were observed
infrequently. Small punctuate white matter lesions were frequently observed.
Severe Hypoglycaemia and Brain Structure
No significant correlation was identified between any summary measure of previous exposure to
severe hypoglycaemia and the presence of any structural MRI neuroimaging abnormalities. In
particular, no correlation was observed between the presence of high-intensity lesions in the
cerebral white matter (p=0.018, p=0.90), or cerebral atrophy (p=-0.026, p=0.84) and any
summary measure ofprevious severe hypoglycaemia exposure.
Diabetic Retinopathy and Structural Brain Abnormalities
No associations were observed between Diabetic Retinopathy and the presence of cerebral
atrophy, as either ventricular or sulcal atrophy, or regional brain volumes (Table 7.8). However,
the presence of Diabetic Retinopathy was associated with more frequent small punctate high-
intensity peri-ventricular white matter lesions (SPWML) in the region of the basal ganglia. One
third (33.3%) of those with Diabetic Retinopathy had a degree of peri-ventricular SPWMLs in the
basal ganglia, which were usually mild (<10 lesions), relative to 4.7% of those who did not have
Diabetic Retinopathy. More advanced degrees of SPWML were not observed. The robustness of
the association was evaluated using MANCOVA, which also considered the influence of age and
gender. The relationship remained statistically significant (p=0.005), but Diabetic Retinopathy
accounted for a small proportion of the variance in SPWMLs scores (Eta2=0.012) and the
presence of SPWML was not associated with neuropsychological performance. SPWML in the
Hippocampus or Centrum Semi-Ovale, or a summation of SPWML in all three areas, were no
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more frequent in those who had Diabetic Retinopathy. White matter lesions, as Leukoaraiosis,
rated by a variety of published rating scales, (Breteler et al., 1994b;Breteler et al., 1994a;Fazekas
et al., 1987;Longstreth, Jr. et al., 1996;Mirsen TR et al., 1991;Shimada et al., 1990;Van Swieten
et al., 1990) were no more common in those who had Diabetic Retinopathy.
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Table 7.8. Diabetic Retinopathy status, Age and Regional Brain Volumes. Data are presented
after adjustment for Intra-Cranial Volume (MANCOVA).
No Retinopathy Retinopathy Effect Effect
Estimated Estimated of of
Brain Volume Marginal Mean Marginal Mean Retinopathy Age
(cm3) (95% CI)) (95% CI)
1259 1262 p=0.86 p=0.11
Whole Brain
(1238-1281) (1238-1287) Eta2<0.01 Eta2=0.04
22.1 18.0 p=0.08 p=0.57
Lateral Ventricles
(19-25) (15-21) Eta2=0.05 Eta2<0.01
78 75 p=0.12 p=0.78
Right Temporal Lobe (75-80) (72-77) Eta2=0.04 Eta2=<0.01
73 72 p=0.09 p=0.91
Left Temporal Lobe
(71-75) (70-75) Eta2=0.06 Eta2<0.01
Right Amygdala- 4.4 4.3 p=0.47 p=0.004
Hippocampal Complex (4.2-4.6) (4.1-4.5) Eta2<0.01 Eta2=0.14
Left Amygdala- 4.4 4.3 p=0.57 p=0.007
Hippocampal Complex (4.2-4.6) (4.1-4.5) Eta2<0.01 Eta2=0.12
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Interaction: Diabetic Retinopathy, Severe Hypoglycaemia and Brain Structure
Cerebral atrophy or white matter lesions, in the form of small punctate lesions or leukoaraiosis,
were no more prevalent in those who had background retinopathy and who had also experienced
severe hypoglycaemia compared to those with only background retinopathy.
Diabetes Onset Age and Structural MRI Abnormalities
The relationship between Diabetes Onset Age and subjectively-rated MRI scan abnormalities is
shown in Table 7.9. An EOD was associated with a significantly higher prevalence of ventricular
atrophy (Figure 7.3). Ventricular atrophy was commonly observed, present in 60% of EOD
subjects and 20% of LOD subjects [p=0.01, odds ratio=4.6 (95% CI=1.4-14.8), multiple logistic
regression], and was generally mild-to-moderate (EOD 50% mild, 10% moderate; LOD 13%
mild, 7% moderate). Subjectively-rated sulcal atrophy was uncommon and no more prevalent in
those with an EOD [p=0.81, odds ratio=1.3 (95% CI 0.15-11.1), 9% EOD scans vs. 7% of LOD
scans, multiple logistic regression], MRI scans were also rated for the presence of small punctate
white matter lesions (SPWML) (Figures 7.2a, 7.2b) and leukoaraiosis (Figure 7.1). An EOD was
associated with a significantly higher frequency of SPWML in the region of the Hippocampus
(14% EOD vs. 2% LOD) but the Diabetes Onset Age grouping (EOD/LOD) did not
independently predict the presence of SPWML in the region of the Basal Ganglia, Centrum Semi-
Ovale, or the total number of SPWML observed in all brain areas. The presence of leukoaraiosis
was not consistently different between the EOD/LOD groups, although an EOD independently
predicted the presence of leukoaraiosis when the scoring method of Wahlund et al (Wahlund ct
ah, 1990) was used (EOD 59% vs. 24% LOD, odds ratio=4.5 (95% CI=1.5-13.3), p=0.007,
logistic regression). However, given the multiple analyses and rating scales utilised this
difference may reflect Type 1 statistical error, or the inherent attributes of the rating scales, rather
than a true representative difference in white matter pathology associated with Diabetes Onset
Age.
172
Table 7.9. Subjective ratings ofMRI scan appearances and Diabetes Onset Age group.
EOD LOD Effect of Diabetes Onset
n=22 n=45 Age Group
(% of scans) (% of scans) (Log Regression)
Ventricular Atrophy 60 20 OR=4.6, p=0.010
Sulcal Atrophy 9 7 NS
Leukoaraiosis
Wahlund 59 24 OR=4.5, p=0.007
Longstreth 55 53 NS
Van Swieten (superficial/deep WML) 0/0 2/2 NS/NS
Breteler 18 27 NS
Fazekas (superficial/deep WML) 55/0 60/18 NS/NS
Shimada 0 11 NS
Mirsen (superficial/deep WML) 41/0 42/9 NS/NS
SPWML
Hippocampal 14 2 0.03
Basal Ganglia 5 20 0.38
Centrum Semi-ovale 9 22 0.08
% with punctate WML 18 40 0.17
NS = non-significant EOD/LOD effect in the final multiple logistic regression model.
OR=odds ratio.
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Diabetes Onset Age and MRI Brain Volumes
Genera] linear modelling, which co-varied for head size (as Intracranial Volume) and Gender,
identified Diabetes Onset Age group as a significant independent multi-variate determinant of
those regional brain volumes that were assessed in the present study (F=2.4, p=0.04, Eta2=0.22).
The relationships between Diabetes Onset Age group and brain volumes are summarised in Table
7.10. An EOD was associated with a comparatively larger volume of the Lateral Ventricles
(F=11.1, p=0.002, Eta2=0.16), with an absolute difference in volume of 6.6 cm3, equating to a
36.9% greater Ventricular volume than that observed in those in whom the onset of diabetes was
later (LOD group), independently of Intra-Cranial Volume. The influence of an early onset age
of Type 1 diabetes appeared specific as an EOD was not associated with any other significant
differences in either the volume of the whole brain, temporal lobes or amygdala-hippocampal
complex after considering co-variates (MANCOVA).
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Table 7.10. Diabetes Onset Age group and Regional Brain Volumes (cm3).
EOD LOD
Effect of Diabetes Effect
Brain Volume Estimated Estimated
(cm3)
Onset Age Group of Age
Marginal Marginal
(MANCOVA) (MANCOVA)
Mean (SEM) Mean (SEM)
F=0.58 F=1.6
1270 1258






























7.5.1 Severe Hypoglycaemia and Cognitive Ability
In the present study no significant relationship was identified between any summary measure of
previous exposure to severe hypoglycaemia and cognitive disadvantage. This observation is
entirely consistent with those reported by the prospective studies which have evaluated the
relationship between severe hypoglycaemia exposure and subsequent neuropsychological
performance, which have included the Diabetes Control and Complications Trial (DCCT) (The
DCCT Investigators, 1996;Austin and Deary, 1999), the Stockholm Diabetes Intervention Study
(SDIS) (Reichard et al., 1991), and the EDIC study (Jacobson et al., 2007). In each of these
studies no evidence of impaired cognitive function was identified in young adults who had been
exposed to recurrent severe hypoglycaemia. However, retrospective cross-sectional studies in
adults with type 1 diabetes (Langan et al., 1991;Lincoln et al., 1996;Sachon et al., 1992;Wredling
et al., 1990;Langan et al., 1991) have identified modest decrements in aspects of cognitive ability,
directly related to the frequency of previous recurrent severe hypoglycaemia. These cross-
sectional studies examined people who developed type 1 diabetes in adulthood and who were
older than the participants of the present study. Their observations conflict with the findings of
the present study. Others have suggested that this may reflect relative vulnerability of the aging
brain to severe hypoglycaemia, but the recently published findings of the EDIC study (Jacobson
et al., 2007) mitigate this interpretation, as participants were of a similar age to those evaluated by
the cross-sectional studies. Other factors, such as selection bias and methodological weaknesses
may offer some explanation for the divergent findings of the prospective and cross-sectional
studies. However, no convincing evidence exists which definitively demonstrates that repeated
exposure to severe hypoglycaemia, at least during adulthood, is detrimental to subsequent
neuropsychological performance. Some caveats require to be applied to this statement. Firstly,
the severe hypoglycaemia exposure data of the present study were collected retrospectively. This
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does not allow examination of the timing of severe hypoglycaemia with respect to age, which
may be of particular importance in early childhood as some have reported relative vulnerability of
the childhood brain to a hypoglycaemic insult, although data are conflicting and inconsistent.
However, structured retrospective assessments of preceding severe hypoglycaemia have been
shown to be reproducible over a modest period (Deary et al., 1993) and are seldom sufficiently
inaccurate to fail to delineate those naive or heavily exposed to severe hypoglycaemia. Secondly,
protracted severe hypoglycaemia is undoubtedly damaging to the human brain but is extremely
uncommon in routine clinical practice in those with Type 1 diabetes, except in the setting of a
deliberate attempt at self-harm or following alcohol ingestion (Arky et al., 1968). Such episodes
of protracted severe hypoglycaemia do cause structural brain damage (Boeve et al.,
1995;Chalmers et al., 1991;Chan et al., 2003;Finelli, 2001;Gold and Marshall, 1996;Holemans et
al., 2001;Maekawa et al., 2006;Perros et al., 1994;Rajbhandari et al., 1998;Richardson et al.,
1981;Yoneda and Yamamoto, 2005). Thirdly, the apparently reassuring findings with respect to
exposure to severe hypoglycaemia from the present study do not exclude detrimental effects on
those domains of cognitive ability which were not examined: the assessment of cognitive abilities
in the present study was not all embracing; learning and memory ability, abstract reasoning and a
detailed examination of executive functions were not performed. However, the findings of the
EDIC study, which did examine all recognised domains of cognitive ability in detail would
suggest that the present observations are representative: no detrimental effect of any prospective
measure of severe hypoglycaemia exposure was associated with cognitive disadvantage
(Jacobson et al., 2007).
7.5.2 Severe Hypoglycaemia and Structural Brain Abnormalities
In the present study, in addition to the absence of any discernible effect of severe hypoglycaemia
on the aspects of cognitive ability that were assessed, structural abnormalities of the brain were
not observed in association with a history of preceding severe hypoglycacmia. In particular, no
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relationship was identified between the frequency of previous severe hypoglycaemia and cerebral
atrophy, in contrast to the observations of an earlier study (Perros et al., 1997) which examined a
small number of participants (n=22) recruited from a larger cohort (Deary et ah, 1993;Langan et
ah, 1991), who were chronologically older and had developed Type 1 diabetes in adulthood. In
addition, in analysing these earlier results Perros had not accounted for some potential
confounders, most notably the difference between the incidence of microvascular disease between
the study groups (82% in those previously exposed to severe hypoglycaemia vs. 55% in those
who were not exposed to severe hypoglycaemia). These differences may underlie the apparent
disparity between the observations of the present study, which suggest that recurrent severe
hypoglycaemia may not be detrimental to the brain, at least in young adults below the age of 45
years who do not have advanced or end-stage microangiopathy. This reassurance cannot at
present be applied to older people with Type 1 diabetes, those with a longer duration of the
disorder, or those in whom advanced microangiopathy is present.
7.5.3 Diabetic Retinopathy and Neuropsychological Performance
A significant independent association was observed between the presence of Background
Diabetic Retinopathy (early retinopathy) and cognitive ability, which remained robust when
between-subjects factors and covariates (age, gender, pre-morbid 1Q, severe hypoglycaemia
exposure and duration of diabetes) were considered. The subgroup that had Background Diabetic
Retinopathy perfonned less well on cognitive tests of fluid intelligence, information processing
speed, and the ability to maintain attention and concentration. The magnitude of the relative
disadvantage in cognitive performance was moderate (Eta2=0.09-0.17, 0.4-0.7SD), i.e.
approximately equivalent to 6-10 IQ points, and similar to that observed by other studies that
have examined the relationship between microangiopathy and cognition (Dejgaard ct al.,
1991;Ryan et al., 1992;Ryan et al., 1993). However, the differences observed in the present study
may be evident at a lower cumulative degree of glycaemic exposure than that associated with the
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development of Diabetic Peripheral Neuropathy (Orchard et al., 1997). The present observations
differ from those reported by Dejgaard and colleagues (Dejgaard et al., 1991) in tenns of the
domains of ability compromised by microangiopathy, but are remarkably consistent with the
larger studies performed by Ryan et al: psychomotor speed, sustained attention and visuo-spatial
ability (WAIS-R Block Design Sub-test) were detrimentally affected by microangiopathy. The
mechanism by which the development of Background Diabetic Retinopathy may confer cognitive
disadvantage is unknown. Differences in visual function were considered as being potentially
responsible for the disadvantage observed, yet the visual component of the infonnation
processing pathway (as measured by PI00 latency) is known to be unaffected by Background
Retinopathy (Ewing et al., 1998). It is more likely that the presence of Diabetic Retinopathy, may
be a surrogate marker for the presence of microvascular disease elsewhere within the brain. The
relationship between retinal abnormalities and the development of subsequent cerebral
macrovascular episodes or cognitive impairment is established in middle-aged and elderly
individuals (Ikram et al., 2006;Longstreth, Jr. et al., 2007;Mitchell et al., 2005;Wong et al., 2002).
In the setting of Type 1 diabetes in the younger population studied in the present study it is
unlikely that the presence of Diabetic Retinopathy is a surrogate marker of cerebral
macrovascular disease, indeed no neuroimaging evidence of silent cerebrovascular disease was
observed. Rather, the presence of Background Diabetic Retinopathy is more likely to be a
surrogate for preceding chronic hyperglycemia, accompanying sub-optimal control of diabetes.
The present observations infer that the cerebral circulation may not be as immune to the
development of microangiopathy as previously thought, although neuropathological study would
be required to prove this assumption beyond doubt. Such neuropathological data is not presently
available.
High-intensity white-matter lesions (leukoaraiosis) are abnonnalities detected on T2-weighted
magnetic resonance images representing areas of increased water content, gliosis and
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demyelination within white-matter (Pantoni and Garcia, 1995) and are thought to signify foci of
microvascular ischemia (Englund, 2002). The small punctate white matter lesions (SPWML), of
the type that were associated with Background Retinopathy in this study, are thought to
correspond to enlarged peri-vascular spaces, in keeping with the structural alterations observed in
association with diabetic microangiopathy in other tissues. The intra-cranial circulation, with the
exception of the ophthalmic artery, was previously considered to be spared from the development
of typical diabetic microangiopathy. The correlation observed in the present study between
Background Retinopathy and SPWML in the region of the Basal Ganglia has not been previously
reported and would suggest that microangiopathy can affect cerebral microvessels beyond the
confines of the ophthalmic artery. Basal Ganglia abnormalities have been observed in young
people with type 1 diabetes: basal ganglia infarction has been observed in association with
microvascular complications (Bellassoued et al., 2001) and Basal Ganglia pathology in the setting
of keto-acidosis (Ertl-Wagner et al., 1999;Roe et al., 1996;Rogers et al., 1990). The apparent
vulnerability of the Basal Ganglia may relate to microvascular disease of the Lenticulo-Striatal
Arteries, penetrating arteries which supply a threshold watershed zone in the deep gray matter.
The association observed between Background Retinopathy and white matter lesions is consistent
with other observations associating retinal vascular abnormalities with white matter lesions on
cranial MRI scans. Data from studies of subjects with Type 2 diabetes have previously described
independent associations between the presence of Diabetic Retinopathy , Hypertension and white-
matter abnormalities (Inoue et al., 1996). Hypertensive retinopathy is associated with cerebral
high-intensity white matter lesions (Wong and Mitchell, 2007)1740(Ikram et al.,
2006;Longstreth, Jr. et al., 2007) implying that the presence of retinal microangiopathy is a
surrogate marker for more generalised cerebral microangiopathy at least in those with
hypertension. Despite the association observed in the present study between Background
Retinopathy and small punctuate white matter lesions (enlarged peri-vascular spaces), the
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presence of these white matter lesions was not associated with cognitive ability. This may imply
that Diabetic Retinopathy and enlarged peri-vascular spaces do not in fact represent an identical
histopathological abnormality. Alternatively, the pathogenesis of Diabetic Retinopathy and
enlarged peri-vascular spaces may be similar, with non-exudative retinopathy representing an
early manifestation and enlarged peri-vascular spaces indicating more advanced damage. A
further explanation is offered by the difference in sensitivity for the detection of microangiopathy
provided by cerebral magnetic resonance imaging when compared with ophthalmoscopy and
digital retinal imaging. The pathognomonic lesion of background diabetic retinopathy, the
microaneurysm, is a few microns in size, whereas the voxel size utilised in MRI neuroimaging
protocols is several orders ofmagnitude greater.
Irrespective of the association between background retinopathy and structural abnormalities of
the brain, the pathogenesis of the cognitive disadvantage in the subgroup with established
background diabetic retinopathy is likely to have a vascular aetiology. Functional MRI studies
suggest that cerebrovascular responsiveness may be important during normal cognitive activity,
as discrete changes in regional cerebral blood flow occur during cognitive tasks (Rosenthal et ah,
2001). Long duration type 1 diabetes complicated by Diabetic Retinopathy has been shown to be
associated with impaired cerebrovascular reactivity in response to Acetazolamide (Fulesdi et ah,
1997) and it is possible that impairment of vascular reactivity could in part explain the cognitive
disadvantage observed in the present study. In addition, the results of the present study support
the concept of a "microvascular-mediated" effect on cognitive function in people with diabetes of
long duration, as a significant contributory factor in the pathogenesis of a "diabetic
encephalopathy". The exclusion and inclusion criteria resulted in the recruitment of a group of
people who had Type 1 diabetes of long duration, yet had a low microvascular disease burden
relative to the general population of individuals with similar disease duration. In view of this, the
findings of the present study, with respect to the apparently detrimental effects of
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microangiopathy on the brain, could be reasonably expected to under-estimate the magnitude of
disadvantage which is likely in the general population of people with Type 1 diabetes of similar
disease duration.
An interaction between multiple complications of diabetes and cognitive performance has been
reported previously. Ryan and colleagues identified an association between poorer cognitive
performance and Peripheral Neuropathy in adults who had developed type 1 diabetes in
childhood or adolescence, while no direct detrimental effect of severe hypoglycaemia alone was
detected (Ryan et al., 1992). A statistically greater degree of cognitive dysfunction was observed
when Peripheral Neuropathy co-existed with a history of preceding exposure to recurrent severe
hypoglycaemia, although the magnitude of additional variance accounted for by this interaction
was small and perhaps of academic interest rather than a clinically meaningful affect. The
present study did not identify a greater degree of cognitive disadvantage in those who had
Background Retinopathy and a history of exposure to recurrent severe hypoglycacmia when
compared to those who had Background Retinopathy alone. However, the sub-groups (n=8 vs.
n=17) for this analysis were small, and no firm conclusions regarding the presence or absence of
an interaction between microangiopathy, severe hypoglycaemia and cognitive ability can be
drawn from the present study which was underpowered to address this issue.
7.5.4 Problems with the Definition of "Early Onset Diabetes"
In the present study an early onset age of Type 1 diabetes (EOD) was defined as an age at the
diagnosis of diabetes at, or below, seven years. Studies of cognitive ability in children with Type
1 diabetes have varied in their definition of an "early onset" and "later onset" of Type 1 diabetes,
with definitions ranging between four and seven years for early onset diabetes (EOD) (Ack et al.,
1961;Alvarez and Rovet, 1997;Bjorgaas et al., 1997;Chabriat et al., 1994;Hagen et al.,
1990;Hershey et al., 1997;Holmes and Richman, 1985;Northam et al., 1999;Northam et al.,
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2001;Rovet et al., 1988a;Ryan et al., 1985a;Sarac et al., 2005;Schoenle et al., 2002;Service,
1995;Wolters et al., 1996;Wysocki et al., 2003;Ack et al., 1961;Ack et al., 1961). MRI
neurodevelopmental studies have demonstrated that human brain volume increases rapidly in the
first two to three years of life and by 5-10 years adult whole brain volumes are attained (Durston
et al., 2001;Lenroot and Giedd, 2006). Subsequent neurodevelopment involves proportional
changes in the ratio of cortical gray matter to cerebral white-matter: cortical gray matter decreases
from a maximal volume at 4 years of age through a remodelling process known as "pruning" to
approach adult volume by 10-17 years, with the age at maturation being gender and regionally-
specific (Lenroot and Giedd, 2006), whilst cerebral white matter volumes progressively increase
until the 3rd decade of life through the process of myelination (Durston et al., 2001;Lenroot and
Giedd, 2006). An EOD of seven years or less was selected as a compromise between the
cognitive and neuro-developmental studies, so as to provide some degree of comparability
between the findings of the present study and the body of literature describing cognitive ability in
children with Type 1 diabetes whilst providing a sufficiently mature cut-off age such that an adult
whole brain volume would have been largely attained in those defined as LOD.
7.5.5 Cognitive Ability and Early Onset Diabetes
Before interpreting the observations of the present study specific methodological issues require
consideration. Firstly, the cognitive assessment utilised in the present study was not all
encompassing; frontal and executive functions were not assessed in any depth, and memory and
learning abilities were not evaluated. Instead, an emphasis was placed upon the assessment of
information processing and fluid intelligence, as deficits in these abilities had been identified in
previous studies of people with Type 1 diabetes at our centre (Deary et al., 1993;Langan et al.,
1991). Secondly, the cross-sectional design of the present study can merely infer associations
rather than causality, which requires detailed and careful prospective assessment. Finally, the
National Adult Reading Test (NART) was used to estimate the maximum intellectual attainment
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(crystallised intelligence) of participants (Nelson and Willison, 1991). NART scores are
relatively resistant to organic brain disease throughout adult life and predict pre-morbid
intellectual ability (crystallised intelligence) with a greater degree of accuracy than estimates
derived from socio-economic demographics. Whilst the NART is a valid estimate of crystallised
intelligence in healthy adults who have completed intellectual development in the absence of any
significant childhood pathology, its validity remains relatively untested in the setting of childhood
disease. The early childhood development of Type 1 diabetes could theoretically interfere with
the normal attainment of crystallised intelligence, particularly if diabetes developed during the
critical period of rapid brain growth evident during early childhood ncurodevelopment. It is
therefore possible that the use of the NART in the present study may have underestimated the
magnitude of any detrimental effect that an EOD had on cognitive ability. However, to have not
included a marker of pre-morbid intellectual ability in the analysis of cognitive ability would
confound any meaningful interpretation of results.
Accepting the above caveats, the present study identified an association between the diagnosis of
Type 1 diabetes at, or below the age of seven years (EOD), and relatively poorer fluid intelligence
ability (WAIS-R performance IQ) and slower psychomotor speed (Simple and Choice reaction
time), an association that was independent of all other factors identified as being significant
determinants of cognitive performance (pre-morbid intellectual ability, the presence of
background retinopathy and gender) and other factors of interest that appeared to have no
statistically significant effect on cognitive ability (diabetes duration and severe hypoglycaemia
exposure). The specific cognitive abilities that appeared to have been compromised by the
development of diabetes in early childhood were generally consistent with previous observations
in children who had developed Type 1 diabetes at an early age, although direct comparisons are
hampered by the inconsistency of the definition of an EOD between individual studies;
comparatively lower fluid intelligence scores (WAIS-R performance IQ) (Holmes and Richman,
184
1985;Northam et al., 1999;Rovet et al., 1988a;Rovet et al., 1988b;Ryan et al., 1985a;Rovet et al.,
1988a) and slower information processing speed (Bjorgaas et al., 1997;Hagen et al.,
1990;Northam et al., 2001;Ryan et al., 1985a;Service, 1995;Bjorgaas et al., 1997;Ryan et al.,
1985a) have been previously observed, although no effect on information processing ability has
also been reported (Kail et al., 2000). The other cognitive abilities examined by the present study
(early visual information processing, frontal and executive functions and the ability to sustain
attention and concentration) did not appear to be disadvantaged by the development of diabetes at
an early age. This is not entirely consistent with published observations: poorer performance has
been described in association with an EOD in attention ability (Alvarez and Rovet, 1997;Bjorgaas
et al., 1997;Hagen et al., 1990;Northam et al., 2001;Rovet and Ehrlich, 1999;Ryan et al.,
1985a;Wolters et al., 1996;Rovet and Ehrlich, 1999). Differences in executive function, relative
to healthy controls, have also been reported in children developing Type 1 diabetes at a young
age (Hagen et al., 1990;Hershey et al., 1997;Northam et al., 2001;Sarac et al., 2005;Service,
1995). The disparities between the present study findings and published literature highlights
difficulties within this research area; relative deficits in cognitive abilities are generally identified
in those with an EOD but inconsistencies in the specific cognitive abilities affected arc common.
These inconsistencies may reflect the heterogeneity of the clinical characteristics of the study
samples and control group selection, sample size issues, the varied psychometric instruments used
to evaluate intellectual performance and diversity in the definitions used to characterise early
onset diabetes.
The present study was not designed to determine the pathogenesis of the cognitive disadvantage
observed in those with an EOD but may offer some clues as to causality. As an EOD influenced
cognitive ability independently of the presence of Background Retinopathy, a surrogate marker of
lifetime glycaemic exposure, and duration of diabetes this implies that the pathogenesis is
unlikely to simply reflect cumulative glycaemic exposure. Experts have hypothesised that the
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cognitive disadvantage associated with an EOD may relate to severe hypoglycaemic exposure
during early childhood neurodevelopment (Ryan, 1988), a hypothesis based upon retrospective
reports of a higher frequency of hypoglycaemic-seizures in children who developed diabetes at a
very young age (Daneman et al., 1989;Davis and Jones, 1998;Golden et ah, 1985;Ternand et ah,
1982). Subsequent evaluation has largely refuted this hypothesis as the prospective studies within
this field have determined that the diagnosis of Type 1 diabetes in early childhood is associated
with poorer neuropsychological performance across a broad range of cognitive domains
(Northam et ah, 2001), whereas the detrimental effects of early life exposure to severe
hypoglycaemia appear more specific and modest in effect size (Northam et ah, 2001;Rovet and
Ehrlich, 1999;Schoenle et ah, 2002). The assessment of severe hypoglycaemia exposure in the
present study was retrospective and, as such, insufficient to accurately delineate the precise age at
which exposure to severe hypoglycaemia, or hypoglycaemia-associated seizures had occurred.
This relative weakness of the present study means that it cannot be definitively concluded that
severe hypoglycaemia is not injurious to the developing brain and the acquisition of intellectual
abilities, despite the lack of statistical associations between any summary measure of severe
hypoglycaemia exposure and intellectual performance. The unfavourable effects of an EOD on
intellectual ability therefore appear to be independent of cumulative glycaemic load,
microvascular complications and duration of diabetes, and have previously been shown to be
independent of severe hypoglycaemia exposure (Northam et ah, 2001;Schoenle et ah, 2002). The
pathogenesis of these cognitive consequences remains uncertain and alternative explanations may
be required. Alternative hypotheses have suggested that school attendance problems (Hagen et
ah, 1990;McCarthy et ah, 2002;McCarthy et ah, 2003;Parker et ah, 1994;Rovet et ah, 1987;Ryan
et ah, 1985b), behavioural difficulties (McCarthy et ah, 2002;Rovet et ah, 1987) and perhaps
abnormal myelination as a consequence of diabetes per se (Vlassara El et ah, 1983) may be
potential factors. The relative-deficiency of insulin during childhood neurodevelopment could
also potentially contribute. Insulin has anabolic effects in many tissues, receptor expression in
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specific brain areas which are involved in cognition, particularly the neocortex and medial
temporal lobe, and may influence cognition through effects on neurotransmitter metabolism and
synaptic plasticity (Biessels et al., 1994). However, it is not known whether insulin has
neurotrophic effects during childhood and adolescence which contribute significantly to central
nervous system maturation and intellectual development.
7.5.6 Brain Structure and Early Onset Diabetes
The present study compared measures of brain structure in two groups of subjects who had
developed Type 1 diabetes during childhood or adolescence. A significantly higher frequency of
structural brain abnormalities was observed in those with an onset of diabetes < 7 years of age
(EOD). Abnormalities were present in 60% of EOD subjects and included macroscopic
abnormalities, apparent on routine clinical inspection of MRI brain scans, and sub-clinical
differences in regional brain volumes, elicited through detailed volumetric analysis. General
linear modelling (MANCOVA) was used to determine the independent effect of the age of onset
of diabetes (EOD/LOD) on regional brain volumes. Intra-cranial volume is gender and gene
dependent, such that > 90% of whole brain volume and sub-regional volumes are inherited
(White T et al., 2002): males and those of greater somatic size have proportionally larger brains,
although gender-specific differences also significantly influence regional brain volumes such that
the absolute volume of the Hippocampus is comparable between genders, whereas the volume of
the Caudate is proportionally greater and the Amygdala smaller in females (Lenroot and Giedd,
2006). In order to facilitate the detection of brain volume changes caused by an early onset age
of diabetes (EOD), intra-cranial volume and age were entered as co-variates and gender as a
between-subjects factor for all volumetric analyses. It could be argued that co-varying for intra¬
cranial volume could potentially mask any reduction in cerebral volume consequent upon the
development of diabetes at an early age, under the premise that early onset diabetes could impair
brain growth and hence the volume of the skull (intra-cranial volume). However, as no
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correlation between intra-cranial volume and age at diagnosis of diabetes was observed, co-
variance for intra-cranial volume within the volumetric analysis appeared appropriate. The lack
of correlation between an early childhood onset of diabetes and head size was unsurprising as the
development of microcephaly is generally associated with a major in utero or early life brain
insult.
The comparatively higher frequency of ventricular atrophy (odds ratio=4.6), which was in general
mild, and the relatively greater lateral ventricular volumes, consistent with a sub-clinical degree
of central brain atrophy, in those with an EOD are consistent with the study hypothesis i.e. that
the development of Type 1 diabetes at an early age would detrimentally affect brain structure.
Ventricular atrophy with enlargement of the lateral ventricles are characteristically observed as a
feature of normal brain aging and the co-existence of these features in the EOD group could be
reflect sub-optimal brain development, or alternatively, an advanced state of brain aging relative
to chronological age. During normal childhood neurodevelopment the volume of the Lateral
Ventricles increases, being greater in males than in females (Lenroot and Giedd, 2006). The
process underlying this increase in Ventricular cavity size is thought to represent "pruning" or
selective programmed neuronal and glial cell death and it is unclear whether the development of
diabetes during childhood modulates this process, favouring a greater degree of cell loss. The
cross-sectional design of the present study does not permit clarification of which process is
responsible, but as the higher frequency of ventricular atrophy and greater lateral ventricular
volumes in the EOD group were observed independently of diabetes duration and chronological
age, this implies that sub-optimal neurodevelopment rather than a state of advanced brain aging
may be more likely. No direct measurements of gray or white matter volumes were obtained in
the present study and it remains uncertain whether the differences in ventricular atrophy and
lateral ventricular volume observed in the EOD group represent a reduction in the volume of gray
matter, white matter or a combination of both.
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In addition to structural changes consistent with mild brain atrophy, differences in the frequency
of high-intensity white-matter lesions were inconsistently observed between EOD and LOD
groups. MRI scans were rated for the presence of two different types of white-matter lesion;
leukoaraiosis, high intensity white matter lesions observed on T2-weighted images thought to
represent foci of microvascular ischaemia (Englund, 2002;Fazekas et al., 1991), and small
punctuate white-matter lesions (SPWML) thought to represent enlarged peri-vascular spaces.
Rating scales for leukoaraiosis differ in their sensitivity in scoring WML, with some being
relatively insensitive to minor degrees of leukoaraiosis (Fazekas et al., 2002;Mantyla et al.,
1997;Wardlaw et al., 2004). Certain rating scales appeared relatively insensitive to the
leukoaraiosis observed in the present study and attempts at analysis were inappropriate due to
small numbers of positively scored scans(Shimada et al., 1990), whereas others appeared more
sensitive in scoring the type of leukoaraiosis observed (Fazekas et al., 1987;Longstreth, Jr. et al.,
1996;Mirsen TR et al., 1991;Wahlund et al., 1990;Wahlund et al., 1990). Of those scales which
scored the type of leukoaraiosis observed in the present study, an EOD was not consistently
identified as an independent predictor of the presence of leukoaraiosis: a significantly higher
frequency of leukoaraiosis was observed when the Wahlund rating scale was used (Wahlund et
al., 1990) but not with any other rating scale(Fazekas et al., 1987;Mirsen TR et al., 1991). This
inconsistency may reflect differences in sensitivity and scoring criteria inherent in the rating
scales, or alternatively Type 1 statistical error. Alternatively, if the difference in leukoaraiosis
determined by the method of Wahlund et al is considered significant, this may add corroboration
to animal work suggesting that abnormal myelination occurs as a consequence of diabetes
(Vlassara H et al., 1983), although the independence from surrogates of glycaemic exposure
(Background Retinopathy) may mitigate this interpretation. Hippocampal small punctate white-
matter lesions (SPWML) were observed more frequently in those who developed diabetes at an
early age (EOD). The hippocampus appears vulnerable in diabetes and mesial temporal lobe
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sclerosis has been reported in up to 15% of IDDM subjects who developed diabetes at < 6 years
of age (Davis et al., 2002). In the present study, the validity of the statistically higher frequency
of Hippocampal SPWML should be viewed with considerable caution as the statistical analysis
was based upon 3 cases of Hippocampal SPWML in EOD subjects vs. 1 case in LOD subjects,
and no other significant differences were observed in other areas of white-matter. Therefore,
from the present study it cannot be concluded with any degree of certainty that an EOD is
associated with either the leukoaraiosis or SPWML. As white matter abnormalities are thought to
be manifestations of cerebral microvascular disease (Englund, 2002;Fazekas et al., 1991;Pantoni
and Garcia, 1995), and the structural brain abnormalities associated with an EOD were present
independently of microangiopathy elsewhere (Diabetic Retinopathy) and diabetes duration, an
alternative pathogenesis is implied. This is in keeping with the neuropsychological findings of
the present study.
The present study did not account for other potential confounding factors related to Type 1
diabetes that could potentially account for at least some of the differences in cognitive ability and
brain structure identified by the present study. The most prominent diabetes-related factor that
was not explored was the effect of exposure to episodes of diabetic keto-acidosis (DKA) on brain
structure and function. This specific factor was not examined as preceeding exposure to DKA
could not be accurately determined as the patient group from which participants were recruited
consisted of young adults, many of whom had developed Type 1 diabetes in early childhood and
had only relocated to the Edinburgh area in their late-teens or early twenties from across the
United Kingdom. It was therefore not possible to attain a preceeding DKA history with any
degree of accuracy, particularly with respect to the timing of episodes, and as such no formal
attempt was made to collect this data. As such, DKA must remain as a potential confounding
factor, which could account for at least some of the variance in cognitive ability and brain
structure not captured by the linear modelling techniques utilised in the present study.
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In conclusion, the present study indicates that subtle structural abnormalities of the brain,
consistent with a mild degree of central brain atrophy, and modest deficits in cognitive
performance are common in adults who had developed Type 1 diabetes before their seventh
birthday. The co-existence of structural brain abnormalities and cognitive disadvantage strongly
implies that normal neurodcvelopment may be adversely affected by the early childhood onset of
Type 1 diabetes. The pathogenesis of the cognitive disadvantage and structural brain
abnonnalities observed in those who had developed Type 1 diabetes in early childhood is
uncertain. Previous prospective reports have suggested that the cognitive disadvantage associated
with an EOD is independent of that associated with severe hypoglycaemia exposure (Northam et
al., 2001;Schoenle et al., 2002) and the present study infers that cognitive disadvantage and
structural brain abnormalities are unlikely to be a consequence of chronic hyperglycaemia and the
development of microangiopathy, or a manifestation of the duration of diabetes. Prospective
evaluation of neurodevelopment in children with Type 1 diabetes is required to validate the above
findings and further elucidate the pathogenesis of the negative effects that an early onset of Type
1 diabetes appears to confer upon the central nervous system.
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CHAPTER 8: INFLUENCE OF DIABETES-SPECIFIC FACTORS ON
OBJECTIVELY RATED STRUCTURAL BRAIN ABNORMALITIES IN TYPE 1
DIABETES
8.1 INTRODUCTION
The neuroimaging associations of Type 1 diabetes remain under explored. Several diabetes-
specific factors have been reported in the literature as being associated with the presence of
structural brain abnormalities in case reports and small case-control studies. These diabetes-
specific factors include exposure to protracted and profound degrees of severe hypoglycaemia,
the development of Diabetic Keto-Acidosis in children and adolescents, and the development of
microvascular complications as a consequence of chronic exposure to hyperglycaemia.
Anecdotal reports have reported permanent neuro-imaging abnormalities following exposure to
protracted and profound degrees of hypoglycaemia in Type 1 diabetes (Bakshi et al., 2000;Boeve
et al., 1995;Chalmers et al., 1991;Chan et al., 2003;Finelli, 2001;Gold and Marshall,
1996;Holemans et al., 2001;Koppel and Daras, 1993;Maekawa et al., 2006;Perros et al.,
1994;Rajbhandari et al., 1998;Richardson et al., 1981;Yoneda and Yamamoto, 2005). The neuro-
radiological abnormalities summarised by these case reports confinn that abnormalities
consequent upon profound hypoglycaemia predominantly affect the cortical gray matter, sub¬
cortical gray matter structures, particularly the hippocampus and basal ganglia, but can also affect
the brain stem if hypoglycaemia is particularly protracted. This pattern is consistent with that
reported in rodent models of hypoglycaemic brain injury (Auer and Siesjo, 1993). It remains
unresolved whether recurrent episodes of severe hypoglycaemia, in the absence of protracted
coma, can have long-tenn deleterious effects on cerebral structure in Type 1 diabetes. A study of
a small sub-group of the subjects previously examined by Langan et al (Langan et al., 1991) were
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re-examined by Perros who reported that cortical atrophy was more prevalent in those with a
history of frequent exposure to severe hypoglycaemia (n=l 1) relative to those who were nai've to
severe hypoglycaemia (n=l 1) (Perros et al., 1997). This small study is the sole study published to
date which has attempted to examine the neuro-radiological associations of severe hypoglycaemia
exposure in a structured manner.
The effects of microangiopathy on cerebral structure in Type 1 diabetes has been examined in
three cross-sectional studies. Dejgaard and colleagues examined sixteen patients with long-
duration Type 1 diabetes, complicated by proliferative diabetic retinopathy and peripheral
neuropathy, relative the appearances observed in non-diabetic healthy controls (n=40). High-
intensity white matter lesions were observed in 69% of the diabetes group, of whom 31% were
also considered to have a degree of subjectively-rated cerebral atrophy. The white matter lesions
observed by Dejgaard were non-specific in their distribution, were small in size, infrequent in
number and more common in the microangiopathic group (69%) relative to healthy age-matched
controls (12%). Dejgaard et al interpreted the higher prevalence of white-matter lesions observed
in the microangiopathic group as being indicative of the presence of intra-cranial
microangiopathy, complicating Type 1 diabetes, or alternatively as being indicative of small foci
of ischaemia, known as Leukoaraiosis (Pantoni and Garcia, 1995) as part of a subcortical
arteriosclerotic encephalopathy (Dejgaard et al., 1991). Youssem and colleagues (Yousem et al.,
1991) compared the frequency of white-matter lesions in 25 adult patients with Type 1 diabetes
complicated by proliferative diabetic retinopathy (severe retinopathy) relative to 10 age-matched
healthy control subjects and did not identify any structural brain abnonnalities. Lunetta and co¬
workers examined ten patients with Type 1 diabetes, who had a relatively short median duration
of diabetes, variable hypoglycaemia exposure and differing degrees of microangiopathy (Lunetta
et al., 1994) and reported an increased Cerebro-Ventricular Index, a surrogate of central brain
atrophy, in 70% of the diabetes group, and a degree of subjectively-rated cortical atrophy in some
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participants (Lunetta et al., 1994). The small studies summarised above appear to provide
conflicting insights into the structural brain associations of microangiopathy, each utilising
differing MRI methodologies and studying diverse patient groups. The relationship between
Type 1 diabetes and white matter lesions remains under evaluated at present with the limited data
inferring that the prevalence of white matter change and perhaps cerebral atrophy may be greater
in those with T1DM complicated by microangiopathy.
The onset of Type 1 diabetes in early childhood is associated with a degree of cognitive
disadvantage in prospective studies (Northam et al., 2001;Rovet and Ehrlich, 1999;Schoenle et
al., 2002). Experts have hypothesised that the association may be explained by diabetes-specific
organic factors (Ryan et al., 1985a), such as exposure to severe hypoglycaemia or diabetic keto¬
acidosis in early life, whereas others have suggested that socio-behavioural factors could explain
the differences observed (Fallstrom, 1974;Rovet et al., 1987b). Despite an extensive body of
literature exploring the neuropsychological consequences of early life exposure to severe
hypoglycaemia, there is an extremely limited body of evidence relating to brain structure
(Christiaens et al., 2003), with no case reports of neuroimaging sequelae of severe hypoglycaemia
published in children with Type 1 diabetes. In contrast, diabetic keto-acidosis remains the
leading cause of death and disability in children with Type 1 diabetes (Edge et al., 1999) and an
extensive body of case reports and case-series have identified neuroimaging abnormalities
consequent upon diabetic keto-acidosis (Greene et al., 1990;Hoffman et al., 1999;Iwai et al.,
1987;Keane et al., 2002;McAloon et al., 1990;Roe et al., 1996;Rogers et al., 1990;Shrier et al.,
1999). DKA can be complicated by neurological deterioration and permanent neuroradiological
abnormalities, most commonly as cerebral infarction in severe cases. The pattern of brain injury
differs significantly from that appears to be associated with hypoglycaemic brain damage.
However, no studies to date have examined the neuroimaging associations of an early life onset
of Type 1 diabetes.
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8.2 AIMS
The present study examined a large group of adults with type 1 diabetes of relatively long
duration: a subgroup had developed the disorder during childhood or adolescence, and as a
consequence were exposed to the potential negative consequences of diabetes during
neurodevelopment and a second subgroup in which the onset of diabetes had occurred after
neurodevelopment was largely complete. The present study was designed to achieve a number of
aims:
1. To determine the prevalence of white matter abnormalities and cerebral atrophy in a
population of young adults with T1DM.
2. To determine whether structural brain abnormalities, such as white matter lesions or
cerebral atrophy, were disadvantageous to aspects of cognitive ability in T1DM.
3. To explore whether diabetes-specific factors independently influenced the presence of
either white matter abnormalities or cerebral atrophy.
As no healthy age-matched control group was included, the present study was not designed to
examine the effects of Type 1 diabetes per se on brain structural outcome measures, rather
concentrated on determining the consequences of the diabetes-specific disease factors of interest
on macroscopic neuroimaging outcomes of interest.
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8.3 SUBJECTS AND METHODS
8.3.1 Study Design
The study was cross-sectional in design and the study protocol was completed in sequential order:
1. detailed Magnetic Resonance Imaging (MRI) of the brain;
2. neuropsychological test battery;
3. retinal examination;
4. assessment of preceding severe hypoglycaemia;
Each component was evaluated and scored blind to all other information.
8.3.2 Subjects
Recruitment criteria were selected with the explicit aim of obtaining a cohort with a long duration
of diabetes (> 10 years), sufficient to ensure some exposure to the metabolic consequences of
interest (severe hypoglycaemia, diabetic retinopathy, disease duration), but without accruing
other significant co-morbidity which may confound the interpretation of ncuroimaging findings.
One hundred and thirty three subjects were recruited of whom 71 had developed Type 1 diabetes
in childhood or adolescence (age at diagnosis < 18 years) with the remaining 62 having
developed T1DM after their 18th birthday and had therefore largely completed neurodevelopment
before the onset of diabetes. For the total cohort of 133 individuals, an upper age limit of 45
years was applied to minimise the potential confounding effects of ageing on brain structure and
cognitive ability, but also to minimise the likelihood of recruiting subjects with silent
macrovascular disease of the cerebral circulation (Klein et al., 2004;Nathan et ah, 2005;Stettler et
ah, 2006). Those invited to participate either had no clinical evidence of diabetic microvascular
complications or had early microangiopathy, manifest as background diabetic retinopathy alone.
As many of the cognitive ability tests utilised were highly dependent on visual function, those
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with more advanced degrees of diabetic retinopathy (Airlie House grading > 2) (1991b) including
diabetic maculopathy, pre-proliferative retinopathy, proliferative retinopathy or those who had
previously received laser treatment for diabetic retinopathy were excluded from participation.
The presence of any clinically apparent degree of diabetic neuropathy, the presence of
microalbuminuria, or overt proteinuria were also exclusion criteria. Other exclusions included
essential hypertension (defined as BP > 140/90 mmHg), any previous central nervous system
pathology, previous alcohol or drug misuse, or other multi-system disease known to affect the
central nervous system. The aim was to recruit only those in whom diabetes-related factors were
likely to account for any differences observed in their cognitive performance or brain structure.
The clinical characteristics of those studied are summarised in Table 8.1.
Table 8.1. Clinical characteristics of participants.
Mean (± SD) Median (Range)
n=133 n=133
Age (years) 32.3 (± 7.0) 32 (20-45)
Sex (male:female) 68:65 51.1% male
NART (pre-morbid ability) 33.2 (± 6.2) 34(15-46)
HbAlc at time of study (%) 8.5 (± 1.3) 8.4 (5.5-12.5)
Blood Pressure (mmHg) 123/74 (± 13/9) 120/74 (88/50-140/88)
Age at Diagnosis of T1DM (years) 16.1 (±8.4) 15 (1-36)
Duration ofDiabetes (years) 16.1 (±5.7) 15 (9-31)
Background Retinopathy (na'fve:retinopathy) 84:49 36.8% Retinopathy
Severe Hypoglycaemia
Median Total Episodes (% exposed, range) 13.8 (± 29.5) 4 (0-200), 67% exposed
Median Total Coma (% exposed, range) 3.0 (± 6.9)
1 (0-50), 53% exposed
1.9 (±4.9) 0 (0-29), 33% exposedMedian Total Seizures (% exposed, range)
HbAlc normal reference range 5.0-6.5%.
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8.3.3 Methods
An outline of the methods utilised for neuro-imaging and the evaluation of structural brain
abnonnalities, and a list of the battery of tests used to assess intelligence and cognitive ability are
provided in this section. Detailed descriptions of the neuro-imaging techniques, the
characteristics of the neuropsychological test battery and the manner in which the clinical
complications of Type 1 diabetes were evaluated are provided in the Methods Chapter, Section
6.4.
Assessment of the Clinical Complications of Type 1 Diabetes
Background diabetic retinopathy was defined by the presence of at least two or more
microaneurysms in one eye (Airlie House Gradings la-lc) (1991b) and assessed using direct
ophthalmoscopy and digital retinal imaging. Exposure to severe hypoglycaemia was assessed
retrospectively using a validated formatted hypoglycaemia questionnaire (Deary et al., 1993).
Participants were requested to discuss their severe hypoglycacmia history with relatives or friends
before completing questionnaires, to improve the accuracy of estimates. The following
parameters were recorded: the total lifetime number of episodes, the frequency of episodes, the
total number of episodes of convulsions, coma, and other episodes requiring medical assistance to
treat the hypoglycaemia. Severe hypoglycaemia was defined as any episode of hypoglycaemia
sufficient in severity to require external assistance to facilitate recovery, similar to the definition
used in the Diabetes Control and Complications Trial criteria (1997). The retrospective
ascertainment of severe hypoglycaemia utilised in the series of studies comprising this thesis is a
methodological weakness relative to the gold-standard methodology of prospective
ascertainment, although is sufficient to determine with a degree of accuracy those nai've to and
those previously exposed to severe hypoglycaemia. To overcome this relative methodological
deficit would take decades of meticulous prospective evaluation, which is neither practicable nor
easily funded.
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Magnetic Resonance Imaging Protocol
MRI examinations of the brain were performed using a 1,0T SPE Magnetom scanner (Siemens,
Erlangen, Germany). The first scan provided simultaneous proton-density and T2-weighted
images that were used to calculate whole brain and cerebrospinal fluid volumes using a
supervised cluster analysis package (ANALYZE, Mayo Foundation, Rochester, MN, USA). The
second scan, for the regional volumetric analysis, was a three dimensional magnetization
prepared for rapid-acquisition gradient echo sequence consisting of an 180 inversion pulse
followed by a fast low-angle shot collection giving 128 contiguous 1.88mm thick slices in the
coronal plane orthogonal to the Talairach plane. Inhomogeneity corrections were performed on
Sun Microsystem workstations using ANALYZE to outline neuroanatomical structures. The
regional brain volumes of interest were identified and their areas outlined and volumes calculated
by summing voxels in the regions of interest. Additional detail of the MRI methods utilised are
provided in the Methods Chapter, Section 6.6.
Assessment ofHigh-Intensity White Matter Lesion Burden
Each MRI scan was reviewed by an experienced Neuroradiologist (Professor Wardlaw) and
scored independently, and blinded to clinical factors, for the presence of high-intensity white
matter lesions, also known as Leukoaraiosis (Breteler et al., 1994a;Breteler et al., 1994b;Fazekas
et al., 1987;Longstreth, Jr. et al., 1996;Mirsen TR et al., 1991;Shimada et al., 1990;Van Swieten
et al., 1990;Wahlund et al., 1990). Several scoring systems were used to capture the intensity,
distribution (PVWH, DWMH) and appearance of white-matter lesions as no single scale was
judged to be an adequate summary (Fazekas et al., 2002;Mantyla et al., 1997). The scoring of all
MRI scans was performed by a single rater (Professor Wardlaw) to minimise the potential
confounder of inter-observer variability (Wardlaw et al., 2004).
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The presence of a distinctly different type of white matter abnormality, the small punctate white-
matter lesion (SPWML), which was frequently observed but not accounted for by any of the
above rating scales was also rated. A scale of 0-3 was utilised to quantity the severity of
SPWML: 0=None; l=Mild <10 Lesions; 2=Moderate 10-20 Lesions; 3=Severe > 20 Lesions.
This scale was used to quantity the presence of SPWML, indicating enlarged peri-vascular
spaces, in three distinct brain regions (Hippocampus, Basal Ganglia, Centrum Semi-Ovale) using
the most affected hemisphere.
Assessment of the Presence and Degree of Cerebral Atrophy
The presence or absence of cerebral atrophy was subjectively determined by an experienced
Neuroradiologist (Professor Wardlaw)) and the severity rated on a subjective scale of 0-3:
0. No cerebral atrophy;
1. Mild cerebral atrophy;
2. Moderate cerebral atrophy;
3. Severe cerebral atrophy.
When present, cerebral atrophy was defined as being either "Ventricular" or "Sulcal".
Assessment ofNeuropsychological Function and Intelligence
The neuropsychological test battery was delivered by a trained assessor blinded to the clinical
characteristics of participants, provided an assessment of some major cognitive domains and was
sensitive to mild-to-moderate cognitive decrements. The neuropsychological session was
rescheduled if hypoglycaemia was present or if antecedent hypoglycaemia had occurred within
the preceding 24 hours. Details of the neuropsychological test battery are provided in the
Methods Chapter, Section 6.4.
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The neuropsychological tests utilised were:
1. HospitalAnxiety andDepression Scale (Greenwood et ah, 2000)
2. Wechsler Adult Intelligence Scale-Revised (WA1S-R) (Wechsler, 1981)
3. National Adult Reading Test (NART) (Nelson and Willison, 1991)
4. Inspection Time (IT) (McCrimmon et al., 1996)
5. Choice Reaction Time (CRT) (Jensen, 1987)
6. Borkowski Verbal Fluency Test (Borkowski and Benton, 1967)
7. PacedAuditory Serial Addition Task (PASAT) (Deary I.J. ct al., 1991)
8.3.4 Statistical Analyses
All statistical analysis were performed using SPSS vlO.O (®SPSS Inc, Chicago, USA).
Structural Brain Outcome Measures
The relationship between the MRI outcomes of interest (cerebral atrophy, high-intensity white
matter lesions, small punctate white matter lesions, each coded numerically), demographic
variables and diabetes-specific factors was examined initially using bi-variate correlation
(Speannan's rho). The relationships between the diabetes-specific variables of interest,
demographic variables and subjectively-rated cerebral atrophy (coded as present/absent), the
presence of white-matter lesions (coded as present/absent) and small punctate white matter
lesions (coded as present/absent) were thereafter analysed by Multiple Logistic Regression.
Logistic Regression Models were constructed on the basis of correlations (Spearman's rho) and
prior hypotheses. Factors and co-variatcs were entered into each model in a stepwise forward
conditional manner, such that non-significant parameters were ejected from the final model.
Factors entered into the Multiple Logistic Regression Models included: Gender (male/female),
Diabetes Onset Age (coded as Early Onset < 7th birthday, Later Onset > 7lh birthday), Diabetic
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Retinopathy status (coded as present/absent) and Severe Hypoglycaemia exposure (coded as
nai've/exposed). The Multiple Logistic Regression Models also included Age, Systolic Blood
Pressure and Diabetes Duration as co-variates.
Neuropsychological Performance
The relationships between the categorical MRI outcomes of interest (cerebral atrophy, high-
intensity white matter lesions, coded numerically) and neuropsychological performance were
examined using bi-variate correlation (Spearman's rho). On the basis of the results of simple
correlation no further analyses were performed.
8.4 RESULTS
8.4.1 Frequency of Macroscopic Abnormalities on MRI
Table 8.2 summarises the prevalence of cerebral atrophy observed in the 133 participants. In
general, the structural brain abnormalities observed in the cohort were subtle, with severe
abnormalities very uncommon.
Frequency of Brain Atrophy
Ventricular atrophy was commonly observed, being present in 30.8% of subjects. 6.7% of the
cohort had a moderate degree of ventricular atrophy, with no participant exhibiting severe
atrophy. In contrast to ventricular atrophy, sulcal atrophy with atrophy of the cerebral cortex, was
uncommon being present in only 10.5% of participants. When present, the degree of sulcal
atrophy was mild: no participants had moderate to severe atrophy of the cerebral cortex (Table
8.2).
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Table 8.2. Prevalence of cerebral atrophy in 133 participants with T1DM.
Absent Mild Moderate/Severe Prevalence
(% of scans) (% of scans) (% of scans) (% of scans)
Ventricular Atrophy 69.2% 24.1% 6.7% 30.8%
Sulcal Atrophy 89.5% 10.5% None 10.5%
Frequency of Leukoaraiosis and Small Punctate White Matter Lesions
The prevalence of Leukoaraiosis (PVWH, DWMH) and Small Punctate White Matter Lesions
(SPWML) observed in the 133 participants are summarised in Table 8.3. In general, the white
matter abnormalities observed in the cohort were subtle, with severe abnormalities being
infrequently observed.
White matter lesions, as Leukoaraiosis, were commonly observed but were generally mild, focal
rather than confluent, small in number and predominantly located in the peri-ventricular white
matter, as PVWH. DWMH were less commonly observed and when present were also mild. As
expected, the frequency of white matter lesions varied according to the rating scale utilised to
score their presence (Fazekas et al., 2002;Mantyla et al., 1997). Many of the white matter rating
scales, which were primarily developed to objectively rate white matter lesion burden in studies
of the elderly, appeared insensitive to the type of white matter changes observed in this relatively
young cohort of people with Type 1 diabetes. Three validated scales appeared to rate the
relatively subtle degrees of Leukoaraiosis observed in the present study: the methods described
by Fazekas (Fazekas et al., 1987), Longstreth (Longstreth, Jr. et al., 2000) and Wahlund
(Wahlund et al., 1990) appeared more sensitive. Those methodologies described by Breteler
(Breteler et al., 1994a), Shimada (Shimada et al., 1990), Mirsen (Mirsen TR et al., 1991) and Van
Swieten (Van Swieten et al., 1990) appeared insensitive. The low frequency of white matter
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changes scored by these latter methodologies rendered attempts at further analysis inappropriate
(Table 8.3).
Table 8.3. Prevalence of Leukoaraiosis and SPWML in 133 subjects with T1DM.
Absent Mild Moderate/Severe Prevalence
(% of scans) (% of scans) (% of scans) (% of scans)
LEUKOARAIOSIS
Fazekas
Peri-ventricular WML 39.8% 59.4% 0.8% 60.2%
Deep WML 85.7% 13.5% 0.8% 14.3%
Longstreth 44.3% 54.9% 0.8% 55.7%
Wahlund 69.9% 30.1% None 30.1%
Breteler 87.2% 12% 0.8% 12.8%
Mirsen
Peri-ventricularWML 93.4% 6.6% None 6.6%
Deep WML 96% 3.2% 0.8% 4.0%
Shimada 96.2% 3.8% None 3.8%
Van Swieten
AnteriorWML 99.2% 0.8% None 0.8%
PosteriorWML 98.4% 1.6% None 1.6%
SPWML
Total (all areas) 53.4% 31.6% 15.0% 46.6%
Hippocampus 78.2% 21.8% None 21.8%
Basal Ganglia 69.2% 27.8% 3.0% 30.8%
Centrum Semi-Ovale 66.9% 21.1% 12.0% 33.1%
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8.4.2 Structural Brain Outcome Measures and Diabetes-Specific Factors
The prevalence of cerebral atrophy and white matter lesions according to the presence of Diabetic
Retinopathy and Diabetes Onset Age Group is summarised in Table 8.4.
Table 8.4. Prevalence of structural brain abnormalities by Retinopathy Status and
Diabetes Onset Age Group in 133 participants.
Background No Chi2-test Early Later Chi2-test
Retinopathy Retinopathy Onset Onset
n=48 00c n=26 n=107
(% of scans) (% of scans) (% of scans) (% of scans)
Ventricular Atrophy 32.6% 35.1% p=0.84 60% 29.6% p=0.02*
Sulcal Atrophy 14.6% 8.2% p=0.26 7.7% 11.4% p=0.74
LEUKOARAIOSIS
Fazekas (PVWH) 68.9% 58.3% p=0.26 52.0% 63.7% p=0.36
Longstreth 60.0% 55.9% p=0.71 48.0% 58.8% p=0.37
Wahlund 37.8% 27.4% p=0.06 36.0% 29.4% p=0.42
SPWML
Total (all areas) 48.9% 45.2% p=0.71 28.0% 50.9% p=0.04*
Hippocampus 31.1% 15.5% p=0.04* 4.0% 24.5% p=0.02*
Basal Ganglia 37.8% 26.2% p=0.24 8.0% 36.3% p=0.007**
Centrum Semi-Ovale 40.0% 28.6% p=0.24 20% 36.3% p=0.16
Early Onset = diagnosis before 7th birthday; Later Onset = diagnosis > 7th birthday.
* = p<0.05. ** = p<0.01.
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Background Diabetic Retinopathy
The presence of Background Diabetic Retinopathy did not appear to exert a major influence on
the prevalence of macroscopic neuroradiological abnormalities. The sole exception to this was
the observation of a two-fold greater prevalence of SPWML in the region of the Hippocampus in
those with Retinopathy (p=0.04, Chi2-test).
Diabetes Onset Age
The age at onset of diabetes appeared to exert a greater influence on brain structural outcomes:
Ventricular Atrophy was twice as prevalent in those diagnosed before the age of 7 years (p=0.02),
whereas the prevalence of SPWML appeared greater in the region of the Hippocampus (p=0.02),
Basal Ganglia (p=0.007) and in total SPWML burden (p=0.04) in those in whom the onset of
diabetes was in later childhood, adolescence or in adulthood.
Duration of Diabetes
The duration of diabetes appeared to weakly correlate with the total burden of SPWML in all
areas (r2=-0.19, p=0.03) and the presence of Basal Ganglia SPWML (r2=-0.20, p=0.03), with a
non-significant trend for Hippocampal and Centrum Semi-Ovale SPWML. Diabetes duration
was also correlated with Leukoaraiosis scores using the Longstreth rating scale (r2=-0.24,
p=0.007) but not on any other scales. Diabetes duration did not correlate with either type of
cerebral atrophy.
Severe Hypoglycaemia
No summary measure of preceding exposure to severe hypoglycaemia appeared to correlate with
any of the structural brain outcomes of interest. In particular, the presence of cerebral atrophy,
high intensity white matter lesions, or SPWML were not influenced by summary measures of
severe hypoglycaemia (Table 8.5).
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Table 8.5. Spearman's correlates between summary measures of preceding severe




















8.4.3 Structural Brain Outcome Measures and Demographic Factors
With the exception of a borderline correlation observed between Systolic Blood Pressure and the
presence of Sulcal Atrophy (r2=-0.21, p=0.08) no other demographic factors appeared to be
significantly correlated with the presence of Cerebral Atrophy. In particular, age and gender did
not correlate with the presence ofVentricular or Sulcal Atrophy.
No demographic factors (age, gender, blood pressure) were significantly correlated with the
presence of Leukoaraiosis, as either PVWH or DWMH.
Age was correlated with the presence of SPWML in all areas (r2=0.29-0.33, p=0.0001-0.002) and
a trend between Systolic Blood Pressure (r2=-0.21, p=0.08). No other demographic factor
correlated with the presence of SPWML.
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8.4.4 Independent Predictors of Structural Brain Outcomes
Multiple Logistic Regression was used to determine whether the associations identified between
diabetes-specific factors (Retinopathy Status; Diabetes Onset Age Group), demographics and the
categorical structural outcomes were independent.
Ventricular Atrophy
The only independent predictor of the presence of Ventricular Atrophy, as determined by
Multiple Logistic Regression, was the Diabetes Onset Age Group. An early onset of diabetes
before the 7lh birthday independently predicted the presence of Ventricular Atrophy [(3=1.3,
SE=0.51, EXP(P)=3.6, 95% CI of p= 1.3-9.6, p=0.01, Log Regression]. An early onset of
diabetes was independently associated with a significantly higher risk of Ventricular Atrophy
(Estimated odds ratio=3.6).
Leukoaraiosis
The only variable to independently predict the presence of Leukoaraiosis was the duration of
diabetes [Longstreth rating scale: p=-0.07, SE=0.03, EXP(P)=0.93, 95% CI of p=0.87-0.99,
p=0.035, Log Regression], A shorter duration of diabetes was associated with a modest increased
prevalence of PVWH. Leukoaraiosis as determined by the Fazekas or Wahlund scales were
unrelated to any identified diabetes-specific or demographic factors.
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Small Punctate White Matter Lesions
Several factors were identified as being independent predictors of the presence of SPWML by
Multiple Logistic Regression:
(a) Presence or Absence of SPWML
The presence of SPWML in any area brain was independently predicted by Diabetes Onset Age
[P—0.08, SE=0.03, EXP(P)=1.11, 95% CI of p=1.01-1.16, p=0.02, Log Regression]. SPWML
were significantly less frequently observed in those in whom the onset of T1DM was before their
7lh birthday.
(b) SPWML in the region of the Hippocampus
Two factors independently predicted the presence of SPWML in the region of the Hippocampus.
Diabetes Onset Age [p=0.15, SE=0.05, EXP(P)=1.17, 95% CI of p=1.05-1.29, p=0.004, Log
Regression] and Retinopathy status [P=-1.22, SE=0.55, EXP(P)=0.30, 95% CI of p=0.10-0.86,
p=0.03, Log Regression]. Hippocampal SPWML were significantly more prevalent in those with
a later onset of diabetes, with disease onset after their 7th birthday, and in those who had
Background Diabetic Retinopathy.
(c) SPWML in the region of the Basal Ganglia
Following Logistic Regression no factor emerged which independently predicted the presence of
SPWML in the region of the Basal Ganglia.
(d) SPWML in the region of the Centrum Semi-Ovale
The presence of SPWML in the region of the Centrum Semi-Ovale was independently predicted
by Diabetes Onset Age [p=0.10, SE=0.04, EXP(p)=1.10, 95% CI of p=1.02-1.19, p=0.01, Log
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Regression]. No other factors were independent predictors. SPWML were significantly less
prevalent in the region of the Centrum Semi-Ovale in those with an early onset of T1DM.
8.4.5 Structural Brain Outcomes and Neuropsychological Performance
The Spearman's correlates observed between the structural brain outcome measures of interest
(Cerebral Atrophy, White Matter Lesions and Small Punctate White Matter Lesions) and
performance on the tests of intelligence and neuropsychological performance are summarised in
Table 8.6.





Atrophy Atrophy (Total SPWML)
(PVWH)
Performance IQ 0.14 -0.01 -0.15 -0.01 0.07 -0.14
(WAIS-R) p=0.90 p=0.92 p=0.16 p=0.96 p=0.52 p=0.19
Inspection Time -0.07 -0.03 0.09 0.09 -0.19 0.11
(PEST Score) p=0.52 p=0.76 p=0.39 p=0.40 p=0.08 p=0.30
Reaction Time 0.08 0.11 -0.14 0.01 0.03 0.16
(4-Choice Decision Time) p=0.50 p=0.29 p=0.89 p=0.88 p=0.78 p=0.13
Attention/Concentration 0.10 -0.02 -0.03 0.01 0.01 0.15
(PASAT) p=0.38 p=0.83 p=0.76 p=0.94 p=0.94 p=0.16
Verbal Fluency -0.07 -0.06 -0.18 -0.05 0.01 -0.12
(Borkowski VFT) p=0.53 p=0.56 p=0.09 p=0.63 p=0.96 p=0.24
Pre-Morbid IQ -0.004 0.04 -0.01 -0.05 -0.04 -0.07
(NART) p=0.97 p=0.72 p=0.94 p=0.66 p=0.71 p=0.49
All correlations p>0.05.
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No significant correlations were observed between the presence of Cerebral Atrophy and
neuropsychological performance. No significant correlations were observed between the
presence of white matter lesions, as Leukoaraiosis or SPWML, and neuropsychological
performance.
8.5 DISCUSSION
8.5.1 Prevalence of Structural Brain Abnormalities
Structural abnonnalities which are readily apparent on MRI imaging of the brain are commonly
present in adults with Type 1 diabetes. The majority of participants in the present study had
structural abnormalities of the brain, most commonly manifest as a mild degree of high intensity
white matter lesions (60.2%), although central brain atrophy (30.8%) and punctate white-matter
lesions (46.6%) were also common. The presence of some of these structural brain abnonnalities
appeared, at least in part, to be determined by factors specific to diabetes, the two most prominent
of which were the onset of diabetes in early childhood and the presence of microvascular
complications. However, other structural abnormalities, such as the frequency of Sulcal Atrophy
and Leukoaraiosis did not appear to relate to the clinical complications of diabetes examined by
the present study, suggesting other factors may be of importance to their development. As a
healthy control group was not included in the present study it is not possible to evaluate whether
the prevalence of structural brain abnonnalities observed in this group of adults with Type 1
diabetes differs from that which would be expected in age-matched non-diabetics. From the
limited epidemiological evidence which has examined white matter abnormalities in younger
adult populations of similar age to those evaluated in the present study, the CAMERA study
identified a point prevalence of Leukoaraiosis of 42% in healthy adults aged 30-45 years (Kruit et
al., 2004), suggesting that Leukoaraiosis is probably at least as prevalent as in healthy adults.
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8.5.2 Macrovascular Disease
The structural abnormalities reported in this chapter are unlikely to be as a consequence of
macrovascular disease of the cerebral circulation: no participant had MRI evidence of
cerebrovascular disease. In particular, no neuroradiological evidence of Cerebral Infarction,
Lacunar Infarction or previous Intra-Cerebral Haemorrhage was observed in any participant.
This suggests that the strict application of exclusion criteria was effective, consistent with the
epidemiological evidence base which identified the risk factors for Stroke in T1DM (Fuller et al.,
2001;Klein et ah, 2004;Nathan et ah, 2005;Stettler et ah, 2006).
8.5.3 Leukoaraiosis
High intensity white matter lesions, present as Leukoaraiosis, were commonly observed in the
present cohort of young adults with Type 1 diabetes. Leukoaraiosis was present in 30-60% of
participants in the present study, when those rating scales which appeared more sensitive to subtle
degrees of white matter abnormalities were used to quantify their presence (Fazekas et ah,
1987;Longstreth, Jr. et ah, 2000;Wahlund et ah, 1990). However, some rating scales appeared
insensitive to the subtle degree of white matter abnormalities (Breteler et ah, 1994a;Mirsen TR et
ah, 1991;Shimada et ah, 1990;Van Swieten et ah, 1990). The white matter lesions observed in
the present study were at the mild end of the spectrum of severity. Lesions were typically located
in the peri-ventricular white matter (PVWH) and consisted of peri-ventricular rims, caps, or focal
PVWH. Confluent lesions, or lesions extending into the deep white matter were very uncommon.
Two previous studies have reported the prevalence of Leukoaraiosis in T1DM. Dejgaard
identified a five-fold increased frequency of Leukoaraiosis, relative to age-matched controls
(n=40), in a small group (n=16) with T1DM complicated by advanced degrees of diabetic
microangiopathy (Dejgaard et ah, 1991). The prevalence of Leukoaraiosis (69%) reported by
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Dejgaard was similar to that observed in the present study (60.2%), however, direct comparisons
are hampered by methodological differences, particularly with respect to the sensitivity to white
matter changes of the MRI sequences utilised and the rating of Leukoaraiosis. Youssem
compared the frequency of white-matter lesions in 25 adult patients with Type 1 diabetes with
advanced diabetic retinopathy relative to 10 age-matched healthy control subjects using MRI
techniques consisting of T1-weighted and Proton Density images (Yousem et ah, 1991). In
contrast to the current observations and those of Dejgaard (Dejgaard et ah, 1991), no white-matter
lesions were identified and Youssem concluded that white-matter pathology was uncommon in
T1DM. Subsequent advances in MRI technology in the intervening years since this publication
have since revealed that the imaging sequences utilised by Youssem are unsuited for the
quantification of white-matter changes, being unlikely to detect subtle differences.
The neuropathological appearances of mild to moderate PVWH, of the type that were observed in
60% of participants in the present study, are those of demyelination, reactive gliosis without
substantial degenerative changes in blood vessels (Englund, 2002). Severe PVWH and DWMH,
both of which are associated with advancing age, hypertension and increased macrovascular
events [REFS Fazekas ASPS; de Leeuw RSS], were uncommonly observed in the present cohort:
14.3% had DWMH using the Fazekas rating scale (Fazekas et al., 1987) whereas only 4.0% were
judged to have DWMH when the Mirsen scale was used (Mirsen TR et al., 1991). The exclusion
criteria of the present study, which limited age to a maximum of 45 years and which excluded
those with hypertension are likely explanations for the comparatively low prevalence of DWMH
and more severe degrees of PVWH. More severe PVWH and DWMH exhibit similar
pathological appearances described above for mild to moderate PVWH but with additional
features of microvascular ischaemia indicated by irregularity of blood vessel luminal cross-
sectional diameter, peri-vascular hyalinosis and loss of oligodendrocytes and marked damage to
myelin (Englund, 2002). Despite the histopathological evidence for a microvascular basis for
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severe PVWH and DWMH, no association between the presence of Diabetic Retinopathy and
such white matter lesions was observed. The low prevalence of severe PVWH and DWMH, as a
consequence of the study exclusion criteria, may make the present cohort less than ideal to
examine the association between Retinopathy and Leukoaraiosis.
8.5.4 Small Punctate White Matter Lesions
Histologically, SPWML consist of areas of peri-vascular hyalinosis of small arterioles and focal
demyelination (Fazekas et ah, 1991) and the peri-vascular features of SPWML share significant
histological commonality with the limited histological data from study of the brain in Type 1
diabetes in which hyalinosis of cerebral microvessels was also a prominent feature (Reske-
Nielsen and Lundbaek, 1963). In the present study, Diabetes Onset Age group and the presence
of Diabetic Retinopathy independently influenced the frequency of SPWML in specific brain
areas. In those in whom diabetes was diagnosed in later childhood (after their 7th birthday),
adolescence or adulthood, SPWML were more prevalent in the region of the Hippocampus,
Centrum Semi-Ovale and in terms of the cumulative total in all brain areas. Contrary to
expectations that an early onset of Type 1 diabetes would disadvantage normal neurodevelopment
with neuroradiological evidence supportive of this concept, those in whom the onset of diabetes
was in early childhood may be relatively more resistant to the development white matter
pathology, in the form of Small Punctate White Matter Lesions. This relationship was
independent of age, diabetes duration, the presence of Diabetic Retinopathy and other factors. If
a microvascular pathogenesis for the development of SPWML in T1DM is to be assumed, as
described in the middle-aged and elderly (Fazekas et al., 1991), then the present findings are in
keeping with previous observations that those with an early life onset of T1DM may be exhibit
relative resistance to the development of microangiopathy: the median duration of diabetes
required for the development of microvascular complications of diabetes, notably as Diabetic
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Retinopathy, is substantially longer in those with an onset of diabetes before puberty (Holl et al.,
1998;Kostraba et al., 1989;Kullberg et al., 2002;01sen et al., 2004), independently of disease
duration and degree of glycaemic control (Kullberg et al., 2002). In the present study Diabetic
Retinopathy was independently associated with the presence of SPWML in the region of the
Hippocampus, which could be interpreted as being supportive evidence in favour of
microangiopathy affecting the brain. Why this association was only observed for the region of
the Hippocampus remains unclear. The Hippocampus is known to be rich in insulin receptors
(Craft and Watson, 2004) and glucose transporters (McEwen and Reagan, 2004) but structural
changes in association with hyperglycaemia have not been reported, whereas hypoglycaemia-
related damage has been described (Boeve et al., 1995;Chalmers et al., 1991 ;Finelli,
2001;Holemans et al., 2001). As Retinopathy selectively affected this single specific brain area
the alternative interpretation is that the association could represent a Type 1 error.
The clinical relevance of SPWML remains unclear at present, largely through limited
epidemiological data. Available data from the Austrian Stroke Prevention Study suggest that
SPWML may be a benign white matter abnormality in the elderly (Schmidt et al., 2003), at least
relative to the adverse macrovascular prognosis associated with more severe degrees of PVWH
and DWMH (Iwai et al., 1987;Schmidt et al., 2003). The factors that are associated with the
development and progression of SPWML are unclear, although the Austrian Stroke Prevention
Study suggests that progression may be limited over a 6 year period (Schmidt et al., 2003). In the
setting of Type 1 diabetes, prospective studies are required to evaluate the natural history of these
lesions, to determine factors associated with their progression or regression, and to evaluate
whether these lesions are the forebears of further structural brain abnormalities or the
development of cognitive disadvantage. If the hypothesis that the presence of SPWML are
related to cerebral microangiopathy, then it would seem reasonable to assume that the progression
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of Diabetic Retinopathy, which can be objectively determined, would be associated with an
increasing SPWML burden. This hypothesis has not yet been tested.
8.5.5 White Matter Lesions and Neuropsychological Performance
No relationship was observed between the presence of any type of white-matter abnormality, as
Leukoaraiosis or SPWML, and poorer performance on any of the cognitive abilities assessed,
although some cognitive domains were not examined. Given the relatively mild degree of white
matter change observed in the present study this lack of association is perhaps unsurprising.
Studies in older adults and the elderly infer that extensive white matter disease may be necessary
before differences in cognitive abilities become measurable, leading to the suggestion that a
"threshold" of cumulative white matter burden is necessary before cognition becomes impaired
(Desmond, 2002). Correlations between white matter lesion burden have been most consistently
described between psychomotor and information processing speed, with attention & executive
function and global performance becoming impaired in the presence of severe disease (Boone et
al., 1992;Breteler et ah, 1994b;De Groot et ah, 2000;DeCarli et ah, 1995;Junque et ah,
1990;Longstreth, Jr. et ah, 1996;Schmidt et ah, 2003;Ylikoski et ah, 1993). It is unclear whether
the presence of white matter abnormalities in the present study is a marker for the future risk of
developing cognitive impairment and prospective assessment would be required to ascertain this.
8.5.6 Cerebral Atrophy
Mild degrees of Ventricular Atrophy and Sulcal Atrophy were observed in the present study, of
which only Ventricular Atrophy was frequent (30.8%). Epidemiological studies of brain
development and ageing in adults and the elderly have identified chronological age, diastolic
blood pressure and smoking as the major risk factors for the development of brain atrophy (Ikram
et ah, 2007). The exclusion criteria of the current study ensured that only a younger adult
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normotensive group were studied, making these macrovascular risk factors unlikely to be
contributors to the presence of atrophy observed in those studied. No specific factors were
identified, other than the presence of Ventricular Atrophy (r2=0.34, p<0.001, Spearman's
correlate), which correlated with the presence of Sulcal Atrophy. This correlation infers
commonality for the pathogenesis of both types of brain atrophy. In contrast, Ventricular
Atrophy was significantly more prevalent in those in whom diabetes had developed during early
childhood, relative to those who developed the disorder at a later age. However, relatively little is
known about the processes which underlie the development of ventricular atrophy in younger
adults. Neuropathological studies have identified that programmed necrosis of neurones and their
supporting glial cells, a process known as "pruning", occurs from early childhood into adulthood.
This process is thought to contribute, at least in part, to the reduction in total gray matter volume
and the 60-150% increase in the volume of the lateral ventricles that has been observed across the
same timeframe (Durston et ah, 2001). Whether the onset of T1DM during early childhood
neurodevelopment influences the process of "pruning" is unknown. Alternatively, exposure to
the metabolic decompensations associated with the onset of T1DM in early life could contribute
to the development of central brain atrophy. The neuroimaging sequelae of DKA in children and
adolescents have been associated with ventricular dilatation (Hoffman et ah, 1988;Hoffman et ah,
1999;Krane et ah, 1985) whereas no case reports have linked early childhood exposure to severe
hypoglycaemia with ventricular dilatation, although such a relationship has been reported
following protracted severe hypoglycaemia in neonates (Vannucci and Vannucci, 2001) and
adults (Gold and Marshall, 1996;Maekawa et ah, 2006).
The presence of mild Ventricular Atrophy did not correlate with performance on any test of the
neuropsychological battery and therefore the clinical relevance remains unclear. From the
present data it is not possible to determine what underlies the increased lateral ventricle volumes
observed in those with an "early onset" of Type 1 diabetes. Longitudinal studies of human
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neurodevelopment suggest that changes in gray matter volume through "pruning" are responsible
for the increase in lateral ventricle cavity size during normal neurodevelopment (Durston et al.,
2001;Lenroot and Giedd, 2006). Prospective evaluation of the neuroimaging associations of
Type 1 diabetes across neurodevelopment would be necessary to provide further clarity.
8.5.7 Severe Hypoglycaemia and Structural Brain Outcomes
No summary of exposure to severe hypoglycaemia was associated with measurable differences in
brain structure in the present study. The literature summarising the structural brain associations
of severe hypoglycaemia is limited. Case studies following exposure to protracted and profound
severe hypoglycaemia have identified a distinct pattern ofpennanent brain injury where structural
abnormalities preferentially affect the neocortex, hippocampus and basal ganglia (Bakshi et ah,
2000;Boeve et ah, 1995;Chalmers et ah, 1991;Chan et ah, 2003;Finelli, 2001;Gold and Marshall,
1996;Holemans et ah, 2001;Maekawa et ah, 2006;Meer et ah, 1988;Richardson et ah,
1981;Yoneda and Yamamoto, 2005) and less commonly the brain stem (Perros et ah,
1994;Rajbhandari et ah, 1998). It is beyond doubt that protracted and profound severe
hypoglycaemia can produce pennanent structural brain abnormalities. However, it remains
debatable whether recurrent exposure to less profound episodes of severe hypoglycaemia, of the
type that more commonly present in clinical practice, is permanently injurious to the brain.
Perros examined 22 participants of a previously published cohort (Langan et ah, 1991), in whom
the preceding frequency of severe hypoglycaemia was associated with poorer current intellectual
perfonnance (WAIS-R Performance IQ). Perros identified a greater frequency of cortical atrophy
(45.5%) in the 11 subjects with a previous history of exposure to severe hypoglycaemia relative
to the remaining 11 participants who naive to severe hypoglycaemia in whom cortical atrophy
was not observed (Perros et ah, 1997). The reasons underlying the disparity between present
observations and those of Perros are not clear, but may reflect the smaller sample size and
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perhaps recruitment bias as those studied were selected from a larger cohort on the basis of their
cognitive ability differences. The present study, in which no neuropsychological or
neuroradiological differences were associated with severe hypoglycaemia exposure, is consistent
with the findings of the EDIC study (Jacobson et al., 2007). Both studies infer that repeated
exposure to severe hypoglycaemia may have no major measurable negative consequences in
adults who have T1DM. However, unlike the EDIC study the present study examined only some
cognitive abilities and did not examine regional differences in gray or white matter density or
volume. Musen and colleagues recently reported subtle differences in gray matter density in
association with a preceding exposure to severe hypoglycaemia, notably in the cerebellum
(Musen et al., 2006). However, the practical meaning of this observation remains unclear.
Therefore, subtle differences in brain structure or function may indeed be related to severe
hypoglycaemia exposure, the clinical meaning ofwhich remains unclear at present.
8.5.8 Conclusions
The present study has identified that structural abnormalities of the brain, manifest as different
types of white matter abnormalities and ventricular atrophy, are common in young adults who
have Type 1 diabetes. In general, these abnormalities are subtle and do not appear to be
associated with measurable differences of brain function, within the limitations inherent in the
methods utilised to measure cognitive abilities in the present study. The clinical relevance of
these abnormalities of brain structure are not presently apparent and prospective study will be
required to determine whether these abnormalities progress, regress or remain unaltered with
time. The use of more detailed and novel neuroradiological techniques, such as Voxel Based
Morphometry (VBM) for the delineation of subtle regional gray matter differences, and Diffusion
Tensor Imaging (DTI) for the analysis of white matter tractography, may assist in clarifying
which processes underlie the present observations.
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9. APOE GENOTYPE AND COGNITIVE FUNCTION IN TYPE 1 DIABETES
9.1 Introduction
Permanent cognitive impairment is a rare consequence of insulin-induced hypoglycaemia and in
many of the cases reported in the literature appears consequent upon protracted severe
hypoglycaemia, often precipitated by a deliberate attempt at self-harm, or in association with
alcohol consumption (Arky et al., 1968). In insulin-treated diabetes episodic severe
hypoglycaemia is common, with an annual prevalence of 30% in Type 1 diabetes and a higher
incidence in people with impaired awareness of hypoglycaemia and strict glycaemic control
(1991a). Whether recurrent exposure to severe hypoglycaemia promotes the development of
long-term cognitive sequelae is unresolved and remains debatable. Retrospective cross-sectional
studies have indicated that in at least some people with type 1 diabetes a modest cognitive
decrement may accrue following repeated exposure severe hypoglycaemia (Langan et al.,
1991;Lincoln et al., 1996;Sachon et al., 1992;Wredling et al., 1990). This observation has not
been replicated by prospective studies over an evaluation period extending for up to 10 years
(1996;Austin and Deary, 1999;Jacobson et al., 2007;Reichard et al., 1996). Cross-sectional
studies have reported a range of individual differences in cognitive decrements in those exposed
to severe hypoglycaemia (Langan et al., 1991), suggesting that factors, other than
neuroglycopenia per se, may influence the subsequent risk of developing cognitive impairment.
Chronological age, diabetes duration and the presence of co-existent microvascular and
macrovascular complications have all been proposed as potential mediators of increased
susceptibility to hypoglycaemia-induccd cognitive impairment (Deary et al., 1993;Langan et al.,
1991). Genetic factors have been identified as significant modulators of outcome in a variety of
neurological diseases (Corder et al., 1993;Wright, 2005) and could partly mediate the
susceptibility to severe hypoglycaemia-induccd cognitive impairment. The role of genetic factors
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as mediators of cognitive dysfunction following severe hypoglycaemia has not been previously
examined.
9.1.2 Polymorphism of the Apoliprotein-E Gene
Polymorphism of the gene for Apolipoprotein-E (APOE) is the most important single genetic
determinant of late-onset Alzheimer's disease (Corder et al., 1993). The APOE gene has three
common alleles (e2, b3, e4) coding for three corresponding protein isoforms, designated as E2,
E3 and E4 respectively, each of which vary in their biological activity. The APOE E4 isoform
has the least biological activity and the bioactivity of the protein isoform appears to be of clinical
importance. Apolipoprotein-E (APOE) mediates central nervous system cholesterol transport in
an isoform-specific manner and is an important determinant of neuronal repair and cytoskeletal
maintenance: the likelihood of neuronal recovery and survival following brain injury appears to
be mediated in an isoform-specific manner with the least active E4 isoform conferring a
disadvantage (Maclullich AMJ et al., 1998).
9.1.3 APOE Polymorphisms and the Brain in Healthy Individuals
The APOE s4 allele appears to influence aspects of cognitive ageing, even in apparently healthy
individuals, although no negative consequences have been reported as yet in childhood or
adulthood. This lack of effect in early life infers that the disadvantage conferred through the e4
allele is not neurodevelopmental. Children and young adults with an e4 allele appear not to
exhibit any cognitive disadvantage on tests of general intelligence (Turic et al., 2001) and the
relative frequencies of APOE genotypes appears not to differ between high and low-IQ children
(Plomin et al., 1994). In another study of young Chinese women superior fluid intelligence was
observed in association with e4 (Yu et al., 2000). Etowever, by middle-age possession of the e4
allele appears to confer disadvantage. Apparently healthy middle-aged adults possessing an s4
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allele exhibit subtle deficits in learning and memory abilities relative to those with other
genotypes (Flory et al., 2000). APOE genotypes also appear to influence the rate at which certain
cognitive abilities decline with normal ageing: healthy elderly subjects with an e4 allele have
poorer information processing speed and memory abilities (Staehelin et al., 1999) and may
undergo a more rapid rate of loss of cognitive ability than that observed in those with no 84 allele
(Pendleton et al., 2002;Staehelin et al., 1999).
9.1.4 APOE Polymorphisms and Brain Injury
The APOE e4 allele has been associated with poorer cognitive outcomes following exposure to a
wide variety of cerebral insults [Smith JD, Ann Med 2000]. Associations have been reported for
head injury (Crawford et al., 2002;Teasdale et al., 1997), demyelinating disease (Pinholt et al.,
2006), cerebro-vascular accidents (Louko et al., 2006;Sudlow et al., 2006), ex-professional
Boxers (Jordan et al., 1997;Jordan, 2000) and US Football players (Kutner et al., 2000).
9.1.5 APOE Polymorphisms and Cerebral Glucose Metabolism
Polymorphism of the APOE gene appears to influence regional cerebral glucose utilisation.
Elealthy middle-aged relatives of patients with Alzheimer's disease exhibit reduced parietal lobe
glucose metabolism and increased right-left hemisphere asymmetry if they carry the e4 allele
(Small et al., 2000). More widespread abnormalities of regional cerebral glucose utilisation,
affecting the posterior cingulate, parietal, temporal, and prefrontal cortex, have also been reported
in apparently cognitively healthy e4 heterozygotes. The reduction observed in glucose utilisation
was apparent decades before any clinical presentation of Alzheimer's disease could reasonably be
expected and was detectable in the absence of any measurable difference in cognitive ability, as




The hypothesis of the present study was to examine whether possession of an APOE e4 allele was
associated with measurable cognitive disadvantage in an adult group of people with type 1
diabetes, but also to determine whether any differences in cognitive ability observed between the
APOE groups was additionally modified by the subjects' preceding exposure to severe
hypoglycaemia. The present study was under-powered to accurately determine this secondary
aim and the data presented with respect to this aim are exploratory.
9.3 SUBJECTS AND METHODS
9.3.1 Study Design
Ninety-six people with type 1 diabetes were recruited for study and all completed the cross-
sectional study protocol. The study protocol consisted of a battery of neuropsychological
assessments, determination of the APOE genotype, and collection of diabetes related data, with a
particular focus on previous exposure to severe hypoglycaemia. Participants were randomly
selected from two pre-existing study cohorts (63 patients (Deary et al., 1993), 33 patients
(Ferguson et al., 2003) from whom extensive epidemiological data and diabetes-specific data had
been collected. Both cohorts had completed an identical neuropsychological assessment battery,
the description of which is outlined below. Those selected from the cohort examined by Deary
(Deary et al., 1993) included those still living in the Edinburgh area who were still alive and
physically able to attend for blood sampling. A significant number of this 1993 cohort were
deceased at the time of the present project. The remaining 33 participants were recruited from
those examined by Ferguson (Ferguson et al., 2003) and participated in the studies reported in
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Chapters 7 and 8 of this thesis. The relative advantages and disadvantages of the battery of
ability tests that were utilised are discussed in greater detail in the Methods Chapter (Section 6.4).
To minimise the influence of potential confounders in neuropsychological performance, strict
exclusion criteria were applied to those selected for study. These included the presence of
Hypertension (defined as BP > 140/90 mmHg); any previous central nervous system pathology;
any previous history of, or current psychiatric disease; alcoholism; drug misuse; any multi-system
disease known to affect the central nervous system.
9.3.2 Assessment of Neuropsychological Function
The neuropsychological test battery was chosen to be sensitive to cognitive decrements across
diverse cognitive abilities but was weighted towards the assessment of information processing
and current intellectual performance. The assessments were performed by a pre-trained assessor
who remained blinded to the diabetes-specific characteristics and APOE genotype of participants.
The neuropsychological test battery was administered in a standardised pre-determined order.
Incipient hypoglycaemia, or hypoglycaemia within the preceding 24-hours, was excluded before
neuropsychological assessment. Evidence of biochemical (capillary glucose concentration <3.5
mmol/L) or symptomatic hypoglycaemia resulted in rescheduling of the neuropsychological
session. The psychometric instruments used to evaluate the performance of participants were:
Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983)
The potential confounding effects of low mood and anxiety were evaluated. Further detail is
given in the Methods Chapter (6.5).
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Wechsler Adult Intelligence Scale Revised (WAIS-R) (Wechsler, 1981)
The performance sub-tests measure current intellectual performance (fluid intelligence, non¬
verbal intelligence) and are very sensitive to disruption by organic brain disease and ageing. The
four performance sub-tests utilised included the Picture Completion, Object Assembly, Block
Design and Digit Symbol tests. Further detail is given in the Methods Chapter (6.4).
National Adult Reading Test (NART) (Nelson and Willison, 1991)
Performance on the NART is relatively resistant to the detrimental effects of age and most types
of organic brain disease. NART performance correlates more closely with pre-morbid 1Q than
demographic variables and was used to control for the confounding effects of prior intellectual
ability (pre-morbid 1Q, crystallised intelligence) in the present study. Further detail is given in
the Methods Chapter (6.4).
Inspection Time (McCrimmon et al., 1996)
Inspection Time provides an assessment of visual perceptual speed, a component of information
processing ability. Participants discriminated between the spatial position (left or right) of the
longer of two briefly presented vertical lines. The stimuli were backward-masked, the
presentation duration was varied, and the duration of time required to reliably distinguish the
stimulus (85% correct) was termed the 'inspection time'. Further detail is given in the Methods
Chapter (6.4).
Choice Reaction Time (Jensen, 1987)
Choice reaction time was used to assess psychomotor speed and completed the tests of
information processing ability. Simple reaction time and 2, 4, 8-Choice reaction time were firstly
assessed in ascending order, and provided a pre-practice element to the assessment. Thereafter 8,
4 ,2-Choice reaction time and simple reaction time were examined in descending order and
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utilised for subsequent analyses. Further detail is given in the Methods Chapter (6.4).
Borkowski Verbal Fluency Test (controlled association) (Borkowski and Benton, 1967)
The Borkowski Verbal Fluency Test is thought to assess frontal lobe and executive function.
Participants have 60 seconds to state as many words as possible, beginning with letters of the
alphabet specified by the assessor. The letters J, S, U and M were utilised. Further detail is given
in the Methods Chapter (6.4).
Paced Auditory Serial Addition Task (PASAT) (Deary I.J. et al., 1991)
The PASAT was used to assess the ability to sustain attention and concentration. Participants
listened to a number list, which they were required to add together according to a given rule.
After a practice period, two consecutive 61-number trials were administered with 4s and 2s
between successive digits respectively. Further detail is given in the Methods Chapter (6.4).
9.3.3 Assessment of Severe Hypoglycaemia Exposure
Severe hypoglycaemia was defined as an episode requiring external assistance to facilitate
recovery (The DCCT Research Group, 1997) and exposure was assessed retrospectively using a
validated and formatted hypoglycaemia questionnaire (Deary et al., 1993). Participants were
asked to discuss their history of severe hypoglycaemia with family members, partners or friends
before completing questionnaires to improve the accuracy of estimates. The total number of
lifetime episodes, frequency of episodes, and total numbers of hypoglycaemic seizures, coma, and
episodes requiring medical intervention were recorded for each subject. The retrospective
ascertainment of severe hypoglycaemia utilised in the series of studies comprising this thesis is a
methodological weakness relative to the gold-standard methodology of prospective
ascertainment, although is sufficient to determine with a degree of accuracy those naive to and
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those previously exposed to severe hypoglycaemia. To overcome this relative methodological
deficit would take decades of meticulous prospective evaluation, which is neither practical or
easily funded.
9.3.4 Determination of Apolipoprotein-E Genotype
DNA was extracted from venous blood from all subjects using standard methods. APOE
genotyping was performed using a one stage PCR-RFLP assay as described by Wenham et al
(Wenham et al., 1991). Further detail is given in the Methods Chapter (6.9).
9.3.5 Statistical Analysis
SPSS vl2.0 (®SPSS Inc, Chicago, USA) was used for all statistical analysis. Bi-variate
correlation was used to identify demographic factors which significantly influenced
neuropsychological performance. From the correlations observed a multivariate linear model
(MANCOVA) was constructed which included age, duration of diabetes and pre-morbid
intellectual ability (NART) as co-variates and gender, severe hypoglycaemia category and APOE
genotype as between-subjects factors. Severe hypoglycaemia was dichotomised into two groups
based upon the total number of previous episodes of severe hypoglycaemia experienced by the
subject: (1) nai've to severe hypoglycacmia; (2) previously exposed to severe hypoglycaemia. For
the purposes of analysis APOE genotype was categorised into two groups on the basis of the
presence of the e4 allele: (1) The e4- group included those subjects with an 82/2, 82/3, or 83/3
genotype; (2) the e4+ group included those with one or more e4 allele, i.e. e2/4, e3/4, or s4/4
genotypes. MANCOVA was used to determine the independent significance (p) and the
magnitude of effect size (Eta2) that each variable of interest contributed towards performance on
the battery of psychometric tests.
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9.3.6 Subjects
The clinical characteristics of participants are shown in Table 9.1. Participants were randomly
recruited from two pre-existing patient cohorts. Sixty-three participants were recruited from the
surviviors of the cohort examined by Deary (Deary et al., 1993) with a further 33 patients
recruited from the cohort examined by Ferguson (Ferguson et ah, 2003). Data on glycaemic
control have not been included as the laboratory reference ranges and the methodologies utilised
(HbA|, HbAic) for estimating Glycated Haemoglobin changed across the two time frames during
which data from participants were collated.
Sub-division of participants by APOE e4 produced two groups, e4+ (n=21) and s4- (n=75). The
clinical characteristics of these groups are summarised in Table 9.1. Each subgroup had similar
pre-morbid intellectual ability (NART), degree of education and had experienced a similar
cumulative exposure to severe hypoglycaemia. Those possessing e4 were significantly older
(p=0.033, t-test) by a mean of 3.7 years and had tended to have had longer duration diabetes by a
mean of 4.1 years (p=0.059, t-test). The differences observed between these demographic factors
in the £4+ and e4- subgroups were controlled for in subsequent multivariate analyses.
230



















































Dataremeans±SDwi hedi nandr geibrackets.
231
9.4 RESULTS
9.4.1 Multivariate Predictors of Cognitive Ability
The F-statistic for each variable that was included in the MANCOVA model in descending order
of their influence on cognitive ability were: Pre-morbid IQ (NART) F=7.9, p<0.0001; Age F=3.5,
p=0.01; APOE group F=2.5, p=0.04; Gender x APOE group interaction F=2.5, p=0.04; Severe
Hypoglycaemia group F=1.1, p=0.35; APOE group x Severe Hypoglycaemia group interaction
F=0.88, p=0.50; Duration of diabetes F=0.60, p=0.70; Gender F=0.25, p=0.94.
9.4.2 Severe Hypoglycaemia and Neuropsychological Performance
The range of exposure to severe hypoglycaemia of those studied was wide, from those nai've to
severe hypoglycaemia (30%) to those who had experienced in excess of ten episodes (29%)
(Table 9.1). No significant correlation (Spearman's rho) was observed between preceding
exposure to severe hypoglycaemia (dichotomised as naive or exposed) and performance on any
cognitive ability test: WAIS-R Performance IQ r=-0.14, p=0.18; Borkowski Verbal Fluency
r=0.014, p=0.89; PASAT r2=-0.013, p=0.90; PEST Score r2=0.033, p=0.76; Median 4-Choice
Decision Time r~=0.098, p=0.37. The differences in estimated marginal means, following
MANCOVA, for those with and without a history of severe hypoglycaemia are summarised in
Table 9.2.
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9.4.3 APOE 84 and Neuropsychological Performance
On initial multivariate testing APOE genotype, coded by the presence or absence of the e4 allele,
was a significant independent predictor of performance on the battery of neuropsychological
tests. The APOE e4 allele was independently associated with a disadvantage in current
intellectual performance (WAIS-R performance IQ, p=0.037, Eta2=0.072) and a trend towards
poorer frontal lobe and executive functions (Borkowski Verbal Fluency, p=0.063, Eta2=0.057)
after consideration of the potential confounding effects of age, gender, duration of diabetes,
preceding severe hypoglycaemia and pre-morbid intellectual ability (NART). The relative
disadvantage in cognitive ability observed in association with the APOE e4 allele appeared to be
gender-specific (APOE x gender interaction: F=2.5, p=0.04, Eta2=0.15). Taking account of the
gender-spccific influence of APOE genotype on cognitive performance, multivariate analysis
(MANCOVA) was performed thereafter on a gender-specific basis, using a similar multivariate
model but excluding gender as a between-subjects factor. This gender-specific sub-analysis
demonstrated that the APOE genotype was only a significant determinant of cognitive
performance in female participants, with no statistically significant differences observed in male
participants (Table 9.3). The significant differences in cognitive ability observed in women
related to poorer performance of APOE e4 carriers on specific neuropsychological tests. Poorer
performance was observed in current intellectual performance (WAIS-R performance test score,
p=0.005, Eta2=0.37) and frontal lobe and executive function (Borkowski VFT, p=0.029,
Eta2=0.13). The magnitude of the difference observed in ability in association with possession of
the APOE e4 allele in female participants was moderate-to-largc (Eta2). No differences were
observed in early visual information processing ability, psychomotor speed or in the ability to
sustain attention and concentration. Performance subtests of the WAIS-R each measure different
aspects of current intellectual performance. A further multivariate analysis with the WAIS-R
subtests (Picture Completion, Block Design, Object Assembly and Digit Symbol tests) as
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dependent variables was performed to clarify which particular intellectual abilities were
compromised in those with the APOE e4 allele. An identical model to that employed in the
gender-specific analysis was utilised for this aim. The performance of participants on the WAIS-
R subtests is summarised in Table 9.4. Significantly poorer performance was observed in
association with the 84 allele in female participants on the Object Assembly, Block Design and
Digit Symbol performance subtests.
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9.4.4 Apolipoprotein-E Genotype and Severe Hypoglycaemia
There was no statistical evidence of a meaningful interaction between APOE genotype, previous
exposure to severe hypoglycaemia and cognitive ability (APOE x Severe Hypoglycaemia
interaction: F=0.66, p=0.68, Eta2=0.05). The cognitive ability of subjects with the APOE e4
allele, when subdivided into those exposed previously to severe hypoglycaemia (n=15) and those
naive to severe hypoglycaemia (n=6), is summarised in Table 9.2. No significant difference in
cognitive ability was demonstrated between the subgroups, although the numbers of subjects in
the exploratory analysis are sufficiently small, to preclude the exclusion of a non-significant
difference. On the basis of the present pilot data no trends were identified to suggest that a
clinically meaningful interaction between APOE genotype and exposure to severe hypoglycaemia
would be likely, even if a larger study were undertaken.
9.5 DISCUSSION
The present study identified a significant cognitive disadvantage in association with the presence
of the APOE e4 allele in adults with Type 1 diabetes. The differences in perfonnance observed
did not encompass all aspects of cognitive ability, were gender-specific and appeared to be
evident at a younger age (39 years) than has been previously reported in people who do not have
diabetes. The cognitive deficits observed in the present study were limited to perfonnance on
tests of current intellectual performance (WAIS-R performance IQ subtests) and frontal lobe and
executive functions (Borkowski Verbal Fluency). Significant differences in ability were only
observed in women with Type 1 diabetes. Women with one or more e4 allele exhibited
significantly poorer performance on the Object Assembly, Block Design and Digit Symbol tests
of the WAIS-R and poorer fontal lobe and executive function, as determined by performance in
the Borkowski Verbal Fluency task. Performance on the particular WAIS-R subtests
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disadvantaged by possession of the e4-allele provide measures of visual constructional ability
(OA: lesions affecting the occipital lobes, particularly on the non-dominant side), visuo-spatial
ability (BD: most strongly affected by non-dominant hemisphere lesions, typically those
involving the posterior aspects of the parietal lobe), psychomotor speed, visual-motor speed and
short-term visual memory (DSST: non-specific cortical localisation). The brain areas sub-serving
these specific modalities are anatomically located in the non-dominant occipital lobe and non-
dominant posterior parietal lobe. The Digit Symbol test provides a measure of psychomotor
speed, visual-motor speed and short-term visual memory and is sensitive to subtle differences in
ability but poorly localised in the cerebral hemispheres (Lezak, 2004). Poorer performance in
these subtests has been associated with lesions of the non-dominant hemisphere, with particular
localisation to the non-dominant occipital lobe (object assembly) and the posterior region of the
non-dominant parietal lobe (block design subtest) (Lezak, 2004).
Regional cerebral glucose utilisation (CMRgiu) is known to be influenced by APOE genotype in
apparently cognitively normal healthy middle-aged adults many years before the clinical
presentation of dementia of the Alzheimer's type (Small et al., 2000). Reductions in the CMRgiu
have been identified using 18-Fluoro-Deoxyglucose PET in the parietal lobes (Rciman et al.,
2001;Reiman et al., 2004;Reiman et al., 2005;Small et al., 2000;Reiman et al., 2005), posterior
cingulate gyrus (medial temporal lobe), temporal lobes and pre-frontal cortex (Reiman et al.,
2001;Reiman et al., 2004;Reiman et al., 2005) of apparently healthy middle-aged adults with one
or more APOE e4 allele. Reiman et al also identified a relationship between APOE £4 gene dose
and reduced CMRg!u, such that £4 heterozygotes exhibited reduced metabolism in the brain
regions described above, but greater reductions were observed in £4 homozygotes. These reports
of altered regional brain glucose metabolism are consistent with the cognitive findings of the
present study. Only performance on those specific cognitive ability tests which arc anatomically
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associated with the cortical areas identified by the above PET studies appeared to be
detrimentally affected in APOE s4 allele carriers.
Female susceptibility to APOE e4-associated cognitive disadvantage is not a novel observation
and has been described across a number of cognitive domains. Mortensen et al prospectively
measured WAIS-R performance in healthy participants from the age of 50 to 80 years and
observed poorer WAIS-R performance IQ scores, and a more rapid rare of cognitive decline, in
80 year old women with the e4 allele (Mortensen and Hogh, 2001). These women performed
more poorly on the Object Assembly and Block Design performance subtests, and tended to score
less well on the Digit Symbol test, an identical pattern to the cognitive disadvantage observed in
female participants with Type 1 diabetes in the present study, albeit at a considerably greater
chronological age. The mechanisms underlying these clinical observations are not well defined
but animal models may offer some clues to causality. In an APOE knockout mouse model, where
human APOE isofonns substituted host isoforms, only female e4 mice exhibited memory and
spatial-ability deficits whereas male e4 mice showed no deficits (Raber et al., 1998). Thereafter,
the same research group identified that Androgens may be important in the pathogenesis of
APOE e4 related cognitive disadvantage: treating male e4 mice with an androgen-receptor
antagonist produced memory and spatial impairment, whereas treating female e4 mice with
Androgens reversed s4-associated cognitive deficits (Raber et al., 2000).
Age influences the effect of APOE e4 on cognitive ability: neuropsychological performance in
healthy children (Turic et al., 2001) and healthy young adults (Yu et al., 2000) is not affected by
the e4 allele but middle-aged, otherwise healthy adults (mean age 46 years) have been observed
to have impaired learning and memory ability (Flory et al., 2000). The younger age (median age
39 years) at which e4-associated cognitive disadvantage was observed in adults with type 1
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diabetes in the present study, implies premature susceptibility compared with non-diabetic
individuals.
Laboratory and clinical evidence supports the concept of e4-associated premature cognitive
ageing in diabetes. Elderly people with type 2 diabetes and 84 exhibit greater cognitive
decrement (Kalmijn et al., 1996) and an accelerated cognitive decline (Haan et al., 1999)
compared to age-matched e4 healthy controls; APOE from people with diabetes is irreversibly
glycated and exhibits less in-vitro bioactivity (Shuvaev et al., 1999) when compared to non-
diabetic controls. APOE bioactivity appears to have clinical relevance as outcomes from a
variety of cerebral pathologies are poorer in individuals possessing the least biologically active
E4-isoform (Smith, 2000). As the present study did not include a healthy comparator group, the
notion that APOE e4 is associated with premature cognitive ageing in type 1 diabetes is
speculative at present, whereas this has been demonstrated in type 2 diabetes (Haan et al.,
1999;Kalmijn et al., 1996).
The present study did not support the hypothesis that polymorphism of the APOE gene may
contribute to the susceptibility to hypoglycaemia-induced cognitive decrement in people with
type 1 diabetes. The number of subjects in each e4 sub-group (n=15 vs. n=6) does not give
sufficient power to allow definitive conclusions and further, appropriately powered, investigation
is required to evaluate this hypothesis. Irrespective of the influence of APOE alleles, cognitive
performance was unaffected by severe hypoglycaemia per se, consistent with the conclusions of
the Diabetes Control and Complications Trial (1996) and the Stockholm Diabetes Intervention
Study (Reichard et al., 1991), in which many participants had type 1 diabetes of relatively short
duration, but conflicting with retrospective cross-sectional studies (Langan et al., 1991;Lincoln et
al., 1996;Sachon et al., 1992;Wredling RAM et al., 1992), which examined older subjects with
241
diabetes of long duration.
In conclusion, the data in this modestly-powered study suggest that APOE e4 confers a cognitive
disadvantage in young women who have type 1 diabetes. Further investigation is required to
verify these findings and to determine whether the APOE e4 allele is associated with premature
or accelerated cognitive ageing in people who have type 1 diabetes, the diabetes-specific factors
that may be mediating any such disadvantage, and the possible interaction with gender.
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10. CONCLUSIONS AND FUTURE DIRECTIONS
The series of clinical studies presented in this thesis identified associations between the clinical
complications of Type 1 diabetes and the age of disease onset and related these circumscribed
differences in cognitive ability and brain structure, each apparently specific to the particular type
of diabetes complication. The studies discussed below did not include a "healthy" non-diabetic
control group and were designed to explore the effects of "diabetes-specific" factors on the
cognitive and brain structural outcomes of interest. As such, the effects of Type 1 diabetes per se
remain relatively under explored, most notably with respect to the subtleties of brain structure.
10.1 Severe Hypoglycaemia and the Brain in Type 1 Diabetes
Repeated exposure to severe hypoglycaemia did not appear to be associated with measurable
differences in cognitive ability or brain structure in the cohort of subjects examined within this
study, within the significant limitations imposed by the collection of retrospective data
summarising preceeding severe hypoglycaemia exposure. Previous cross-sectional studies have
suggested a modest cognitive decrement may accrue following repeated exposure to severe
hypoglycaemia whereas large scale prospective studies have not confirmed this association. The
present study was not without limitations: not all cognitive domains were examined and the
neuroimaging methodologies utilised assessed global macroscopic structural changes but only
assessed detailed volumetric measurements in specific regions of interest. Therefore, it cannot be
definitively concluded from the present data that severe hypoglycaemia exposure was not
detrimental to all aspects of cognitive ability or brain structure given these caveats. Despite these
caveats, the present findings with respect to severe hypoglycaemia exposure are reassuring and do
not infer that any substantial differences in cognitive performance or brain structure are likely in
younger people with Type 1 diabetes. Future research could utilise different forms of MR!
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neuroimaging to search for very subtle structural brain associations, particularly Voxel Based
Morphometry (VBM) which has been recently shown to be a sensitive technique for identifying
subtle regional differences in gray matter density (Musen G., 2006), although the practical
meaning of such subtle change remains questionable.
10.2 Diabetic Retinopathy and the Brain in Type 1 Diabetes
The present study identified an association between the presence of mild degrees of Diabetic
Retinopathy and poorer cognitive abilities, primarily affecting fluid intelligence and information
processing speed but also disadvantageous to early visual information processing abilities and the
ability to sustain attention and concentration. This observation was consistent with previously
published work from Ryan and colleagues (Ryan C.M., 1992) who identified a similar pattern of
impairment in neuropsychological performance in association with the presence of peripheral
neuropathy. These findings strongly suggest that the presence of microangiopathy is
disadvantageous to aspects of human cognitive ability. The structural brain associations of
Diabetic Retinopathy were modest, restricted to the presence of SPWML in a regional brain area,
and perhaps could represent Type 1 error. The hypothesis that the presence of Diabetic
Retinopathy is a surrogate marker for intra-cranial microangiopathy elsewhere in the cerebral
circulation is therefore not proven. Future studies could be directed at evaluating the
neuroimaging associations of greater microangiopathic burdens, as Proliferative Retinopathy,
Nephropathy and Neuropathy. However, neuropathological studies in Type 1 diabetes are
lacking and detailed histopathological studies of the brain would garner more valuable
information.
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10.3 'Early Onset Diabetes' and the Brain in Type 1 Diabetes
The present observations lend support to the hypothesis that organic factors, relating to diabetes
per se or the development of acute metabolic decompensations in early life, are likely to be
largely responsible for the "early onset" of diabetes effect on cognitive abilities and intelligence
reported by multiple authors over the last 45 years. The differences in cognitive ability identified
in association with "early onset" diabetes were specific, affecting fluid intelligence and
infonnation processing speed and are consistent with the reports of others. The differences
described in brain structure, with an increased prevalence of subjectively-rated central brain
atrophy and greater lateral ventricle cavity volumes, in those with an early childhood onset of
Type 1 diabetes is novel and supports an organic process. These differences could not be
attributed to any identifiable diabetes-related factor and the present design could not determine
whether the associations observed were related to early childhood exposure to severe
hypoglycaemia, diabetic keto-acidosis or any other disease-specific factor. The present series of
studies comprising this thesis did not attempt to contrast the dieffering effects of a childhood
onset of Type 1 diabetes, relative to an onset after the attainment of full intellectual maturity at
the age of eighteen years. Such an analysis was not performed, despite two potentially suitable
cohorts being available for analysis, due to the interdependent confounding effects of diabetes
duration and age. For obvious reasons, it is not possible to match a "childhood onset" and "adult
onset" group for both age and disease duration, leading to substantial difficulties in the
interpretation of any subsequent outcomes, which may render such an analysis near
uninterpretable. Future case-control studies will be required to prospectively chart the
neurodevelopmental effects of Type 1 diabetes and identify the key components which mediate
the development of central brain atrophy. Prospective assessment of the present cohort may also
be of value to determine whether the degree of central brain atrophy alters with time and whether
associated differences in cognitive ability emerge.
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10.4 Neuroimaging Associations of Type 1 Diabetes
Abnormalities readily apparent on routine MRI of the brain are present in the majority of young
adults who have Type 1 diabetes. Those abnormalities most commonly observed were a mild
degree of central brain atrophy, mild degrees of Leukoaraiosis and Small Punctate White Matter
Lesions. These abnormalities were statistically associated with diabetes-related disease variables
but were not independent determinants of performance on a range of cognitive ability tests. The
practical significance of these subtle structural brain abnormalities is not apparent at present and
prospective assessment will be required to determine their natural history and future associations
with cognitive performance. It is unclear whether the presence of cerebral white matter
abnormalities is a risk factor for the future development of macrovascular events, or the
development of cognitive decline in Type 1 diabetes, as has been noted in chronologically older
non-diabetic populations. Diffusion Tensor Imaging, a newer MRI methodology which allows
the delineation of white matter tracts (tractography) may assist in clarifying the extent and white
matter tract bundles compromised by white matter lesions and therefore give clues as to the
cognitive abilities most likely to be disadvantaged.
10.5 Apolipoprotein-E and Type 1 Diabetes
An association between the presence of the APOE e4 allele and poorer cognitive function was
observed in the present study. This independent association was observed only in women and
appeared to be of medium effect size. The hypothesis that cognitive abilities would be poorer in
those with APOE e4 who were exposed to severe hypoglycaemia was not proven and the study
was underpowered to achieve his aim. It can be concluded that possession of the s4 allele of the
APOE gene is likely to be disadvantageous to cognitive abilities in women with Type 1 diabetes,
but whether this will result in more rapid cognitive decline relative to non-e4 carriers or the
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development of early dementia in earlier life is presently not known. A prospective study would
be required to determine the validity of the present observations and additionally test the
hypotheses that the presence of microangiopathy or intercurrent episodes of severe
hypoglycaemia may mediate any cognitive disadvantage. The addition of neuroimaging and a
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